



European  
Crohn's and Colitis  
Organisation

Vienna  
Austria

# Inflammatory Bowel Diseases

Final Programme



13<sup>th</sup> Congress of ECCO  
Reed Messe Vienna  
February 14-17, 2018

[www.ecco-ibd.eu](http://www.ecco-ibd.eu)



European  
Crohn's and Colitis  
Organisation

# Video recordings of the ECCO Congress



Missed an excellent presentation at the  
ECCO Congress? No time to attend?

- Watch video recordings of ECCO'18 and past Congresses on the e-CCO Learning Platform
- Accessible for all ECCO Members
- Presentation availability is subject to speaker authorisation



Scan and visit  
[www.e-learning.ecco-ibd.eu](http://www.e-learning.ecco-ibd.eu)



# Word of welcome

## *Dear Colleagues,*

Currently, we are witnessing major scientific advances in every field of IBD, from understanding the causes of these diseases to milestone developments in diagnostic tools and advanced therapies. The theme for the ECCO Congress 2018 is "Science improving patients' lives," devoting special attention to discoveries and innovations that can have an impact on disease management. In the programme for 2018 we have special sections on early stage disease, paediatric IBD, prediction, novel treatment strategies, diagnosis and management of dysplasia, best perioperative care and other aspects that are essential for returning our patients with IBD to a normal life. Our basic science session will be devoted to updating the rapidly evolving concepts of IBD pathogenesis.

In the past, the ECCO Congress has attracted over 6,200 delegates from all over the world, becoming the world's reference IBD event for the presentation and dissemination of advances in the field. It has become an indispensable event for every scientist and clinician with a focus on IBD. Preceding the main Congress, there is a wide offer of Educational Courses covering basic and advanced topics for physicians, nurses, clinical and basic investigators, and pharmaceutical research.

Besides the core Programme, the organisation is fostering meetings of study groups and committees, facilitating dissemination of ongoing research projects supported by the European Commission with ECCO involvement. You can find more information on our Congress website ([www.ecco-ibd.eu/ecco18](http://www.ecco-ibd.eu/ecco18)).

This year, the Congress will be held in the city of Vienna from February 14–17. Vienna has hosted a previous ECCO Congress with great success and is indeed ECCO's hometown where we have our Office that is continuously developing an outstanding work for the performance and expansion of the organisation. Vienna is an attractive and lovely city, one of the capitals of European culture, which provides an additional attraction to our meeting.

On behalf of the Organising Committee and the whole ECCO Team, I extend a warm welcome to the 13<sup>th</sup> Congress of ECCO.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Panés", written in a cursive style.

Julián Panés  
ECCO President & Chair of Organising Committee




Julián Panés

# Table of contents

Word of welcome.....	3
ECCO Structure .....	5
Scientific Information: A-Z .....	11
Scientific programme day by day.....	21
Abstract presentation format .....	39
Digital oral presentations.....	43
Hard copy poster presentations/poster exhibition .....	71
Educational programme .....	75
15 <sup>th</sup> IBD Intensive Advanced Course .....	75
9 <sup>h</sup> N-ECCO School.....	78
3 <sup>rd</sup> ECCO Endoscopy Workshop .....	81
5 <sup>th</sup> N-ECCO Research Forum.....	82
4 <sup>th</sup> Basic ECCO: EduCational COurse for Industry.....	83
4 <sup>th</sup> Y-ECCO Basic Science Workshop .....	85
4 <sup>th</sup> EpiCom Workshop .....	86
7 <sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP.....	87
12 <sup>th</sup> N-ECCO Network Meeting .....	90
6 <sup>th</sup> ClinCom Workshop.....	94
5 <sup>th</sup> ECCO-ESGAR Ultrasound-MRI Workshop.....	95
6 <sup>th</sup> SciCom Workshop: Fat in IBD .....	96
5 <sup>th</sup> P-ECCO Educational Course .....	97
3 <sup>rd</sup> H-ECCO IBD Masterclass.....	99
3 <sup>rd</sup> D-ECCO Workshop .....	101
Industry sponsored satellite symposia .....	104
Congress information.....	111
ECCO Interaction: Hearts and Minds .....	119
Corporate Members.....	122
Floor plans.....	123
Index of authors .....	126

# ECCO Structure



## Governing Board

President  
 President-Elect  
 Past-President  
 Secretary  
 Treasurer  
 Education Officer  
 Scientific Officer

Julián Panés (Spain)  
 Silvio Danese (Italy)  
 Séverine Vermeire (Belgium)  
 Laurent Peyrin-Biroulet (France)  
 Ailsa Hart (United Kingdom)  
 James Lindsay (United Kingdom)  
 Gerhard Rogler (Switzerland)

### *ClinCom*

Chair	Marc Ferrante (Belgium)
Members	Krisztina Gecse (The Netherlands) Javier Gisbert (Spain) John Mansfield (United Kingdom) Edyta Zagorowicz (Poland)

### *EduCom*

Chair	Peter Irving (United Kingdom)
Members	Pascal Juillerat (Switzerland) Konstantinos Katsanos (Greece) Peter Lakatos (Hungary/Canada) Antonio López-Sanromán (Spain) Giovanni Maconi (Italy)

### *EpiCom*

Chair	Ebbe Langholz (Denmark)
Members	Naila Arebi (United Kingdom) Laurent Beaugerie (France) Nynne Nyboe Andersen (Denmark) Marieke Pierik (The Netherlands)

### *GuiCom*

Chair	Christian Maaser (Germany)
Members	Glen Doherty (Ireland) Gionata Fiorino (Italy) Joana Torres (Portugal) Stephan Vavricka (Switzerland)

### *N-ECCO*

Chair	Palle Bager (Denmark)
Members	Usha Chauhan (Canada) Kay Greveson (United Kingdom) Liesbeth Moortgat (Belgium) Susanna Jäghult (Sweden)

### *P-ECCO*

Chair	Richard Russell (United Kingdom)
Members	Salvatore Cucchiara (Italy) Jaroslaw Kierkus (Poland) Patrick van Rheenen (The Netherlands) David Wilson (United Kingdom)

### SciCom

Chair	Britta Siegmund (Germany)
Members	Shomron Ben-Horin (Israel) Charlie Lees (United Kingdom) Florian Rieder (United States) Janneke van der Woude (The Netherlands)

### S-ECCO

Chair	Oded Zmora (Israel)
Members	Michel Adamina (Switzerland) Paulo Kotze (Brazil) Yves Panis (France) Antonino Spinelli (Italy)

### Y-ECCO

Chair	Isabelle Cleynen (Belgium)
Members	Dominik Bettenworth (Germany) Johan Burisch (Denmark) Nik Sheng Ding (Australia) Nuha Yassin (United Kingdom)

### D-ECCO Working Group

Chair	Rotem Sigall-Boneh (Israel)
Members	Konstantinos Gerasimidis (United Kingdom) Arie Levine (Israel) Miranda Lomer (United Kingdom) Nicolette Wierdsma (The Netherlands)

### H-ECCO Working Group

Chair	Roger Feakins (United Kingdom)
Members	Paula Borralho Nunes (Portugal) Magali Svrcek (France) Vincenzo Villanacci (Italy)

### Organising Committee – 13<sup>th</sup> Congress of ECCO

Chair	Julián Panés (Spain)
Members	Silvio Danese (Italy) Laurent Peyrin-Biroulet (France) Florian Rieder (United States) Pascal Juillerat (Switzerland)

## National Representatives

(as of January 15, 2018)



Christoph Högenauer  
Alexander Moschen



Péter Lakatos  
Tamás Molnár



Cathérine Reenaers  
Pieter Dewint



Jane McCarthy  
Garret Cullen



Ante Bogut  
Emil Babić



Henit Yanai  
Matti Waterman



Zoya Spassova  
Iskren Kotzev



Emma Calabrese  
Sandro Ardizzone



Željko Krznarić  
Ante Tonkic



Aleksejs Derovs  
Jelena Derova



Ioannis Kaimakliotis  
Theodora Demetriou



Limas Kupčinskas  
Gediminas Kiudelis



Tomáš Douda  
Pavel Drastich



Pierre Ellul



Jørn Brynskov  
Signe Wildt



Vlada Dumbravă  
Svetlana Turcan



Karin Kull  
Triin Remmel



Kristin Kaasen Jørgensen  
Marte Lie Høvik



Clas-Göran af Björkesten  
Pauliina Molander



Maria Kłopocka  
Małgorzata Śladek



Arnaud Bourreille  
Xavier Roblin



Paula Ministro  
Ana Isabel Vieira



Britta Siegmund  
Raja Atreya



Mihai Mircea Diculescu  
Adrian Goldis



Ioannis Koutroubakis  
Giorgos Bamias



Elena Belousova  
Alexander Potapov



Mirjana Cvetkovic  
Marijana Protić



Pierre Michetti  
Frank Seibold



Martin Huorka  
Mária Zakuciová



Andrea van der Meulen-de Jong  
Dirk de Jong



Ivan Ferkolj  
David Drobne



Yusuf Ziya Erzin  
Filiz Akyüz



Pilar Nos Mateu  
Manuel Barreiro de Acosta



Tetyana Zvyagintseva  
Andrey Dorofeyev



Michael Eberhardson  
Ann-Sofie Backman



Tariq Ahmad  
Barney Hawthorne

## Honorary Members

(as of January 15, 2018)

Filip Baert (Belgium)  
Renzo Caprilli (Italy)  
Yehuda Chowers (Israel)  
Jean-Frédéric Colombel (United States)  
Geert D'Haens (The Netherlands)  
Axel Dignass (Germany)  
Miquel Gassull (Spain)  
Daniel Hommes (United States)

Gerassimos Mantzaris (Greece)  
Pierre Michetti (Switzerland)  
Pia Munkholm (Denmark)  
Walter Reinisch (Austria)  
Herbert Tilg (Austria)  
Simon Travis (United Kingdom)  
Boris Vučelić (Croatia)

## Corporate Members

(as of January 15, 2018)

AbbVie  
Amgen  
Biogen  
Bühlmann Laboratories  
Celgene  
Celltrion  
Cosmo Pharmaceuticals

Dr. Falk Pharma  
Eli Lilly  
Gilead  
Grifols  
Janssen  
MSD  
Pfizer

Roche  
Sandoz  
Shire  
Takeda Pharmaceuticals Europe  
Tigenix  
Tillotts Pharma  
Vifor Pharma



European  
Crohn's and Colitis  
Organisation

Announcement  
2019

# Inflammatory Bowel Diseases



© Den Blå Planet, National Aquarium Denmark

14<sup>th</sup> Congress of ECCO  
March 6-9, 2019

- Bella Center Copenhagen
- EACCME applied
- Register at the 13<sup>th</sup> Congress of ECCO in Vienna

Scan and contact the ECCO Office  
[www.ecco-ibd.eu](http://www.ecco-ibd.eu)



# Scientific Information: A-Z

## Awards – ECCO Fellowships & Grants

On Friday, February 16, 2018, 15:30-16:10 ECCO officially announces the following prizes:

- ECCO Pioneer Award 2018
- ECCO-AOCC Visiting Travel Grant 2018
- ECCO-IOIBD Fellowship 2018
- ECCO Travel Awards 2018
- ECCO Grants 2018
- ECCO Fellowships 2018

The awarded candidates will officially be handed over their prize by naming the title of their fellowship/grant research project.

For further information and guidelines for these awards, please refer to [www.ecco-ibd.eu](http://www.ecco-ibd.eu).

## Business meetings

Attendance of business meetings is upon invitation only.

General Assembly: Thursday, February 15, 20:00-21:00, in room Strauss 1-2. For other business meetings please inform yourself at the ECCO Booth.

## Compliance

Based on the EFPIA HCP Code and the guidelines and codes of practice applicable to Austria, Pharmig Code of Conduct, ECCO has adopted measures that allow compliance with applicable regulations regarding publicity and promotion of medicines at the ECCO Congress 2018.

- Exhibitors have been asked to respect the Code of Practice in the context of the ECCO'18 Exhibitor & Sponsor Prospectus.
- Exhibitors have been alerted to the regulations about the promotion of prescription-only medicine, explaining that non-prescribing congress delegates can be identified with the NP sign on the congress badge.
- In the course of the online and onsite registration, the congress delegates will also be informed about the regulations regarding publicity and promotion of medicine and are asked to indicate their prescriber/non-prescriber status accordingly.

## Disclosure policy

ECCO has diligently maintained a disclosure policy of potential conflicts of interests (CoI) and its aim is to foster transparency and to ensure scientific rigour and objectivity in all of its scientific and educational activities. Therefore, all presenters, including invited faculty members and abstract presenters, are required to disclose any relevant financial support or relationship that may lead to a potential conflict. Please note that the responsibility for the content of each presentation lies with the presenting author.

All presenters are required to complete a Conflict of Interest form to disclose any financial support as well as advisory and consultancy roles in the biomedical industry. All submitted forms are open to public scrutiny on the ECCO Website ([www.ecco-ibd.eu/about-ecco/ecco-disclosures](http://www.ecco-ibd.eu/about-ecco/ecco-disclosures)) providing a comprehensive overview of potential conflicts of interest of presenters. As soon as the CoI Forms are online, the IBD Community is also notified by the ECCO eNewsletter about the online access to the up-to date disclosure information. In addition, these conflicts are requested to be shown at the beginning of each presentation on a PowerPoint slide.

In order to facilitate the process and reinforce the 2<sup>nd</sup> slide policy, faculty speakers are reminded to disclose their potential conflicts of interest in their ppt in line with UEMS regulations.

Based on the submitted Col form of each speaker, a draft Col slide has been prepared and is made available in the Speakers' centre with a reminder that if the respective presentation does not yet include a disclosure form, the slide draft should be checked/amended and included in the ppt.

Conflicts of interest may include financial relationships or when the individual has the opportunity to influence the content of a presentation, and can comprise grants, honoraria, shares, paid positions on advisory boards etc. ECCO expects many presenters to have some conflicts of interest, which do not prevent them from presenting their work given that the conflict is disclosed.

### *EACCME – Continuing Medical Education*

The 13<sup>th</sup> Congress of ECCO in Vienna is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), [www.uems.net](http://www.uems.net). Thursday, February 15, counts for 5 CME, Friday, February 16, counts for 6 CME and Saturday, February 17, counts for 3 CME credits. Thus, a maximum of **15 CME credits** can be obtained for the scientific sessions of the core programme.



For the **16<sup>th</sup> IBD Intensive Advanced Course** for Junior Gastroenterologists (upon invitation only) **9 CME credits** will be accredited. Please refer to page 75.

For the **3<sup>rd</sup> ECCO Endoscopy Workshop** for Regular Members of ECCO (pre-registered participants only) **4 CME credits** will be accredited. Please refer to page 81.

For the **4<sup>th</sup> Y-ECCO Basic Science Workshop** for Regular Members of ECCO (pre-registered participants only) **2 CME credits** will be accredited. Please refer to page 85.

For the **4<sup>th</sup> EpiCom Workshop** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 86.

For the **7<sup>th</sup> S-ECCO IBD Masterclass** for Regular Members of ECCO (pre-registered participants only) **6 CME credits** will be accredited. Please refer to page 87.

For the **6<sup>th</sup> ClinCom Workshop** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 94.

For the **5<sup>th</sup> ECCO-ESGAR Ultrasound-MRI Workshop** for Regular Members of ECCO (pre-registered participants only) **4 CME credits** will be accredited. Please refer to page 95.

For the **6<sup>th</sup> SciCom Workshop** for Regular Members of ECCO (pre-registered participants only) **2 CME credits** will be accredited. Please refer to page 96.

For the **5<sup>th</sup> P-ECCO Educational Course** for Regular Members of ECCO (pre-registered participants only) **2 CME credits** will be accredited. Please refer to page 97.

For the **3<sup>rd</sup> H-ECCO IBD Masterclass** for Regular Members of ECCO (pre-registered participants only) **6 CME credits** will be accredited. Please refer to page 99.

For the **3<sup>rd</sup> D-ECCO Workshop** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 101.

In order to obtain CME credits ECCO requires feedback on its educational activities. Therefore, you will receive an e-mail with a link to the online evaluation platform at the end of the congress. You will be able to evaluate the Scientific Programme and any educational activities you attended. Once you have submitted your surveys, your CME Certificates will be available for download or print.

### *Plenary session*

The plenary session is held from Thursday, February 15 to Saturday, February 17, 2018 and starts off with the official welcome & opening of the core scientific programme. The programme includes all official speeches, with a mixture of invited speakers and oral presentations of the best submitted abstracts.

### *Oral presentations – Best abstracts*

Out of 1,319 submitted abstracts the 38 best submitted abstracts have carefully been chosen by a panel of referees and selected for oral presentation during the Scientific Programme. For the presentation schedule, please refer to the Scientific Programme (page 21).

### *Digital oral presentations*

Abstracts have been selected from the ranking by taking ~90 abstracts after those 38 selected for presentation in the scientific programme. These abstracts will be presented as digital oral presentations, with a 5 minute oral presentation in several rooms in the Congress Centre at Messe on Thursday, February 15, 2018 from 17:30-18:30 or on Friday, February 16, 2018 from 17:20-18:20. Please find the schedule and selected abstracts for each digital oral presentation room on page 43.

### *Hard copy poster presentations/Poster exhibition*

The remaining accepted abstracts will be displayed as hard copy posters throughout the congress in the exhibition hall. For further details on all posters included in the poster exhibition, please refer to page 71.

### *Scientific congress theme*

This year's congress theme is "Science improving patients' lives".

### *Top tips for chairs*

All chairs are kindly asked to watch the session on "Top tips for chairs" available at the ECCO Website: [www.ecco-ibd.eu/toptips](http://www.ecco-ibd.eu/toptips). In this video, Laurence Egan will give essential information on how to chair scientific sessions in a light humorous manner – do not miss out on it!



European  
Crohn's and Colitis  
Organisation

Vienna  
Austria

# How to receive your CME Certificates



## Submit your evaluation forms online!

CME Certificates for the ECCO'18 Scientific Programme and accredited Educational Courses will be available online at the end of the Congress. To download your certificates, follow these steps:

### Check your account details

- Visit the ECCO Website to make sure your e-mail address and login details are up-to-date.

### Check your e-mail

- At the end of the Congress, you will receive an e-mail with a link to the online evaluation platform.

### Fill out your evaluation forms

- You will be able to evaluate the Scientific Programme and any Educational Activities you attended.

### Download your certificates

- Once you have submitted your surveys, your CME Certificates will be available for download or print.

Scan and contact the ECCO Office  
[www.ecco-ibd.eu](http://www.ecco-ibd.eu)





European  
Crohn's and Colitis  
Organisation

Vienna  
Austria

# e-CCO Learning

Open access  
preview @ the  
ECCO Booth

# e-CCO

## Congress special: Open access preview

**Are you looking for educational material? Check out...**

### Latest Talking Heads

- New Drugs in IBD
- Expectations of histopathologists
- Top strategy trials
- Perspectives on biosimilars
- Dietary therapy in IBD
- Azathioprine monotherapy

### ECCO IBD Curriculum

### Latest e-Courses

- Diagnostic techniques and monitoring
- Managing non-inflammatory symptoms
- IBD in elderly

### ECCO e-Library

- Congress Abstracts
- Congress Webcasts
- Congress Presentations

### Upcoming e-Courses

- Paediatric UC
- History on the histology of the patient
- Complementary therapies and psychological factors

### Educational Audio Podcasts



Scan and visit

[www.e-learning.ecco-ibd.eu](http://www.e-learning.ecco-ibd.eu)





European  
Crohn's and Colitis  
Organisation

# Research Grants and Fellowships 2019



Fund your innovative scientific research  
with ECCO's Fellowships and Grants

## **ECCO Pioneer Award**

- EUR 250,000 for innovative and collaborative research projects between at least 2 IBD centres

**First Application deadline: June 1, 2018**

## **ECCO Fellowships**

- EUR 60,000 for young and enthusiastic scientists to research in a host institute abroad

## **ECCO Grants**

- EUR 50,000 for innovative, and original research projects

## **ECCO Travel Awards**

- EUR 1,500 for young doctors and nurses to enable visits of European IBD centres

**Application deadline: September 1, 2018**

Scan and visit

[www.ecco-ibd.eu](http://www.ecco-ibd.eu)



## Educational programme

WED Feb 14, 2018	Room	08:30-08:45	08:45-10:00	10:00-13:00	13:00-13:30	13:30-14:00	14:00-14:30	14:30-15:30	15:30-16:15	16:15-16:30	16:30-16:45	16:45-17:00	17:00-17:30	17:30-18:00	
	Strauss 3 (Ground Floor)	16 <sup>th</sup> IBD Intensive Advanced Course											p. 75		
	Schubert 1-2 (Level 1)	9 <sup>th</sup> N-ECCO School											p. 78		
	Lehar 4 (Ground Floor)	3 <sup>rd</sup> ECCO Endoscopy Workshop												p. 81	
	Lehar 1 (Ground Floor)	5 <sup>th</sup> N-ECCO Research Forum												p. 82	
	Stolz 1 (Ground Floor)	4 <sup>th</sup> Basic ECCO: EduCational Course for Industry											p. 83		
	Schubert 4-5 (Level 1)	4 <sup>th</sup> Y-ECCO Basic Science Workshop											p. 85		
	Lehar 2 (Ground Floor)	4 <sup>th</sup> EpiCom Workshop											p. 86		

THU Feb 15, 2018	Room	07:30-07:45	07:45-08:00	08:00-08:15	08:15-08:45	08:45-09:00	09:00-10:00	10:00-11:40	11:40-11:55	11:55-12:00	12:00-12:15	12:15-13:30	13:30-13:45	13:45-17:00	17:00-17:15	17:15-17:20	
	Strauss 3 (Ground Floor)	16 <sup>th</sup> IBD Intensive Advanced Course											p. 77				
	Stolz 1-2 (Ground Floor)	7 <sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP												p. 87			
	Strauss 1-2 (Ground Floor)	12 <sup>th</sup> N-ECCO Network Meeting											p. 90	N-ECCO Network Meeting ISSS p. 110	12 <sup>th</sup> N-ECCO Network Meeting p. 90		
	Lehar 1 (Ground Floor)	6 <sup>th</sup> ClinCom Workshop											p. 94				
	Lehar 3 (Level 1)	5 <sup>th</sup> ECCO-ESGAR Ultrasound-MRI Workshop											p. 95				
	Lehar 4 (Ground Floor)	6 <sup>th</sup> SciCom Workshop: Fat in IBD – much more than an innocent bystander											p. 96				
	Schubert 4-5 (Level 1)	5 <sup>th</sup> P-ECCO Educational Course											p. 97		3 <sup>rd</sup> H-ECCO IBD Masterclass	p. 99	

FRI Feb 16, 2018	Room	08:00-08:30					18:30-12:00					12:00-12:25				
	Schubert 4-5 (Level 1)	3 <sup>rd</sup> H-ECCO IBD Masterclass										p. 100				
Lehar 4 (Ground Floor)	3 <sup>rd</sup> D-ECCO Workshop														p. 101	

# Programme overview Congress theme: “Science improving patients’ lives”

## Scientific programme

THU Feb 15, 2018	Room	10:30-11:00	11:00-12:00	12:00-12:15	12:15-12:30	12:30-14:00	14:00-14:30	14:30-16:00	16:00-17:20	17:20-17:30	17:30-18:00	18:00-18:30	18:30-18:45	18:45-19:45
	Plenary Hall (Ground Floor)		ISSS 1a p. 104		Welcome and Opening p. 21	SS 1: Exploring IBD over time p. 21		SS 2: Novel treatment strategies p. 22	SS 3: Returning to a normal life with IBD p. 23					ISSS 2a p. 105
	Parallel Hall (Ground Floor)		ISSS 1b p. 105											ISSS 2b p. 105
	Exhibition Hall (Ground Floor)	Industry and Poster exhibition p. 71					Coffee Break	Industry and Poster exhibition p. 71						
	Lehar 1-3 (Ground Floor)													ISSS 2c p. 106
	Lehar 1-3, Lehar 4, Stolz 1-2, Strauss 1-2, Strauss 3 (Ground Floor)										DOP Sessions 1-5 p. 43			

FRI Feb 16, 2018	Room	07:15-08:15	08:15-08:30	08:30-09:30	09:30-10:30	10:30-11:00	11:00-12:30	12:30-12:40	12:40-13:20	13:20-13:30	13:30-15:00	15:00-15:30	15:30-16:10	16:10-17:10	17:10-17:20	17:20-18:00	18:00-18:20	18:20-18:35	18:35-19:35	
	Plenary Hall (Ground Floor)	ISSS 3a p. 106		SS 4: The future of IBD diagnosis and disease prediction p. 24			SS 5: New opportunities for IBD care and research p. 25		ELSS LS1 p. 107		SS 6: Best perioperative management of IBD p. 26		SS 7: ECCO Fellowships & Grants p. 28	SS 8: IBD Horizons p. 29						ISSS 4a p. 108
	Parallel Hall (Ground Floor)	ISSS 3b p. 106							ELSS LS 2 p. 107											
	Exhibition Hall (Ground level)				Industry and Poster exhibition p. 71	Coffee break	Industry and Poster exhibition p. 71	Lunch break and Guided poster Session		Industry and Poster exhibition p. 71		Coffee break	Industry and Poster exhibition p. 71							
	Lehar 1-3 (Ground Floor)	ISSS 3c p. 107							ELSS LS3 p. 108											ISSS 4c p. 110
	Strauss 1-2 (Ground Floor)								ELSS LS4 p.108				SS 9: Basic Science: Evolving concepts of IBD pathogenesis p. 31							ISSS 4d p. 110
Lehar 1-3, Lehar 4, Stolz 1-2, Strauss 1-2, Strauss 3 (Ground Floor)																DOP Sessions 6-10 p. 43				

SAT Feb 17, 2018	Room	08:30-9:30	9:30-10:20	10:20-10:50	10:50-12:20	12:20-12:50	12:50-12:55	12:55-13:00	
	Plenary Hall (Ground Floor)	SS 10: Growing up with IBD safely p. 34				SS 11: Colorectal Cancer in IBD p. 36	SS 12: ECCO Lecture p. 37	Awards and closing remarks p. 37	The ECCO Film 2018 p. 37
	Exhibition (Ground Floor)		Industry and Poster exhibition p. 71	Coffee break	Industry and Poster exhibition p. 71				



European  
Crohn's and Colitis  
Organisation

# ECCO Pioneer Award



Fund your innovative scientific research  
with the ECCO Pioneer Award

**The ECCO Pioneer Award aims to enhance visionary, collaborative, and interdisciplinary scientific research in IBD centres.**

## **2019: Open to all topics in IBD**

- EUR 250,000 prize
- 1 exceptional award per year
- Fund up to 24 months of basic/clinical research in IBD
- For innovative and collaborative research projects between at least 2 equal participating institutions

**Application deadline (1<sup>st</sup> phase): June 1, 2018**

Scan and contact the ECCO Office  
[www.ecco-ibd.eu](http://www.ecco-ibd.eu)





European  
Crohn's and Colitis  
Organisation

Vienna  
Austria

# Highlights of ECCO'18



## The ECCO'18 Congress in a nutshell

### Take-home messages from the Scientific Programme:

- Watch a summary of selected top abstracts
- Recorded just for you and your colleagues at home
- Available in the eLibrary right after the Congress

Scan and visit

[www.ecco-ibd.eu/highlights](http://www.ecco-ibd.eu/highlights)



# “Science improving patients’ lives”

**Thursday, February 15, 2018**

*Scientific programme day by day (as of January 15, 2018)*

*Plenary Hall, Hall D, Messe Wien*

<b>11:00 - 12:00</b>	<b>Industry sponsored satellite symposia 1a &amp; 1b</b> Please refer to pages 104-105
<b>12:15 - 12:20</b>	<b>1: Welcome</b> Rainer Schöfl, Linz, Austria
<b>12:20 - 12:30</b>	<b>2: Opening</b> Julián Panés, Barcelona, Spain
<b>12:30 - 14:00</b>	<b>Scientific session 1: Exploring IBD over time</b> Axel Dignass, Frankfurt, Germany Charlotte Hedin, Stockholm, Sweden
12:30 - 12:50	<b>3: Can we diagnose pre-symptomatic IBD?</b> Joana Torres, Lisbon, Portugal
12:50 - 13:00	<b>4: OP001: Gut barrier dysfunction – a primary defect in twins with Crohn’s Disease predominantly caused by genetic predisposition</b> Å. V. Keita <sup>1</sup> , C.M. Lindqvist <sup>2</sup> , Å. Öst <sup>3</sup> , C. DL Magana <sup>1</sup> , I. Schoultz <sup>2</sup> , J. Halfvarson <sup>4</sup> <sup>1</sup> Linköping University, Department Of Clinical And Experimental Medicine, Linköping, Sweden, <sup>2</sup> Örebro University, Department of Medical Sciences, Örebro, Sweden, <sup>3</sup> Aleris Medilab, Department of Pathology and Cytology, Täby, Sweden, <sup>4</sup> Örebro University, Department of Gastroenterology, Örebro, Sweden
13:00 - 13:20	<b>5: Targeting early disease - lessons from rheumatoid arthritis</b> Daniel Aletaha, Vienna, Austria
13:20 - 13:30	<b>6: OP002: Assessment of disease activity patterns during the first 10 years after diagnosis in a population-based Crohn’s Disease cohort shows a quiescent disease course for a substantial proportion of the population</b> D. Wintjens <sup>1,2</sup> , F. Bergey <sup>3</sup> , E. Saccenti <sup>4</sup> , S. Jeuring <sup>1,2</sup> , M. Romberg-Camps <sup>5</sup> , L. Oostenbrug <sup>5</sup> , A. Masclee <sup>1,2</sup> , D. Jonkers <sup>1,2</sup> , V. Martins dos Santos <sup>3,4</sup> , M. Pierik <sup>1,2</sup> <sup>1</sup> Maastricht University Medical Center +, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht, The Netherlands, <sup>2</sup> Maastricht University Medical Center +, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands, <sup>3</sup> LifeGlimmer GmbH, Berlin, Germany, <sup>4</sup> Wageningen University & Research, Laboratory of Systems and Synthetic Biology, Wageningen, The Netherlands, <sup>5</sup> Zuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen/Heerlen, The Netherlands



Y-ECCO  
Abstract Award

OP = Oral presentation – Best abstracts

## Thursday, February 15, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

13:30 - 13:40	<b>7: OP003: Temporal changes in immune pathways with consecutive biological therapies as measured by serum proteomics</b> <b>M. de Bruyn</b> <sup>1,2</sup> , V. Ballet <sup>3</sup> , S. Verstockt <sup>3</sup> , B. Verstockt <sup>1,3</sup> , G. Van Assche <sup>1,3</sup> , M. Ferrante <sup>1,3</sup> , K. Machiels <sup>1</sup> , S. Vermeire <sup>1,3</sup> <sup>1</sup> Translational Research center for GastroIntestinal Disorders (TARGID), Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium, <sup>2</sup> Rega Institute for Medical Research, Microbiology and Immunology, Leuven, Belgium, <sup>3</sup> University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium, <sup>4</sup> Laboratory of Complex Genetics, Human Genetics, Leuven, Belgium
13:40 - 14:00	<b>8: Evolution of disease pathways over time in CD – early versus late disease</b> Gerhard Rogler, Zurich, Switzerland
<b>14:00 - 14:30</b>	<b>Coffee break</b>
<b>14:30 - 16:00</b>	<b>Scientific session 2: Novel treatment strategies</b> Matthieu Allez, Paris, France Tim Raine, Cambridge, United Kingdom
14:30 - 14:50	<b>9: Combining new drugs with different mechanisms</b> Shomron Ben-Horin, Ramat Gan, Israel
14:50 - 15:00	<b>10: OP004: The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in Ulcerative Colitis</b> <b>H. Schmitt</b> <sup>1</sup> , U. Billmeier <sup>1</sup> , J. Ulmschneider <sup>1</sup> , C. Admyre <sup>2</sup> , T. Knittel <sup>2</sup> , A. Zargari <sup>2</sup> , M.F. Neurath <sup>1</sup> , R. Atreya <sup>1</sup> <sup>1</sup> Friedrich-Alexander-University Erlangen-Nürnberg, First Department of Medicine, Erlangen, Germany, <sup>2</sup> InDex Pharmaceuticals AB, Stockholm, Sweden
15:00 - 15:20	<b>11: Stem cell therapy for perianal CD – multidisciplinary management</b> Silvio Danese, Milan, Italy Damián García-Olmo, Madrid, Spain
15:20 - 15:30	<b>12: OP005: Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's Disease patients</b> <b>A. Strik</b> <sup>1</sup> , M. Löwenberg <sup>1</sup> , C. Ponsioen <sup>1</sup> , K. Gece <sup>2</sup> , C. Buskens <sup>3</sup> , W. Bemelman <sup>3</sup> , G. D'Haens <sup>1</sup> <sup>1</sup> Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands, <sup>2</sup> Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, <sup>3</sup> Academic Medical Center (AMC), Department of Surgery, Amsterdam, The Netherlands
15:30 - 15:40	<b>13: OP006: Apremilast for active Ulcerative Colitis: A phase 2, randomised, double-blind, placebo-controlled induction study</b> <b>S. Danese</b> <sup>1</sup> , M. Neurath <sup>2</sup> , A. Kopon <sup>3</sup> , S. Zakko <sup>4</sup> , T. Simmons <sup>5</sup> , R. Fogel <sup>6</sup> , J. Maccaroni <sup>7</sup> , X. Zhan <sup>7</sup> , K. Usiskin <sup>7</sup> , D. Chitkara <sup>7</sup> <sup>1</sup> Instituto Clínico Humanitas, Milan, Italy, <sup>2</sup> University Erlangen, Nurnberg, Germany, <sup>3</sup> Toruskie Centrum Gastrologiczne Gastromed, Torun, Poland, <sup>4</sup> Connecticut Clinical Research Foundation of Bristol Hospital, Bristol, United States, <sup>5</sup> West Gastroenterology Medical Group, Los Angeles, United States, <sup>6</sup> Clinical Research Institute of Michigan, Chesterfield, United States, <sup>7</sup> Celgene Corporation, Summit, United States
15:40 - 16:00	<b>14: Small molecules are back</b> Laurent Peyrin-Biroulet, Vandoeuvre-Les-Nancy, France

OP = Oral presentation – Best abstracts

## Thursday, February 15, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

<b>16:00 - 17:20</b>		<b>Scientific session 3: Returning to a normal life with IBD</b> Barry Hall, Dublin, Ireland Paula Ministro, Viseu, Portugal
	16:00 - 16:20	<b>15: Sexual dysfunction in IBD patients</b> Eugeni Domènech, Badalona, Spain
	16:20 - 16:40	<b>16: How to prevent disability</b> Jean-Frédéric Colombel, New York City, United States
	16:40 - 16:50	<b>17: OP007: Detection of mucosal healing with a serum marker panel in adalimumab treated patients with Ulcerative Colitis</b> <b>M. de Bruyn</b> <sup>1,2</sup> , R. Ringold <sup>3</sup> , E. Martens <sup>2</sup> , M. Ferrante <sup>1,4</sup> , G. Van Assche <sup>1,4</sup> , G. Opdenakker <sup>2</sup> , A. Dukler <sup>3</sup> , S. Vermeire <sup>1,4</sup> 1Translational Research center for GastroIntestinal Disorders (TARGID), Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium, 2Rega Institute for Medical Research, Microbiology and Immunology, Leuven, Belgium, 3Kepler Diagnostics, Inc., Simi Valley, United States, 4University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium
 <b>Y-ECCO Abstract Award</b>	16:50 - 17:00	<b>18: OP008: <math>\alpha 4\beta 7</math> integrin-dependent gut homing of non-classical monocytes is essential for intestinal wound healing mediated by M2 macrophages</b> L. Schleier <sup>1</sup> , M. Wiendl <sup>1</sup> , M.-T. Binder <sup>1</sup> , R. Atreya <sup>1</sup> , A. Watson <sup>2</sup> , C. Neufert <sup>1</sup> , I. Atreya <sup>1</sup> , M.F. Neurath <sup>1</sup> , <b>S. Zundler</b> <sup>1</sup> <sup>1</sup> University of Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany, <sup>2</sup> University of East Anglia, Norwich Medical School, Norwich, United Kingdom
	17:00 - 17:20	<b>19: Patient perspective on treatment goals</b> Corey Siegel, Lebanon, United States
<b>17:30 - 18:30</b>		<b>Digital Oral Presentations (Sessions 1-5)</b> Please refer to page 43
<b>18:45 - 19:45</b>		<b>Industry sponsored satellite symposia 2a &amp; 2b &amp; 2c</b> Please refer to pages 105-106

## Friday, February 16, 2018

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

07:15 - 08:15	<b>Industry sponsored satellite symposia, 3a &amp; 3b &amp; 3c</b> Please refer to pages 106-107
08:30 - 10:30	<b>Scientific session 4: The future of IBD diagnosis and disease prediction</b> Iris Dotan, Petah Tikva, Israel Jonas Halfvarson, Örebro, Sweden
08:30 - 08:50	<b>20: ECCO-ESGAR Guidelines: Present and future of diagnostic techniques for IBD</b> Christian Maaser, Lueneburg, Germany Jaap Stoker, Amsterdam, The Netherlands
08:50 - 09:00	<b>21: OP009: A combination of clinical, serological and genetic factors predicts complicated disease course in paediatric-onset Crohn's disease: results from a population-based study.</b> <b>H. Sarter<sup>1,2</sup></b> , G. Savoye <sup>3</sup> , D. Turck <sup>2,4</sup> , F. Vasseur <sup>5</sup> , G. Marot <sup>6,7</sup> , B. Pariente <sup>2,8</sup> , S. Singh <sup>9</sup> , J.F. Colombel <sup>10</sup> , C. Gower-Rousseau <sup>1,2</sup> , M. Fumery <sup>11</sup> <sup>1</sup> Lille Hospital and University, Public Health, Epidemiology and Economic Health, Epimad registry, Regional house of clinical research, Lille, France, <sup>2</sup> Lille University, Lille Inflammation Research International Center LIRIC-UMR 995 Inserm, Lille, France, <sup>3</sup> Rouen Hospital and University, Gastroenterology Unit, Epimad registry, Rouen, France, <sup>4</sup> Lille University Jeanne de Flandre Children's Hospital and Faculty of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Lille, France, <sup>5</sup> Lille University and Hospital, Biostatistics Unit, EA 2694, Lille, France, <sup>6</sup> Lille University and Hospital, EA 2694 - Santé publique: épidémiologie et qualité des soins, Lille, France, <sup>7</sup> Inria Lille Nord Europe, Modal, Lille, France, <sup>8</sup> Gastroenterology Unit, Epimad registry, Lille Hospital and University, Lille, France, <sup>9</sup> Prometheus Laboratories Inc., San Diego, United States, <sup>10</sup> Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, <sup>11</sup> Amiens Hospital and University, Gastroenterology Unit, EPIMAD Registry, Amiens, France
09:00 - 09:10	<b>22: OP010: Shallow whole genome sequencing predicts the future cancer risk of low grade dysplastic lesions arising in Ulcerative Colitis</b> <b>I. Al Bakir<sup>1,2</sup></b> , K. Curtius <sup>1</sup> , A.-M. Baker <sup>1</sup> , T.S.O. Clarke <sup>1</sup> , M. Moorghen <sup>3</sup> , M. Jansen <sup>4</sup> , M. Rodriguez-Justo <sup>4</sup> , S. Leedham <sup>5</sup> , T. Graham <sup>*1</sup> , A. Hart <sup>*2</sup> <sup>1</sup> Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, <sup>2</sup> St. Mark's Hospital, Inflammatory Bowel Disease Unit, Harrow, United Kingdom, <sup>3</sup> St. Mark's Hospital, Pathology Department, Harrow, United Kingdom, <sup>4</sup> University College London Hospital, Pathology Department, London, United Kingdom, <sup>5</sup> Henry Wellcome Building of Genomic Medicine, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
09:10 - 09:20	<b>23: OP011: Integration of whole exome sequencing and RNA sequencing of intestinal biopsies in Inflammatory Bowel Disease identifies inflammation dependent effects</b> <b>R. Barbieri<sup>1</sup></b> , W. Uniken Venema <sup>1</sup> , A. Vich Vila <sup>1</sup> , Y. Li <sup>1</sup> , L. Franke <sup>1</sup> , F. van Dijk <sup>1</sup> , N. De Klein <sup>1</sup> , M. Swertz <sup>1</sup> , S. Sanna <sup>1</sup> , M.D. Voskuil <sup>1</sup> , M. Rivas <sup>2</sup> , R. Xavier <sup>2</sup> , M. Daly <sup>2</sup> , G. Dijkstra <sup>1</sup> , E.A. Festen <sup>1</sup> , R.K. Weersma <sup>1</sup> <sup>1</sup> UMCG, Groningen, The Netherlands, <sup>2</sup> The Broad Institute of MIT and Harvard, Cambridge, United States
09:20 - 09:40	<b>24: Molecular endoscopy for IBD</b> Raja Atreya, Erlangen, Germany

OP = Oral presentation – Best abstracts

## Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

09:40 - 09:50	<p><b>25: OP012: IL-23 is centrally involved in mediating molecular resistance to anti-TNF therapy in Crohn’s Disease patients</b>  <b>H. Schmitt<sup>1</sup></b>, U. Billmeier<sup>1</sup>, W. Dieterich<sup>1</sup>, T. Rath<sup>1</sup>, S. Sonnenwald<sup>2</sup>, S. Reid<sup>2</sup>, S. Hirschmann<sup>1</sup>, K. Hildner<sup>1</sup>, M.J. Waldner<sup>1</sup>, J. Mudter<sup>3</sup>, A. Hartmann<sup>4</sup>, R. Grützmann<sup>5</sup>, C. Neufert<sup>1</sup>, T. Münster<sup>6</sup>, M.F. Neurath<sup>1</sup>, R. Atreya<sup>1</sup>  <sup>1</sup>Friedrich-Alexander-University Erlangen-Nürnberg, First Department of Medicine, Erlangen, Germany, <sup>2</sup>Friedrich-Alexander-University Erlangen-Nürnberg, Department of Biology, Erlangen, Germany, <sup>3</sup>Sana Kliniken Ostholstein, Eutin, Germany, <sup>4</sup>Friedrich-Alexander-University Erlangen-Nürnberg, Department of Pathology, Erlangen, Germany, <sup>5</sup>Friedrich-Alexander-University Erlangen-Nürnberg, Department of Surgery, Erlangen, Germany, <sup>6</sup>Friedrich-Alexander-University Erlangen-Nürnberg, Department of Anesthesiology, Erlangen, Germany</p>
09:50 - 10:00	<p><b>26: OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s Disease</b>  <b>A. Sazonovs<sup>1</sup></b>, N.A. Kennedy<sup>2</sup>, C. Bewshea<sup>2</sup>, L. Moutsianas<sup>1</sup>, G.J. Walker<sup>2</sup>, K. De Lange<sup>1</sup>, J. Goodhand<sup>2</sup>, C. Anderson<sup>1</sup>, J. Barrett<sup>1</sup>, PANTS Investigator Consortium, T. Ahmad<sup>2</sup>  <sup>1</sup>Wellcome Trust Sanger Institute, Hinxton, United Kingdom, <sup>2</sup>University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom</p>
10:00 - 10:10	<p><b>27: OP014: Analysis of 1792 gut metagenomes reveals microbial treatment targets for Inflammatory Bowel Disease and irritable bowel syndrome</b>  <b>A. Vich Vila<sup>1</sup></b>, F. Imhann<sup>1</sup>, V. Collijl<sup>1</sup>, S.A. Jankipersadsing<sup>1</sup>, T. Gurry<sup>2</sup>, Z. Mujagic<sup>3</sup>, A. Kurilshikov<sup>1</sup>, M.J. Bonder<sup>1</sup>, J. Xiaofang<sup>2</sup>, E. Tigchelaar<sup>1</sup>, J. Dekens<sup>1</sup>, V. Peters<sup>1</sup>, M.D. Voskuil<sup>1</sup>, M.C. Visschedijk<sup>1</sup>, F. Eleonora A.M.<sup>1</sup>, G. Dijkstra<sup>1</sup>, A.A. Masclee<sup>3</sup>, M.H. Hofker<sup>1</sup>, R. Xavier<sup>4</sup>, E.J. Alm<sup>2</sup>, J. Fu<sup>1</sup>, C. Wijmenga<sup>1</sup>, D.M. Jonkers<sup>3</sup>, A. Zhernakova<sup>1</sup>, R.K. Weersma<sup>1</sup>  <sup>1</sup>University Medical Center Groningen, Groningen, The Netherlands, <sup>2</sup>Massachusetts Institute of Technology, Boston, United States, <sup>3</sup>Maastricht University Medical Center (MUMC), Maastricht, The Netherlands, <sup>4</sup>Broad Institute, Boston, United States</p>
10:10 - 10:30	<p><b>28: Integration of “omics” and potential for clinical practice</b>            Claudio Focchi, Cleveland, United States</p>
<b>10:30 - 11:00 Coffee break</b>	
<b>Scientific session 5: New opportunities for IBD care and research</b>	
<b>11:00 - 12:30</b>	Dominik Bettenworth, Münster, Germany James Lindsay, London, United Kingdom
11:00 - 11:20	<p><b>29: Remote monitoring</b>            Daniel Baumgart, Berlin, Germany</p>
11:20 - 11:40	<p><b>30: Point of care tests</b>            Ann Gils, Leuven, Belgium</p>
11:40 - 12:00	<p><b>31: Web-based registries</b>            Pascal Juillerat, Bern, Switzerland</p>

OP = Oral presentation – Best abstracts

## Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

12:00 - 12:10	<p><b>32: OP015: Biomarker correlation with endoscopic outcomes in patients with Crohn's Disease: Data from CALM</b>  <b>W. Reinisch<sup>1</sup></b>, R. Panaccione<sup>2</sup>, P. Bossuyt<sup>3</sup>, F. Baert<sup>4</sup>, A. Armuzzi<sup>5</sup>, S. Travis<sup>6</sup>, S. Danese<sup>7</sup>, W.J. Sandborn<sup>8</sup>, G. D'Haens<sup>9</sup>, S. Berg<sup>10</sup>, J.-F. Maa<sup>11</sup>, J. Petersson<sup>11</sup>, E. Neimark<sup>11</sup>, A.M. Robinson<sup>11</sup>, J.-F. Colombel<sup>12</sup></p> <p><sup>1</sup>Medical University of Vienna, Vienna, Austria, <sup>2</sup>University of Calgary, Calgary, Canada, <sup>3</sup>Imelda General Hospital, Bonheiden, Belgium, <sup>4</sup>AZ Delta Roeselare-Menen, Menen, Belgium, <sup>5</sup>Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, <sup>6</sup>Oxford University Hospitals, Oxford, United Kingdom, <sup>7</sup>Istituto Clinico Humanitas, Milan, Italy, <sup>8</sup>University of California San Diego, La Jolla, United States, <sup>9</sup>Academic Medical Center, Amsterdam, The Netherlands, <sup>10</sup>AbbVie AB, Solna, Sweden, <sup>11</sup>AbbVie Inc., North Chicago, United States, <sup>12</sup>Icahn School of Medicine at Mount Sinai, New York, United States</p>
12:10 - 12:30	<p><b>33: Can the patient become an investigator?</b>                  Germari Bianchi, Milan, Italy</p>
12:30 - 13:30	<p><b>Break / Guided Poster Session</b>                  Please refer to page 74</p>
12:40 - 13:20	<p><b>Educational Lunchtime Satellite Symposia LS1 &amp; LS2 &amp; LS3 &amp; LS4</b>                  Please refer to pages 107-108</p>
13:30 - 15:00	<p><b>Scientific session 6: Best perioperative management of IBD</b>                  Yves Panis, Clichy, France                  Walter Reinisch, Vienna, Austria</p>
13:30 - 13:50	<p><b>34: Get your patient fit for surgery</b>                  Peter Irving, London, United Kingdom                  Paulo Kotze, Curitiba, Brazil; Calgary, Canada</p>
13:50 - 14:00	<p><b>35: OP016: Need for primary abdominal surgery, but not repeated surgery, has decreased – a nationwide study of temporal trends in Crohn surgery in Sweden 1990-2014</b>  <b>D. Kalman<sup>1</sup></b>, C. Nordenvall<sup>2</sup>, A. Hallqvist Everhov<sup>3</sup>, J.F. Ludvigsson<sup>4</sup>, M.C. Sachs<sup>5</sup>, A. Ekbom<sup>6</sup>, O. Olén<sup>7</sup>, P. Myrelid<sup>1</sup></p> <p><sup>1</sup>Division of surgery, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University and Department of Surgery, County Council of Östergötland, Linköping, Sweden, <sup>2</sup>Dept. of Molecular Medicine and Surgery, Karolinska Institutet; Center for Digestive Disease, Div. of Coloproctology, Karolinska University Hospital, Stockholm, Sweden, <sup>3</sup>Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, <sup>4</sup>Department Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA, Stockholm, Sweden, <sup>5</sup>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, <sup>6</sup>Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, <sup>7</sup>Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of pediatric gastroenterology and nutrition, Sachs' Children and Youth Hospital, Stockholm, Sweden</p>

OP = Oral presentation – Best abstracts

## Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien (Session 7 & 8)

14:00 - 14:20	<b>36: Enhanced postoperative recovery pathways</b> Gionata Fiorino, Milan, Italy Antonino Spinelli, Milan, Italy
14:20 - 14:30	<b>37: OP017: Transanal minimally-invasive proctectomy with ileal pouch anal anastomosis (Ta-IPAA) in patients with Ulcerative Colitis: A cohort study from the TaTME international database</b> <b>G. Pellino</b> <sup>1,2</sup> , K. Sahnun <sup>2,3</sup> , M. Penna <sup>3,4</sup> , S. Adegbola <sup>2,3</sup> , P. Chandrasinghe <sup>2,3,5</sup> , A. Spinelli <sup>6,7</sup> , R. Hompes <sup>4</sup> , J. Warusavitarne <sup>2,3</sup> , on behalf of the International TaTME Registry Collaborative. <sup>1</sup> Università della Campania, Unit of Colorectal Surgery, Naples, Italy, <sup>2</sup> St Mark's Hospital, Fistula Research Unit, London, United Kingdom, <sup>3</sup> Imperial College, Department of Surgery and Cancer, London, United Kingdom, <sup>4</sup> Oxford University Hospital NHS Trust - Churchill Hospital, Department of Colorectal Surgery, Oxford, United Kingdom, <sup>5</sup> Faculty of Medicine, University of Kelaniya, Department of Surgery, Kelaniya, Sri Lanka, <sup>6</sup> Humanitas University, Colon and Rectal Surgery Unit, Department of General Surgery, Rozzano, Italy, <sup>7</sup> Humanitas University, Humanitas University, Department of Biomedical Sciences, Rozzano, Italy
14:30 - 14:40	<b>38: OP018: High-Fat diet and inflammation drive intestinal fibrosis enhancing epithelial-mesenchymal transition through the activation of S1P3 signaling</b> C. Mascaraque <sup>1</sup> , S. Elangovan <sup>2</sup> , L. Petti <sup>1</sup> , A. Piontini <sup>2</sup> , C. Correale <sup>1</sup> , V. Arena <sup>3</sup> , B. Romano <sup>1</sup> , F. Ungaro <sup>2</sup> , V. Garlatti <sup>2</sup> , S. D'Alessio <sup>2</sup> , G. Fiorino <sup>1</sup> , A. Spinelli <sup>2,4</sup> , S. Danese <sup>1,2</sup> , <b>S. Vetrano</b> <sup>2</sup> <sup>1</sup> Humanitas Research Institute, IBD Center Laboratory of Immunology in Gastroenterology, Rozzano, Italy, <sup>2</sup> Humanitas University, Department of Biomedical Sciences, Rozzano, Italy, <sup>3</sup> Catholic University of Rome, Institute of Pathology, Rome, Italy, <sup>4</sup> Humanitas Research Institute, Colon and Rectal Surgery, Rozzano, Italy
14:40 - 15:00	<b>39: Preventive strategy after resection surgery in CD</b> Pierre Michetti, Lausanne, Switzerland
<b>15:00 - 15:30 Coffee break</b>	

OP = Oral presentation – Best abstracts

## Friday, February 16, 2018, cont.

*Scientific programme day by day (as of January 15, 2018)*

*Plenary Hall, Hall D, Messe Wien (Session 7 & 8)*

*Parallel Hall, Hall C, Messe Wien (Session 9)*

**EITHER:**

 <p>IIS Abstract Award</p>	<p><b>15:30 - 16:10</b></p> <p><b>Scientific session 7: ECCO Fellowships and Grants (Plenary Hall, Hall D, Messe Wien)</b> Gerhard Rogler, Zurich, Switzerland Dino Tarabar, Belgrade, Serbia</p>	
	15:30 - 15:37	<p><b>40: Outcomes from the ECCO-IOIBD Fellowship 2016</b> <b>The interleukin-1 pathway as a putative new target in pediatric inflammatory bowel disease</b> Sharon Veenbergen, Rotterdam, The Netherlands</p>
	15:37 - 15:44	<p><b>41: Outcomes from the ECCO-IOIBD Fellowship 2017</b> <b>Precision Medicine for IBD using advanced machine learning</b> Aria Zand, Los Angeles, United States</p>
	15:44 - 15:50	<p><b>42: Announcement of Fellowships and Grants 2018</b></p>
	15:50 - 16:00	<p><b>43: OP019: In Faecal Microbiota Transplantation (FMT) for Ulcerative Colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short chain fatty acid production are associated with remission (FOCUS study)</b> <b>S. Paramsothy<sup>1,2</sup></b>, M. Kamm<sup>3,4</sup>, S. Nielsen<sup>1</sup>, N. Deshpande<sup>1</sup>, J. Faith<sup>2</sup>, J. Clemente<sup>2</sup>, R. Paramsothy<sup>5</sup>, A. Walsh<sup>6</sup>, J. van den Bogaerde<sup>7</sup>, D. Samuel<sup>8</sup>, R. Leong<sup>8</sup>, S. Connor<sup>2</sup>, W. Ng<sup>5</sup>, E. Lin<sup>9</sup>, M. Wilkins<sup>1</sup>, J.-F. Colombel<sup>2</sup>, T. Borody<sup>9</sup>, H. Mitchell<sup>1</sup>, N. Kaakoush<sup>1</sup> <sup>1</sup>University of New South Wales, Sydney, Australia, <sup>2</sup>Icahn School of Medicine at Mount Sinai, New York, United States, <sup>3</sup>St Vincent's Hospital, Melbourne, Australia, <sup>4</sup>University of Melbourne, Melbourne, Australia, <sup>5</sup>Liverpool Hospital, Sydney, Australia, <sup>6</sup>St Vincent's Hospital, Sydney, Australia, <sup>7</sup>Nambour General Hospital, Nambour, Australia, <sup>8</sup>Bankstown-Lidcombe Hospital, Sydney, Australia, <sup>9</sup>Centre for Digestive Diseases, Sydney, Australia</p>
16:00 - 16:10	<p><b>44: OP020: The clinical determinants affect gut microbial profile of Inflammatory Bowel Disease patients</b> <b>P. Juillerat<sup>1</sup></b>, B. Yilmaz<sup>2</sup>, R. Wiest<sup>1,2</sup>, G. Rogler<sup>3</sup>, A.J. Macpherson<sup>1</sup> <sup>1</sup>Clinic for Visceral Surgery and Medicine, Gastroenterology, Bern, Switzerland, <sup>2</sup>University of Bern, Department of Biomedical Research, Bern, Switzerland, <sup>3</sup>University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland</p>	

OP = Oral presentation – Best abstracts

## Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien (Session 7 & 8)

Parallel Hall, Hall C, Messe Wien (Session 9)

<p><b>16:10 - 17:10</b></p>	<p><b>Scientific session 8: IBD Horizons (Plenary Hall, Hall D, Messe Wien)</b>          Filip Baert, Roeselare, Belgium          Gerassimos Mantzaris, Athens, Greece</p>
<p>16:10 - 16:20</p>	<p><b>45: OP021: Autologous haematopoietic stem cell transplantation for Crohn’s Disease: A retrospective study from the European Society for Blood &amp; Marrow Transplantation (EBMT) Autoimmune Diseases Working Party</b>  <b>C. Brierley<sup>1</sup></b>, C. Castilla-Llorente<sup>2</sup>, M. Labopin<sup>3</sup>, M. Badoglio<sup>3</sup>, M. Rovira<sup>4</sup>, E. Ricart<sup>5</sup>, D. Dierickx<sup>6</sup>, S. Vermeire<sup>7</sup>, P. Hasselblatt<sup>8</sup>, J. Finke<sup>9</sup>, F. Onida<sup>10</sup>, A. Cassinotti<sup>11</sup>, J. Satsangi<sup>12</sup>, M. Kazmi<sup>13</sup>, A. López-Sanromán<sup>14</sup>, D. Farge<sup>15</sup>, S. Travis<sup>16</sup>, C. Hawkey<sup>17</sup>, J. Snowden<sup>18</sup>  <sup>1</sup>Oxford University Hospitals, Department of Haematology, Oxford, United Kingdom, <sup>2</sup>Département d’Hématologie Gustave Roussy, Programme de transplantation des cellules souches, Villejuif, France, <sup>3</sup>Université Pierre et Marie Curie, Saint Antoine Hospital, EBMT Paris Study Office, Department of Haematology, Paris, France, <sup>4</sup>Hospital Clínic of Barcelona, Haematology Department, Barcelona, Spain, <sup>5</sup>Hospital Clínic of Barcelona, Gastroenterology Department, Barcelona, Spain, <sup>6</sup>University Hospitals Leuven, Department of Haematology, Leuven, Belgium, <sup>7</sup>University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, <sup>8</sup>Medical Faculty and University Hospital Freiburg, Department of Medicine II, Freiburg, Germany, <sup>9</sup>University of Freiburg, Department of Gastroenterology, Freiburg, Germany, <sup>10</sup>Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Haematology - BMT Centre, Milan, Spain, <sup>11</sup>Luigi Sacco University Hospital, Gastroenterology Unit, Milan, Italy, <sup>12</sup>Western General Hospital, University of Edinburgh, Gastro-intestinal Unit, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom, <sup>13</sup>Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital, Department of Haematology, London, United Kingdom, <sup>14</sup>Ramon y Cajal Hospital, Gastroenterology and Hepatology Department, Madrid, Spain, <sup>15</sup>AP-HP Hôpital Saint-Louis, Centre de Référence des Maladies auto-immunes systémiques Rares d’Île-de-France (site constitutif), Filière FAI2R, Internal Medicine, Autoimmune and Vascular Diseases Unit, UF 04, Paris, France, <sup>16</sup>Oxford University Hospitals, Translational Gastroenterology Unit, Oxford, United Kingdom, <sup>17</sup>Queen’s Medical Centre, Nottingham Digestive Diseases Centre, School of Clinical Sciences, Nottingham, United Kingdom, <sup>18</sup>Sheffield Teaching Hospitals NHS Foundation Trust, Department of Haematology, Sheffield, United Kingdom</p>
<p>16:20 - 16:30</p>	<p><b>46: OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: Data from the CELEST study</b>  <b>S. Schreiber<sup>1</sup></b>, L. Peyrin-Biroulet<sup>2</sup>, B. Boland<sup>3</sup>, P.D. Higgins<sup>4</sup>, A. Armuzzi<sup>5</sup>, J. Terdiman<sup>6</sup>, W. Zhou<sup>7</sup>, G. Alperovich<sup>8</sup>, F. Cataldi<sup>7</sup>, S. Goteti<sup>7</sup>, A.P. Lacerda<sup>7</sup>  <sup>1</sup>University Hospital Schleswig-Holstein, Kiel, Germany, <sup>2</sup>University of Lorraine, Nancy, France, <sup>3</sup>University of California, San Diego, San Diego, United States, <sup>4</sup>University of Michigan, Ann Arbor, United States, <sup>5</sup>Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, <sup>6</sup>University of California, San Francisco, Medical Center at Parnassus, San Francisco, United States, <sup>7</sup>AbbVie Inc., North Chicago, United States, <sup>8</sup>AbbVie Spain S.L.U., Madrid, Spain</p>

OP = Oral presentation – Best abstracts

## Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien (Session 7 & 8)

Parallel Hall, Hall C, Messe Wien (Session 9)

<p>16:30 - 16:40</p>	<p><b>47: OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in Moderately to Severely active Crohn's Disease (CD)</b>  <b>S. Danese<sup>1</sup></b>, B. Feagan<sup>2</sup>, W. Sandborn<sup>3</sup>, J.-F. Colombel<sup>4</sup>, S. Vermeire<sup>5</sup>, S. Jones<sup>6</sup>, K. Brennan<sup>6</sup>, J. Bornstein<sup>7</sup>  <sup>1</sup>Humanities University, IBD Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy, <sup>2</sup>University of Western Ontario, Robarts Clinical Trials, London, Ontario, Canada, <sup>3</sup>University of California, Inflammatory Bowel Disease Center, Division of Gastroenterology, San Diego, United States, <sup>4</sup>Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, NY, United States, <sup>5</sup>University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, <sup>6</sup>Europe Development Centre, Takeda R&amp;D, London, United Kingdom, <sup>7</sup>Takeda Pharmaceuticals International Co., Cambridge, MA, United States</p>
<p>16:40 - 16:50</p>	<p><b>48: OP024: Long-term safety and efficacy of the anti-MAbCAM monoclonal antibody SHP647 for the treatment of Crohn's Disease: The OPERA II study</b>  <b>G.R. D'Haens<sup>1</sup></b>, W. Reinisch<sup>2</sup>, S.D. Lee<sup>3</sup>, D. Tarabar<sup>4</sup>, E. Louis<sup>5</sup>, M. Klopocka<sup>6</sup>, J. Klaus<sup>7</sup>, S. Schreiber<sup>8</sup>, D.I. Park<sup>9</sup>, X. Hébuterne<sup>10</sup>, F. Cataldi<sup>11</sup>, A. Banerjee<sup>12</sup>, K. Gorelick<sup>13</sup>, W.J. Sandborn<sup>14</sup>  <sup>1</sup>Academic Medical Centre, Amsterdam, The Netherlands, <sup>2</sup>Medical University of Vienna, Vienna, Austria, <sup>3</sup>University of Washington, Seattle, United States, <sup>4</sup>Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, <sup>5</sup>University Hospital CHU of Liège, Liège, Belgium, <sup>6</sup>Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, <sup>7</sup>Universitätsklinikum Ulm, Ulm, Germany, <sup>8</sup>University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany, <sup>9</sup>Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea, <sup>10</sup>Université de Nice Sophia Antipolis, Hôpital de l'Archet, Nice, France, <sup>11</sup>Shire, Lexington, United States, <sup>12</sup>Pfizer, Cambridge, United States, <sup>13</sup>Zymo Consulting Group, Newtown Square, United States, <sup>14</sup>University of California San Diego, La Jolla, United States</p>
<p>16:50 - 17:00</p>	<p><b>49: OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn's Disease: A multicentre consortium propensity score-matched analysis</b>  M. Bohm<sup>1</sup>, S. V Sagi<sup>1</sup>, M. Fischer<sup>1</sup>, S. Kadire<sup>1</sup>, G. Tran<sup>1</sup>, M. Rahal<sup>1</sup>, S. Aniwani<sup>2</sup>, J. Meserve<sup>3</sup>, A. Weiss<sup>4</sup>, G. Kochhar<sup>5</sup>, P. Shashi<sup>6</sup>, D. Faleck<sup>7</sup>, A. Winters<sup>8</sup>, S. Chablaney<sup>9</sup>, J.L. Koliiani-Pace<sup>9</sup>, B. Boland<sup>9</sup>, S. Singh<sup>9</sup>, R. Hirten<sup>9</sup>, E. Shmidt<sup>6</sup>, K. Lasch<sup>8</sup>, M. Luo<sup>8</sup>, D. Hudesman<sup>9</sup>, S. Chang<sup>9</sup>, D. Lukin<sup>4</sup>, K. Sultan<sup>10</sup>, A. Swaminath<sup>11</sup>, N. Gupta<sup>12</sup>, C.A. Siegel<sup>7</sup>, S. Kane<sup>2</sup>, É.V. Loftus<sup>2</sup>, B.E. Sands<sup>6</sup>, W.J. Sandborn<sup>3</sup>, J.-F. Colombel<sup>6</sup>, B. Shen<sup>5</sup>, <b>P.S. Dulai<sup>1</sup></b>  <sup>1</sup>Indiana University, Indianapolis, United States, <sup>2</sup>Mayo Clinic, Rochester, United States, <sup>3</sup>University of California - San Diego, La Jolla, United States, <sup>4</sup>Montefiore Medical Center, New York, United States, <sup>5</sup>Cleveland Clinic Foundation, Cleveland, United States, <sup>6</sup>Icahn School of Medicine at Mount Sinai, New York, United States, <sup>7</sup>Dartmouth-Hitchcock Medical Center, Lebanon, United States, <sup>8</sup>Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States, <sup>9</sup>New York University (NYU), New York, United States, <sup>10</sup>North Shore University Hospital, Manhasset, United States, <sup>11</sup>Lenox Hill Hospital, New York, United States, <sup>12</sup>University of Mississippi, Jackson, United States</p>

OP = Oral presentation – Best abstracts

## Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien (Session 7 & 8)

Parallel Hall, Hall C, Messe Wien (Session 9)

17:00 - 17:10	<p><b>50: OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in Ulcerative Colitis: A multicentre consortium propensity score-matched analysis</b>  D. Faleck<sup>1</sup>, P. Shashi<sup>2</sup>, J. Meserve<sup>3</sup>, M. Rahal<sup>4</sup>, S. Kadire<sup>4</sup>, G. Tran<sup>4</sup>, A. Weiss<sup>5</sup>, A. Winters<sup>1</sup>, S. Chablaney<sup>1</sup>, S. Aniwani<sup>6</sup>, J.L. Koliani-Pace<sup>7</sup>, G. Kochhar<sup>2</sup>, B. Boland<sup>3</sup>, S. Singh<sup>3</sup>, R. Hirten<sup>1</sup>, E. Schmidt<sup>1</sup>, K. Lasch<sup>8</sup>, M. Luo<sup>8</sup>, M. Bohm<sup>4</sup>, S. V. Sagiri<sup>4</sup>, M. Fischer<sup>4</sup>, D. Hudesman<sup>9</sup>, S. Chang<sup>9</sup>, D. Lukin<sup>5</sup>, K. Sultan<sup>10</sup>, A. Swaminath<sup>11</sup>, N. Gupta<sup>12</sup>, C.A. Siegel<sup>7</sup>, B. Shen<sup>2</sup>, W.J. Sandborn<sup>3</sup>, B.E. Sands<sup>1</sup>, J.-F. Colombel<sup>1</sup>, S. Kane<sup>6</sup>, E.V. Loftus<sup>6</sup>, <b>P.S. Dulai<sup>3</sup></b></p> <p><sup>1</sup>Icahn School of Medicine at Mount Sinai, New York, United States, <sup>2</sup>Cleveland Clinic Foundation, Cleveland, United States, <sup>3</sup>University of California - San Diego, La Jolla, United States, <sup>4</sup>Indiana University, Indianapolis, United States, <sup>5</sup>Montefiore Medical Center, New York, United States, <sup>6</sup>Mayo Clinic, Rochester, United States, <sup>7</sup>Dartmouth-Hitchcock Medical Center, Lebanon, United States, <sup>8</sup>Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States, <sup>9</sup>New York University (NYU), New York, United States, <sup>10</sup>North Shore University Hospital, Manhasset, United States, <sup>11</sup>Lenox Hill Hospital, New York, United States, <sup>12</sup>University of Mississippi, Jackson, United States</p>
---------------	---

OR:

<b>15:30 - 17:10</b>	<p><b>Scientific session 9: Basic Science: Evolving concepts of IBD pathogenesis (Parallel Hall, Hall C, Messe Wien)</b>  Massimo Fantini, Rome, Italy  Britta Siegmund, Berlin, Germany</p>
15:30 - 15:50	<p><b>51: Pathogenesis of fistulising IBD</b>  Michael Scharl, Zurich, Switzerland</p>
15:50 - 16:00	<p><b>52: OP027: SUCNR1 receptor mediates intestinal fibrosis</b>  <b>J. Cosin-Roger<sup>1,2</sup></b>, D. Ortiz-Masia<sup>2</sup>, D.C. Macias-Ceja<sup>1</sup>, L. Gisbert-Ferrandiz<sup>2</sup>, P. Salvador<sup>2</sup>, M. Hausmann<sup>3</sup>, G. Rogler<sup>3</sup>, S. Calatayud<sup>2</sup>, M.D. Barrachina<sup>2</sup>  <sup>1</sup>Fisabio, Hospital Dr Peset, Valencia, Spain, <sup>2</sup>University of Valencia, Valencia, Spain, <sup>3</sup>University of Zurich, Gastroenterology, Zurich, Switzerland</p>
16:00 - 16:10	<p><b>53: OP028: Single cell RNA sequencing of t-cells in Crohn's Disease identifies tissue specific drug targets</b>  <b>E. Festen<sup>1</sup></b>, R. Weersma<sup>1</sup>, W.T. Uniken Venema<sup>1</sup>, M.D. Voskuil<sup>1</sup>, D. Graham<sup>2</sup>  <sup>1</sup>University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands, <sup>2</sup>The Broad Institute of MIT and Harvard, Cambridge, United States</p>
16:10 - 16:30	<p><b>54: Stress-induced controllers of intestinal inflammatory reactions</b>  Hermona Soreq, Jerusalem, Israel</p>
16:30 - 16:40	<p><b>55: OP029: Characterisation of Paneth cell dysfunction in XIAP-deficient mice</b>  <b>M. Yabal<sup>1</sup></b>, A. Wahida<sup>1</sup>, B. Popper<sup>2</sup>, K. Steiger<sup>3</sup>, P. Jost<sup>1</sup>  <sup>1</sup>Technical University Munich, III. Medizinische Klinik, Munich, Germany, <sup>2</sup>Ludwig-Maximilian University of Munich, Department for Cell Biology, Munich, Germany, <sup>3</sup>Technical University Munich, Institut for Pathologie, Munich, Germany</p>



Y-ECCO  
Abstract Award

OP = Oral presentation – Best abstracts

## Friday, February 16, 2018, cont.

*Scientific programme day by day (as of January 15, 2018)*

*Plenary Hall, Hall D, Messe Wien (Session 7 & 8)*

*Parallel Hall, Hall C, Messe Wien (Session 9)*

16:40 - 16:50	<p><b>56: OP030: Loss of PTPN2 in dendritic cells promotes T cell activation and expression of co-stimulatory molecules</b>  <b>L. Hering<sup>1</sup></b>, C. Gottier<sup>1</sup>, S. Lang<sup>1</sup>, B. Becher<sup>2</sup>, G. Rogler<sup>1</sup>, M. Scharl<sup>1</sup>, M. Spalinger<sup>1</sup>  <sup>1</sup>University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, <sup>2</sup>University of Zurich, Institute of Experimental Immunology, Zurich, Switzerland</p>
16:50 - 17:10	<p><b>57: How the gut speaks to the liver: Novel insights from PSC pathogenesis</b>  Herbert Tilg, Innsbruck, Austria</p>
<b>17:20 - 18:20</b>	<p><b>Digital oral presentations (Sessions 6 - 10)</b>  Please refer to pages 43-67</p>
<b>18:35-19:35</b>	<p><b>Industry sponsored satellite symposia 4a &amp; 4c &amp; 4d</b>  Please refer to pages 108-110</p>

**OP** = Oral presentation – Best abstracts



European  
Crohn's and Colitis  
Organisation

# ECCO UR-CARE

Online  
now!

United Assessment and Registries for Clinical Research



The IBD Database for your patient records and your research studies

## What to expect

- Comprehensive registry capturing demographics, environmental factors, clinical characteristics, examinations and therapeutic interventions in IBD
- Ground-breaking cross-project cooperation
- Retro- & prospective data collection and evaluation
- Autonomous data management offered to study groups
- Precise data ownership rules

## Highlights

- Quality of care assessment
- High mobility & continuity of care for patients
- Different options of printable patient reports
- Sophisticated, user friendly data export
- Real-life test version
- Core paediatric variables available
- Validation study: Publication in early 2018

Scan and visit

[www.ecco-ibd.eu/ur-care](http://www.ecco-ibd.eu/ur-care)



## Saturday, February 17, 2018

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

<b>Scientific session 10: Growing up with IBD safely</b>	
<b>08:30 - 10:20</b>	Arie Levine, Tel Aviv, Israel Murat Toruner, Ankara, Turkey
 IIS Abstract Award	08:30 - 08:50 <b>58: Safe use of drugs in paediatric and elderly populations</b> Pieter Hindryckx, Ghent, Belgium Gigi Veereman, Brussels, Belgium
	08:50 - 09:00 <b>59: OP031: Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn's Disease: 12 month data from the PANTS study</b> <b>N.A. Kennedy<sup>1</sup></b> , G. Heap <sup>1,2</sup> , B. Hamilton <sup>1</sup> , G.J. Walker <sup>1</sup> , C. Bewshea <sup>1</sup> , S. Bouris <sup>3</sup> , J. Goodhand <sup>1</sup> , PANTS Investigator Consortium, T. Ahmad <sup>1</sup> <sup>1</sup> University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom, <sup>2</sup> Abbvie, Chicago, United States, <sup>3</sup> St Mark's Hospital, IBD Unit, London, United Kingdom
 Y-ECCO Abstract Award	09:00 - 09:10 <b>60: OP032: Outcome of pregnancies in female IBD patients treated with vedolizumab</b> <b>A. Moens<sup>1,2</sup></b> , K. van Hoeve <sup>2,3</sup> , E. Humblet <sup>4</sup> , J.-F. Rahier <sup>5</sup> , P. Bossuyt <sup>6</sup> , S. Dewit <sup>7</sup> , D. Franchimont <sup>8</sup> , E. Macken <sup>9</sup> , J. Nijis <sup>10</sup> , A. Posen <sup>11</sup> , A. Van Hooetegem <sup>12</sup> , W. Van Moerkercke <sup>13</sup> , S. Vermeire <sup>1,2</sup> , M. Ferrante <sup>1,2</sup> <sup>1</sup> University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, <sup>2</sup> KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, <sup>3</sup> University Hospitals Leuven, Department of Paediatric gastroenterology, Leuven, Belgium, <sup>4</sup> Ziekenhuis Oost-Limburg-Campus Sint-Jan, Department of Gastroenterology and Hepatology, Genk, Belgium, <sup>5</sup> CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium, <sup>6</sup> Imeldaziekenhuis, Department of Gastroenterology and Hepatology, Bonheiden, Belgium, <sup>7</sup> Mariaziekenhuis Noord-Limburg, Department of Gastroenterology and Hepatology, Overpelt, Belgium, <sup>8</sup> Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, <sup>9</sup> University Hospital Antwerp, Department of Gastroenterology and Hepatology, Antwerp, Belgium, <sup>10</sup> Sint-Trudo Ziekenhuis, Department of Gastroenterology and Hepatology, Sint-Truiden, Belgium, <sup>11</sup> AZ Vesalius, Department of Gastroenterology and Hepatology, Tongeren, Belgium, <sup>12</sup> AZ Klina, Department of Gastroenterology and Hepatology, Brasschaat, Belgium, <sup>13</sup> AZ Groeninge, Department of Gastroenterology and Hepatology, Kortrijk, Belgium
	09:10 - 09:30 <b>61: ESPGHAN-ECCO Guidelines: Update on Paediatric UC Treatment</b> Richard Russell, Glasgow, United Kingdom Dan Turner, Jerusalem, Israel
	09:30 - 09:40 <b>62: OP033: The effect of tofacitinib on serum lipids and cardiovascular safety in patients with Ulcerative Colitis – results from the tofacitinib Ulcerative Colitis clinical programme</b> B.E. Sands <sup>1</sup> , P.R. Taub <sup>2</sup> , <b>B.G. Feagan<sup>3</sup></b> , A. Armuzzi <sup>4</sup> , G.S. Friedman <sup>5</sup> , M. Moscariello <sup>5</sup> , N. Lawendy <sup>5</sup> , R.D. Pedersen <sup>5</sup> , G. Chan <sup>5</sup> , C.I. Nduaka <sup>5</sup> , D. Quirk <sup>5</sup> , L. Salese <sup>5</sup> , C. Su <sup>5</sup> <sup>1</sup> Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, United States, <sup>2</sup> UC San Diego School of Medicine, Division of Cardiovascular Medicine, La Jolla, CA, United States, <sup>3</sup> Western University, Robarts Clinical Trials, London, ON, Canada, <sup>4</sup> Presidio Columbus Fondazione Policlinico Gemelli Università Cattolica, IBD Unit, Rome, Italy, <sup>5</sup> Pfizer Inc, Collegeville, PA, United States

OP = Oral presentation – Best abstracts

## Saturday, February 17, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

09:40 - 09:50

**63: OP034: The initiation of thiopurines in elderly patients with Inflammatory Bowel Disease is associated with an increased risk of adverse effects: A case-control study of the enaida registry**

**M. Calafat**<sup>1,2</sup>, M. Mañosa<sup>3,4</sup>, F. Cañete<sup>3</sup>, J. Panés<sup>4,5</sup>, V. García Sánchez<sup>4,6</sup>, M. Calvo<sup>7</sup>, F. Rodríguez-Moranta<sup>8</sup>, C. Taxonera<sup>9</sup>, P. Nos<sup>4,10</sup>, A. López Sanromán<sup>11</sup>, M.D. Martín Arranz<sup>12</sup>, M. Mínguez<sup>13</sup>, J.P. Gisbert<sup>4,14</sup>, S. García-López<sup>15</sup>, R. de Francisco<sup>16</sup>, F. Gomollón<sup>4,17</sup>, X. Calvet<sup>4,18</sup>, E. Garcia-Planella<sup>19</sup>, M. Rivero<sup>20</sup>, J. Martínez-Cadilla<sup>21</sup>, F. Argüelles<sup>22</sup>, L. Arias García<sup>23</sup>, M. Cimavilla<sup>24</sup>, Y. Zabana<sup>4,25</sup>, L. Márquez<sup>26</sup>, A. Gutiérrez<sup>4,27</sup>, G. Alcáin<sup>28</sup>, P. Martínez Montiel<sup>29</sup>, J. Lázaro<sup>30</sup>, D. Busquets<sup>31</sup>, M.F. García Sepulcre<sup>32</sup>, C. Verdejo<sup>33</sup>, F. Bermejo<sup>34</sup>, M. Mora<sup>35</sup>, D. Monfort<sup>36</sup>, P. Romero<sup>37</sup>, B. Velayos<sup>38</sup>, C. Rodríguez<sup>39</sup>, A. Rodríguez<sup>40</sup>, O. Merino<sup>41</sup>, A. Rodríguez-Pescador<sup>42</sup>, L. Bujanda<sup>4,43</sup>, Y. Ber<sup>44</sup>, M. Vela<sup>45</sup>, O. Roncero<sup>46</sup>, J.M. Huguet<sup>47</sup>, O. García-Bosch<sup>48</sup>, M. Barreiro-de-Acosta<sup>49</sup>, R.E. Madrigal<sup>50</sup>, L. Ramos<sup>51</sup>, M. Van Domselaar<sup>52</sup>, P. Almela<sup>53</sup>, J. Llaó<sup>54</sup>, A.J. Lucendo<sup>4,55</sup>, C. Muñoz Vilafraña<sup>56</sup>, Á. Abad<sup>57</sup>, M. Charro<sup>58</sup>, J. Legido<sup>59</sup>, J. Riera<sup>1</sup>, S. Khorrami<sup>60</sup>, E. Sesé<sup>61</sup>, A.M. Traperó<sup>62</sup>, E. Domènech<sup>3,4</sup>

<sup>1</sup>Hospital Son Llàtzer, Palma, Spain, <sup>2</sup>Universitat Autònoma de Barcelona, Barcelona, Spain, <sup>3</sup>Hospital Universitari Germans Trias i Pujol, Badalona, Spain, <sup>4</sup>CIBERehd Instituto de Salud Carlos III, Madrid, Spain, <sup>5</sup>Hospital Clínic, Barcelona, Spain, <sup>6</sup>Hospital Reina Sofía, Córdoba, Spain, <sup>7</sup>Hospital Puerta de Hierro, Majadahonda, Spain, <sup>8</sup>Hospital Bellvitge, L'Hospitalet de Llobregat, Spain, <sup>9</sup>Hospital Clínico San Carlos, Madrid, Spain, <sup>10</sup>Hospital La Fe, Valencia, Spain, <sup>11</sup>Hospital Ramón y Cajal, Madrid, Spain, <sup>12</sup>Hospital La Paz, Madrid, Spain, <sup>13</sup>Hospital Clínico de Valencia, Valencia, Spain, <sup>14</sup>Hospital La Princesa, Madrid, Spain, <sup>15</sup>Hospital Universitario Miguel Servet, Zaragoza, Spain, <sup>16</sup>Hospital Universitario Central de Asturias, Oviedo, Spain, <sup>17</sup>Hospital Clínico Lozano Blesa, Zaragoza, Spain, <sup>18</sup>Hospital Parc Taulí, Sabadell, Spain, <sup>19</sup>Hospital Santa Creu i Sant Pau, Barcelona, Spain, <sup>20</sup>Hospital Universitario Marqués de Valdecilla, Santander, Spain, <sup>21</sup>Complejo Hospital Universitario de Vigo, Vigo, Spain, <sup>22</sup>Hospital Virgen de la Macarena, Sevilla, Spain, <sup>23</sup>Hospital Universitario Burgos, Burgos, Spain, <sup>24</sup>Hospital Río Hortega, Valladolid, Spain, <sup>25</sup>Hospital Mutua de Terrassa, Terrassa, Spain, <sup>26</sup>Hospital del mar, Barcelona, Spain, <sup>27</sup>Hospital General Universitario de Alicante, Alicante, Spain, <sup>28</sup>Hospital Clínico de Málaga, Málaga, Spain, <sup>29</sup>Hospital 12 de octubre, Madrid, Spain, <sup>30</sup>Hospital Universitario Fundación Alcorcón, Alcorcón, Spain, <sup>31</sup>Hospital Dr Josep Trueta, Girona, Spain, <sup>32</sup>Hospital General Universitario de Elche, Elche, Spain, <sup>33</sup>Hospital General de Ciudad Real, Ciudad Real, Spain, <sup>34</sup>Hospital Universitario Fuenlabrada, Fuenlabrada, Spain, <sup>35</sup>Hospital Manises, Manises, Spain, <sup>36</sup>Consorci sanitari de Terrassa, Terrassa, Spain, <sup>37</sup>Hospital Santa Lucía, Cartagena, Spain, <sup>38</sup>Hospital Clínico Universitario Valladolid, Valladolid, Spain, <sup>39</sup>CH de Navarra, Pamplona, Spain, <sup>40</sup>Hospital Universitario de Salamanca, Salamanca, Spain, <sup>41</sup>Hospital de Cruces, Barakaldo, Spain, <sup>42</sup>Hospital Galdakao, Galdakao, Spain, <sup>43</sup>Instituto Bionostia UPV/EHU, (Donostia, Spain, <sup>44</sup>Hospital San Jorge, Huesca, Spain, <sup>45</sup>Hospital Nuestra Sra Candelaria, Sta Cruz Tenerife, Spain, <sup>46</sup>Hospital Mancha Centro, Alcazar de San Juan, Spain, <sup>47</sup>Hospital General Universitario Valencia, Valencia, Spain, <sup>48</sup>Hospital Moisés Broggi, St Joan Despí, Spain, <sup>49</sup>CH Santiago, Santiago de Compostela, Spain, <sup>50</sup>CH de Palencia, Palencia, Spain, <sup>51</sup>Hospital Universitario de Canarias, La Laguna, Spain, <sup>52</sup>Hospital Torrejón, Torrejón, Spain, <sup>53</sup>HG de Castelló, Castelló, Spain, <sup>54</sup>Hospital Sant Joan de Déu-Althaia, Manresa, Spain, <sup>55</sup>Hospital General de Tomelloso, Tomelloso, Spain, <sup>56</sup>Hospital Basurto, Bilbao, Spain, <sup>57</sup>Hospital Viladecans, Viladecans, Spain, <sup>58</sup>Hospital Royo Vilanova, Zaragoza, Spain, <sup>59</sup>Hospital General, Segovia, Spain, <sup>60</sup>Hospital Son Espases, Palma, Spain, <sup>61</sup>Hospital Arnau de Vilanova, Lleida, Spain, <sup>62</sup>Complejo Hospitalario de Jaén, Jaén, Spain

OP = Oral presentation – Best abstracts

## Saturday, February 17, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

09:50 - 10:00	<p><b>64: OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations</b>  <b>G. Walker</b><sup>1,2</sup>, J. Harrison<sup>3</sup>, M. Voskuil<sup>4</sup>, G. Heap<sup>1,2</sup>, N. Heerasing<sup>1,2</sup>, P. Hendy<sup>1,2</sup>, J. Koskela<sup>5,6</sup>, M. Daly<sup>5,6</sup>, H. Sokol<sup>7</sup>, D. McGovern<sup>8</sup>, R. Weersma<sup>4</sup>, C. Bewshea<sup>1</sup>, M. Weedon<sup>3</sup>, J. Goodhand<sup>1,2</sup>, N. Kennedy<sup>1,2</sup>, T. Ahmad<sup>1,2</sup>, IBD Pharmacogenetics Study Group  <sup>1</sup>University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom, <sup>2</sup>Royal Devon &amp; Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom, <sup>3</sup>University of Exeter, Exeter Medical School Bioinformatics Team, Exeter, United Kingdom, <sup>4</sup>University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands, <sup>5</sup>The Broad Institute of MIT and Harvard, Cambridge, United States, <sup>6</sup>Massachusetts General Hospital, Analytical and Translational Genetics Unit, Boston, United States, <sup>7</sup>Hôpital Saint-Antoine, Service de Gastroentérologie et Nutrition, Paris, France, <sup>8</sup>Cedars-Sinai Medical Center, Inflammatory Bowel Disease Center, Division of Gastroenterology, Los Angeles, United States</p>
10:00 - 10:20	<p><b>65: Monitoring and improving safety of new agents</b>  Miguel Regueiro, Pittsburgh, United States</p>
<p><b>10:20 - 10:50 Coffee break</b></p>	
<p><b>Scientific session 11: Colorectal Cancer in IBD</b>  <b>10:50 - 12:20</b> Jessica de Bruyn, Amsterdam, The Netherlands  Mircea Diculescu, Bucharest, Romania</p>	
10:50 - 11:10	<p><b>66: Molecular basis of dysplasia in IBD – clues for cancer prevention therapies?</b>  Laurence Egan, Galway, Ireland</p>
11:10 - 11:20	<p><b>67: OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with Inflammatory Bowel Disease: A nationwide cohort study</b>  <b>M. de Jong</b><sup>1</sup>, S. van Tilburg<sup>1,2</sup>, L. Nissen<sup>2</sup>, W. Kievit<sup>1</sup>, I. Nagtegaal<sup>3</sup>, F. Hoentjen<sup>1</sup>, L. Derikx<sup>1,2</sup>  <sup>1</sup>Radboud University Nijmegen Medical Centre, Gastroenterology and Hepatology, Nijmegen, The Netherlands, <sup>2</sup>Jeroen Bosch Hospital, Gastroenterology and hepatology, S Hertogenbosch, The Netherlands, <sup>3</sup>Radboud University Nijmegen Medical Centre, Pathology, Nijmegen, The Netherlands</p>
11:20 - 11:40	<p><b>68: Serrated lesions in IBD</b>  Roger Feakins, London, United Kingdom  Maria Pellise, Barcelona, Spain</p>
11:40 - 11:50	<p><b>69: OP037: Risk of cancer in Inflammatory Bowel Disease patients is associated with age and recent use of immunomodulators, while biologics and aminosalicylates are protective factors – a cross-sectional and follow-up analysis of the Swiss IBD cohort Study</b>  <b>T. Greuter</b><sup>1</sup>, S. Scharl<sup>1</sup>, C. Barthel<sup>1</sup>, J.-B. Rossel<sup>2</sup>, L. Biedermann<sup>1</sup>, B. Misselwitz<sup>1</sup>, S. Vavricka<sup>1</sup>, G. Rogler<sup>1</sup>, M. Scharl<sup>1</sup>, on behalf of the Swiss IBD Cohort Study Group  <sup>1</sup>University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, <sup>2</sup>University Hospital Lausanne - CHUV, Institute of Social and Preventive Medicine, Lausanne, Switzerland</p>



OP = Oral presentation – Best abstracts

## Saturday, February 17, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

11:50 - 12:00	<b>70: OP038: Hobit- and Blimp1-driven tissue resident memory T cells critically control chronic intestinal inflammation</b> <b>S. Zundler<sup>1</sup></b> , E. Becker <sup>1</sup> , M. Spocinska <sup>1</sup> , L. Parga-Vidal <sup>2</sup> , R. Stark <sup>2</sup> , R. Atreya <sup>1</sup> , T. Rath <sup>1</sup> , M. Leppkes <sup>1</sup> , C. Neufert <sup>1</sup> , I. Atreya <sup>1</sup> , K. van Gisbergen <sup>2</sup> , M.F. Neurath <sup>1</sup> <sup>1</sup> University of Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany, <sup>2</sup> Academic Medical Center, Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands
12:00 - 12:20	<b>71: Endoscopic resection of dysplasia – mucosal and submucosal resection</b> Raf Bisschops, Leuven, Belgium
<b>12:20 - 12:50</b>	<b>Scientific session 12: ECCO Lecture</b> Silvio Danese, Milan, Italy Julián Panés, Barcelona, Spain
12:20 - 12:50	<b>72: Is translation the way to treatment personalisation?</b> Yehuda Chowers, Haifa, Israel
<b>12:50 - 12:55</b>	<b>73: Awards and closing remarks</b> Julián Panés, Barcelona, Spain
<b>12:55 - 13:00</b>	<b>74: The ECCO Film</b>



European  
Crohn's and Colitis  
Organisation

Vienna  
Austria

# Abstracts 2018



Look out for your voucher in your  
Final Programme!

## **ECCO Key USB Drive**

- Contains all ECCO'18 Abstracts
- Pick up at ECCO Booth

Scan and contact the ECCO Office  
[www.ecco-ibd.eu](http://www.ecco-ibd.eu)





# Abstract presentation format

## *Oral presentations (OP)*

Out of 1,012 accepted abstracts, the 38 best submitted abstracts have been chosen for oral presentation by a panel of referees and will be presented during the scientific programme of the ECCO Congress. For the presentation title and schedule, please refer to the scientific congress programme per day.

**Note: Oral poster presentations will not be displayed as hard copy posters.**

## *Digital oral presentations (DOP)*

Abstracts have been selected from the ranking by taking ~90 abstracts after those 38 selected for presentation in the scientific programme. These abstracts will be presented as digital oral presentations, with a 5 minute oral presentation in several rooms in the Congress Centre at Messe Wien on Thursday, February 15, 2018 from 17:30-18:30 or on Friday, February 16, 2018 from 17:20-18:20.

The schedule and selected abstracts for each digital oral presentation room can be found on pages 43-69.

**Note: Digital oral presentations will not be displayed as hard copy posters.**

## **DOP award ceremony:**

On Saturday, February 17, 2018 from 12:50-12:55 the poster prizes will be awarded for the ten 'Best Posters'. One abstract of each digital oral presentation room has been nominated by the chairs of the respective session.

Please note that this year for the eighth time, the ECCO Congress hosts a separate nurse poster section in the poster exhibition area in the exhibition hall in Hall C. Please find the link to nurse posters on page 74.

## **DOP award ceremony is chaired by:**

Julián Panés (Spain)

Silvio Danese (Italy)

Laurent Peyrin-Biroulet (France)

Florian Rieder (United States)

Pascal Juillerat (Switzerland)

## *Hard copy poster presentations*

All remaining accepted abstracts are selected for "hard copy poster presentation" and are listed on the ECCO Website ([www.ecco-ibd.eu/ecco18](http://www.ecco-ibd.eu/ecco18)). An overview of the abstract topics including a link to the respective hard copy posters can be found on pages 73-74. Hard copy posters will be installed on poster walls in the poster exhibition area in the exhibition hall in Hall C and will be available for viewing throughout the Congress.

## Reviewers

ECCO gratefully thanks the following reviewers for their valuable time and effort in reviewing abstracts:

### (i) Basic Science

Ingrid Arijis (Belgium), Giorgio Bamias (Greece), Mathilde Body (France), Paula Borrhalho Nunes (Portugal), Oliver Brain (United Kingdom), Flavio Caprioli (Italy), Alessandra Geremia (United Kingdom), Giovanni Monteleone (Italy), Nick Powell (United Kingdom), Gerhard Rogler (Switzerland), Franco Scaldaferrì (Italy), Michael Scharl (Switzerland), Anja Schirbel (Germany), Andrew Stagg (United Kingdom), Monika Tripathi (United Kingdom), Holm Uhlig (United Kingdom), Dominique Velin (Switzerland), Gwenny Fuhler (The Netherlands), Michel Maillard (Switzerland), Britta Siegmund (Germany), Azucena Salas (Spain), Dror Shouval (Israel), Charlotte Hedin (Sweden), Heitor Siffert de Souza (Brazil), Gwo-Tzer Ho (United Kingdom), James Lee (United Kingdom), Mamoru Watanabe (Japan)

### (ii) Clinical: Diagnosis and Outcome

Marco Daperno (Italy), Marietta Iacucci (United Kingdom), Njegica Jojic (Serbia), Silvija Cukovic Cavka (Croatia), Lissy de Ridder (The Netherlands), Corinne Gower-Rousseau (France), Philippe Marteau (France), Richard Pollok (United Kingdom), Guillaume Savoye (France), David Wilson (United Kingdom), Marko Banic (Croatia), Arzu Ensari (Turkey), Roger Feakins (United Kingdom), Richard Hansen (United Kingdom), Stéphane Nancey (France), Florian Rieder (United States), Murat Törüner (Turkey), Matthieu Allez (France), Marina Aloï (Italy), Vito Annese (Italy), Oliver Bachmann (Germany), Filip Baert (Belgium), Carsten Büning (Germany), Cristina Cijevschi (Romania), Gert De Hertogh (Belgium), Martine De Vos (Belgium), Mircea Diculescu (Romania), Glen Doherty (Ireland), Lionata Fiorino (Italy), Marcus Harbord (United Kingdom), Ailsa Hart (United Kingdom), Guru Iyngkaran (Australia), Ayesha Akbar (United Kingdom), Naila Arebi (United Kingdom), Raja Atreya (Germany), Manuel Barreiro de Acosta (Spain), Laurent Beaugier (France), Shomron Ben-Horin (Israel), Ingrid Berset (Norway), Dominik Bettenworth (Germany), Bernd Bokemeyer (Germany), Daniel Burger (United Kingdom), Andrea Cassinotti (Italy), Fabiana Castiglione (Italy), Yehuda Chowers (Israel), Francesco Colombo (Italy), Marilia Cravo (Portugal), Silvio Danese (Italy), Vincenza Di Leo (Italy), Axel Dignass (Germany), Renata D'Inca (Italy), John Mansfield (United Kingdom), Bram Verstockt (Belgium), Emma Calabrese (Italy), Vincenzo Villanacci (Italy), Stuart Taylor (United Kingdom)

### (iii) Clinical: Therapy and Clinical Observation

Franck Carbonnel (France), Katrine Carlsen (Denmark), Mario Cottone (Italy), Rami Eliakim (Israel), Daniel Ginard Vicens (Spain), Javier Perez Gisbert (Spain), Peter Irving (United Kingdom), Sanja Kolacek (Croatia), Paulo Kotze (Brazil), Tom Oresland (Norway), Herbert Tilg (Austria), Niels Vande Casteele (Belgium), Laurence Egan (Ireland), James Lindsay (United Kingdom), Jonathan Rhodes (United Kingdom), Alessandro Armuzzi (Italy), Ulf Müller-Ladner (Germany), Laurent Peyrin-Biroulet (France), Simon Travis (United Kingdom), Kostas Katsanos (Greece), Uri Kopylov (Israel), David Laharie (France), Charlie W. Lees (United Kingdom), Edouard Louis (Belgium), Fernando Magro (Portugal), Gerassimos Mantzaris (Greece), Remo Panaccione (Canada), Konstantinos Papadakis (Greece), Tim Raine (United Kingdom), Elena Ricart (Spain), Xavier Roblin (France), Nik Sheng Ding (Australia), Andreas Sturm (Germany), Dino Tarabar (Serbia), Gert van Assche (Belgium/Canada), Stephan Vavricka (Switzerland), Mahmood Wahed (United Kingdom), Janindra Warusavitarné (United Kingdom), Tomas Douda (Czech Republic), Marc Ferrante (Belgium), Kristina Gecse (Hungary), Paolo Gionchetti

(Italy), Adrian Goldis (Romania), Samuel Huber (Germany), Pascal Juillerat (Switzerland), Konstantinos Karmiris (Greece), Iskren Kotzev (Bulgaria), Ioannis Koutroubakis (Greece), Zeljko Krznaric (Croatia), Ebbe Langholz (Denmark), Scott Levison (United Kingdom), Loris Riccardo Lopetuso (Italy), Juliano Ludvig (Brazil), Christian Maaser (Germany), Jeroen Maljaars (The Netherlands), Pierre Michetti (Switzerland), Paula Ministro (Portugal), Tamas Molnar (Hungary), Iiril L. K. Monstad (Norway), Siew Ng (China), Harald Peeters (Belgium), Guillaume Pineton de Chambrun (France), Valérie Pittet (Switzerland), Francisco Portela (Portugal), Catherine Reenaers (Belgium), Iago Rodríguez Lago (Spain), Gianluca Sampietro (Italy), Shaji Sebastian (United Kingdom), Andreas Stallmach (Germany), Joana Torres (Portugal), John Triantafyllidis (Greece), Janneke van der Woude (The Netherlands), Severine Vermeire (Belgium), Sebastian Zeissig (Germany), Yoram Bouhnik (France), Jaroslav Kierkus (Poland), Pavel Kohout (Czech Republic), Nitsan Maharshak (Israel), John Mansfield (United Kingdom), Kerri Novak (Canada), Yves Panis (France), Gareth Parkes (United Kingdom), Bruce Sands (United States), Giuseppe Sica (Italy), Laurents Stassen (The Netherlands), Kenji Watanabe (Japan), Willem Bemelman (The Netherlands), Gottfried Novacek (Austria), Konstantinos Papamichail (Greece), Dan Turner (Israel), Boris Vucelic (Croatia), Alissa Walsh (Australia), Edyta Zagorowicz (Poland), Hans Strid (Sweden), Robert Koch (Austria), Joline de Groof (The Netherlands), Marieke Pierik (The Netherlands), Triana Lobaton (Spain)

**(iv) Epidemiology**

Dana Duricová (Czech Republic), Selwyn Odes (Israel), Morten Vatn (Norway), Gabor Veres (Hungary), Peter Lakatos (Hungary), Hannah Gordon (United Kingdom), Aykut F. Celik (Turkey), Jonas Halfvarson (Sweden), Jimmy Limdi (United Kingdom), Bjorn Moum (Norway), Bas Oldenburg (The Netherlands), Claudia Ott (Germany), Laimas Jonaitis (Lithuania), Simone Saibeni (Italy), Jochen Maul (Germany), Zhihua Ran (China)

**(v) Genetics**

Shay Ben-Shachar (Israel), Andre Franke (Germany), Miles Parkes (United Kingdom), Jack Satsangi (United Kingdom), Jeffrey Barrett (United Kingdom), John Mansfield (United Kingdom), Bram Verstockt (Belgium)

**(vi) Microbiology**

Gregor Gorkiewicz (Austria), Philippe Seksik (France), Maria Gazouli (Greece), Harry Sokol (France), Markus Tschurtschenthaler (Austria)

**(vii) Nurses**

Palle Bager (Denmark), Usha Chauhan (Canada), Lesley Dibley (United Kingdom), Lisbet Gerdes (Denmark), Kay Greveson (United Kingdom), Karen Kemp (United Kingdom), Matteo Martinato (Italy), Liesbeth Moortgat (Belgium), Lisa Younge (United Kingdom)



European  
Crohn's and Colitis  
Organisation

# Why submit your research to JCC?



## Prompt and professional peer review

JCC publishes research that has undergone rigorous peer review, including an initial screening by one of the Editors and recommendations by independent reviewers. The average time from submission to first decision is two weeks.

### Fast publication speeds

- Fast Advance Access publication of the author manuscript version within one week of acceptance making your work discoverable faster.

### High Impact Factor

- With its 2016 Impact Factor, which now stands at 5.813, JCC ranks highly among gastroenterology and hepatology journals.


### Wide dissemination

- Publishing in JCC will ensure that your article will be seen, read and cited by your research community.

Scan and log in at  
[www.ecco-ibd.eu](http://www.ecco-ibd.eu)



# Digital oral presentations (DOP)



For details, please refer to p. 39.

Please find below an overview of all DOP sessions. The schedule and selected abstracts for each digital oral presentation room can be found on pages 44-69. Please make sure to be there on time.

<b>Digital Oral Presentation Session 1</b> (please refer to page 44-47)	<b>Current understanding efficacy and safety of biologics</b> Miguel Regueiro, Pittsburgh, United States Britta Siegmund, Berlin, Germany
<b>Digital Oral Presentation Session 2</b> (please refer to page 48-49)	<b>IBD Genetics</b> Isabelle Cleynen, Leuven, Belgium Miles Parkes, Cambridge, United Kingdom
<b>Digital Oral Presentation Session 3</b> (please refer to page 50-52)	<b>Old and new immunomodulators</b> Krisztina Gecse, Amsterdam, The Netherlands Ailsa Hart, London, United Kingdom
<b>Digital Oral Presentation Session 4</b> (please refer to page 53-55)	<b>Practicalities of IBD patient care</b> Joana Torres, Lisbon, Portugal Stephan Vavricka, Zurich, Switzerland
<b>Digital Oral Presentation Session 5</b> (please refer to page 56-58)	<b>Best surgical management of IBD</b> Antonino Spinelli, Milan, Italy Oded Zmora, Tel Aviv, Israel
<b>Digital Oral Presentation Session 6</b> (please refer to page 59-61)	<b>Optimisation of biologic therapies</b> Axel Dignass, Frankfurt, Germany Paula Ministro, Viseu, Portugal
<b>Digital Oral Presentation Session 7</b> (please refer to page 61-63)	<b>Novel therapies</b> Marc Ferrante, Leuven, Belgium Peter Irving, London, United Kingdom
<b>Digital Oral Presentation Session 8</b> (please refer to page 63-65)	<b>Treatment strategies</b> Antonio López-Sanromán, Madrid, Spain Christian Maaser, Luneburg, Germany
<b>Digital Oral Presentation Session 9</b> (please refer to page 66-68)	<b>Advances in IBD Pathophysiology</b> TBC Jesús Rivera-Nieves, San Diego, United States
<b>Digital Oral Presentation Session 10</b> (please refer to page 68-69)	<b>Microbes, food and cancer in IBD</b> Gionata Fiorino, Milan, Italy Arie Levine, Tel Aviv, Israel

Please find the detailed schedule for each session on the following pages:

**Thursday, February 15, 2018**

<p><b>17:30 - 18:30</b></p>	<p><b>Digital Oral Presentation Session 1 – Current understanding efficacy and safety of biologics</b>                  Room: Lehar 1-3                  Miguel Regueiro, Pittsburgh, United States                  Britta Siegmund, Berlin, Germany</p>
<p>17:30 - 17:36</p>	<p><b>DOP001: Effectiveness and safety of vedolizumab in anti-TNF naive patients with Inflammatory Bowel Disease – a multicentre retrospective European Crohn’s and Colitis Organisation study</b>  <b>U. Kopylov<sup>1</sup></b>, B. Verstockt<sup>2</sup>, L. Biedermann<sup>3</sup>, S. Sebastian<sup>4</sup>, D. Pugliese<sup>5</sup>, E. Sonnenberg<sup>6</sup>, P.R. Steinhagen<sup>6</sup>, N. Arebi<sup>7</sup>, Y. Ron<sup>8</sup>, T. Kucharzik<sup>9</sup>, X. Roblin<sup>10</sup>, B. Ungar<sup>1</sup>, A. Bar-Gil Shitrit<sup>11</sup>, S. Ardizzone<sup>12</sup>, P. Molander<sup>13</sup>, M. Coletta<sup>14</sup>, L. Peyrin-Biroulet<sup>15</sup>, P. Bossuyt<sup>16</sup>, I. Avni-Biron<sup>17</sup>, E.i. Tsoukal<sup>18</sup>, M. Allocca<sup>19</sup>, K. Katsanos<sup>20</sup>, T. Raine<sup>21</sup>, T. Sipponen<sup>22</sup>, G. Fiorino<sup>23</sup>, S. Ben-Horin<sup>1</sup>, R. Eliakim<sup>1</sup>, A. Armuzzi<sup>5</sup>, B. Siegmund<sup>6</sup>, D.C. Baumgart<sup>6</sup>, N. Kamperidis<sup>7</sup>, N. Maharshak<sup>8</sup>, C. Maaser<sup>9</sup>, G. Mantzaris<sup>18</sup>, H. Yanai<sup>17</sup>, D. Christodoulou<sup>20</sup>, I. Dotan<sup>17</sup>, M. Ferrante<sup>2</sup></p> <p><sup>1</sup>Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, <sup>2</sup>KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, <sup>3</sup>University of Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, <sup>4</sup>Hull Royal Infirmary, Hull &amp; East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, United Kingdom, <sup>5</sup>IBD Unit, Complesso Integrato Columbus, Fondazione Policlinico Gemelli, Università Cattolica, internal Medicine, Gastroenterology Division, Rome, Italy, <sup>6</sup>Charité - University Hospital Berlin, Campus Benjamin Franklin, Department of Gastroenterology and Medicine I, Berlin, Germany, <sup>7</sup>LNWH St. Marks Hospital, Harrow, United Kingdom, <sup>8</sup>Tel Aviv Medical Center, IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel, <sup>9</sup>Hospital Lüneburg, Department of Internal Medicine and Gastroenterology, Lüneburg, Germany, <sup>10</sup>CHU de Saint-Etienne, Gastroenterology, Saint-Etienne, France, <sup>11</sup>Shaare Zedek Medical Center, Digestive diseases Institute, Jerusalem, Israel, <sup>12</sup>ASST Fatebenefratelli - Sacco, Milan, Italy, <sup>13</sup>Helsinki University Central Hospital, Department of Gastroenterology, Department of Medicine, Helsinki, Finland, <sup>14</sup>Department of Pathophysiology and Transplantation, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy, Gastroenterology, Milan, Italy, <sup>15</sup>Nancy University Hospital, Université de Lorraine, Hepatogastroenterology, Vandoeuvre-lès-Nancy, France, <sup>16</sup>Imelda GI Clinical Research Center, Gastroenterology, Bonheiden, Belgium, <sup>17</sup>Rabin Medical Center, Department of Gastroenterology and Liver Diseases, Petach Tikva, Israel, <sup>18</sup>Evaggelimos Hospital, Gastroenterology, Athens, Greece, <sup>19</sup>Humanitas Gradenigo, Gastroenterology, Turin, Italy, <sup>20</sup>University of Ioannina, Gastroenterology, Ioannina, Greece, <sup>21</sup>Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology, Cambridge, United Kingdom, <sup>22</sup>Helsinki University Central Hospital – Meilahti Hospital, Department of Gastroenterology, Helsinki, Finland, <sup>23</sup>Humanitas Research Hospital, Department of Gastroenterology, IBD Center, Rozzano, Italy</p>

Thursday, February 15, 2018, cont.

17:36 - 17:42	<p><b>DOP002: Vedolizumab treatment persistence up to 3 years: Post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS studies</b>  <b>S. Vermeire<sup>1</sup></b>, E.V. Loftus Jr.<sup>2</sup>, J.M. Khalid<sup>3</sup>, D. Tudor<sup>4</sup>, M. Akbari<sup>5</sup>, D. Demuth<sup>3</sup>, L. Peyrin-Biroulet<sup>6</sup></p> <p><sup>1</sup>University Hospitals Leuven, Department of clinical and experimental medicine, Leuven, Belgium, <sup>2</sup>Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Rochester, Minnesota, United States, <sup>3</sup>Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom, <sup>4</sup>Takeda Pharmaceuticals International AG, Zurich, Switzerland, <sup>5</sup>Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, United States, <sup>6</sup>Nancy University Hospital, Lorraine University, Department of Gastroenterology, Nancy, France</p>
17:42 - 17:48	<p><b>DOP003: Ustekinumab induces clinical and biological remission in biologic refractory Crohn's Disease patients: A real world Belgian cohort study</b>  <b>C. Liefferinckx<sup>1,2</sup></b>, B. Verstockt<sup>3</sup>, A. Gils<sup>4</sup>, M. Noman<sup>3</sup>, C. Van Kemseke<sup>5</sup>, E. Macken<sup>6</sup>, M. De Vos<sup>7</sup>, W. Van Moerkercke<sup>8</sup>, J.-F. Rahier<sup>9</sup>, P. Bossuyt<sup>10</sup>, J. Dutré<sup>11</sup>, E. Humblet<sup>12</sup>, D. Staessen<sup>13</sup>, H. Peeters<sup>14</sup>, P. Van Hoogetem<sup>15</sup>, E. Louis<sup>5</sup>, D. Franchimont<sup>1,2</sup>, F. Baert<sup>16</sup>, S. Vermeire<sup>3</sup></p> <p><sup>1</sup>Hopital Erasme, ULB, Department of gastroenterology, Brussels, Belgium, <sup>2</sup>Université libre de Bruxelles, Laboratory of Experimental Gastroenterology, Brussels, Belgium, <sup>3</sup>University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, <sup>4</sup>KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, <sup>5</sup>Centre Hospitalier Universitaire Sart-Tilman, ULG, Department of Gastroenterology, Liège, Belgium, <sup>6</sup>Universiteit ziekenhuis Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, <sup>7</sup>Universitair Ziekenhuis Gent, Department of Gastroenterology, Gent, Belgium, <sup>8</sup>AZ Groeninge, department of Gastroenterology, Kortrijk, Belgium, <sup>9</sup>Centre Hospitalier Universitaire Mont-Godinne, UCL, Department of Gastroenterology, Yvoir, Belgium, <sup>10</sup>Imeldaziekenhuis, department of Gastroenterology, Bonheiden, Belgium, <sup>11</sup>Ziekenhuis Netwerk Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, <sup>12</sup>Ziekenhuis Oost-Limburg - Campus Sint-Jan, Department of Gastroenterology, Genk, Belgium, <sup>13</sup>GZA Sint-Vincentius Ziekenhuis, Department of Gastroenterology, Antwerpen, Belgium, <sup>14</sup>Algemeen Ziekenhuis Sint-Lucas, department of Gastroenterology, Gent, Belgium, <sup>15</sup>Algemeen Ziekenhuis Sint-Lucas, Department</p>
17:48 - 17:54	<p><b>DOP004: Long-term safety of adalimumab in patients with Moderate to Severe Ulcerative Colitis: Interim results of a non-interventional registry, LEGACY</b>  <b>P. Bossuyt<sup>1</sup></b>, R. Atreya<sup>2</sup>, C. Taxonera<sup>3,4</sup>, X. Hebuterne<sup>5,6</sup>, K. Isaacs<sup>7</sup>, P.D. Higgins<sup>8</sup>, J. Lindsay<sup>9</sup>, G. Heap<sup>10</sup>, D. Arikan<sup>10</sup>, V. Kuehn<sup>11</sup>, J. Petersson<sup>10</sup>, A.M. Robinson<sup>10</sup>, E.V. Loftus Jr.<sup>12</sup></p> <p><sup>1</sup>Imelda General Hospital, Bonheiden, Belgium, <sup>2</sup>Friedrich-Alexander-University Erlangen-Nürnberg, Medical Clinic <sup>1</sup>, Erlangen, Germany, <sup>3</sup>Hospital Clínico San Carlos, Inflammatory Bowel Disease Unit, Department of Gastroenterology, Madrid, Spain, <sup>4</sup>Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, <sup>5</sup>Service de Gastroentérologie et Nutrition Clinique, Nice, France, <sup>6</sup>Université de Nice-Sophia-Antipolis, Nice, France, <sup>7</sup>University of North Carolina, Division of Gastroenterology and Hepatology, Chapel Hill, United States, <sup>8</sup>University of Michigan, Ann Arbor, United States, <sup>9</sup>Queen Mary University of London, Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, London, United Kingdom, <sup>10</sup>AbbVie Inc., North Chicago, United States, <sup>11</sup>AbbVie Deutschland GmbH &amp; Co. KG, Ludwigshafen, Germany, <sup>12</sup>Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States</p>

## Thursday, February 15, 2018, cont.

17:54 - 18:00	<p><b>DOP005: Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonists</b>  R. Cohen<sup>1</sup>, <b>F. Bhayat</b><sup>2</sup>, G. Hantsbarger<sup>2</sup>, A. Blake<sup>3</sup>, S. Vermeire<sup>4</sup>  <sup>1</sup>Inflammatory Bowel Disease Center, University of Chicago Medicine, Department of Medicine, Chicago, United States, <sup>2</sup>Takeda Development Center Americas, Inc., Cambridge, United States, <sup>3</sup>Takeda International – UK Branch, London, United Kingdom, <sup>4</sup>University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium</p>
18:00 - 18:06	<p><b>DOP006: A multicentre cohort study to assess the safety of vedolizumab for Inflammatory Bowel Disease</b>  J. Meserve<sup>1</sup>, S. Aniwani<sup>2</sup>, J.L. Koliani-Pace<sup>3</sup>, P. Shashi<sup>4</sup>, A. Weiss<sup>5</sup>, D. Faleck<sup>6</sup>, A. Winters<sup>6</sup>, S. Chablaney<sup>6</sup>, G. Kochhar<sup>4</sup>, B. Boland<sup>1</sup>, S. Singh<sup>1</sup>, R. Hirten<sup>6</sup>, E. Schmidt<sup>6</sup>, M. Bohm<sup>7</sup>, S. V Sagi<sup>7</sup>, M. Fischer<sup>7</sup>, D. Lukin<sup>5</sup>, D. Hudesman<sup>8</sup>, S. Chang<sup>8</sup>, K. Sultan<sup>9</sup>, A. Swaminath<sup>10</sup>, N. Gupta<sup>11</sup>, S. Kane<sup>2</sup>, E.V. Loftus<sup>2</sup>, B. Shen<sup>4</sup>, B.E. Sands<sup>6</sup>, J.-F. Colombel<sup>6</sup>, C.A. Siegel<sup>3</sup>, W.J. Sandborn<sup>1</sup>, <b>P.S. Dulai</b><sup>1</sup>  <sup>1</sup>University of California - San Diego, La Jolla, United States, <sup>2</sup>Mayo Clinic, Rochester, United States, <sup>3</sup>Dartmouth-Hitchcock Medical Center, Lebanon, United States, <sup>4</sup>Cleveland Clinic Foundation, Cleveland, United States, <sup>5</sup>Montefiore Medical Center, New York, United States, <sup>6</sup>Icahn School of Medicine at Mount Sinai, New York, United States, <sup>7</sup>Indiana University, Indianapolis, United States, <sup>8</sup>New York University (NYU), New York, United States, <sup>9</sup>North Shore University Hospital, Manhasset, United States, <sup>10</sup>Lenox Hill Hospital, New York, United States, <sup>11</sup>University of Mississippi, Jackson, United States</p>
18:06 - 18:12	<p><b>DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha resistant Inflammatory Bowel Disease</b>  <b>R. Bor</b><sup>1</sup>, F. Klaudia<sup>2</sup>, P. Miheller<sup>3</sup>, K. Palatka<sup>4</sup>, T. Szamosi<sup>5</sup>, Á. Vincze<sup>6</sup>, M. Rutka<sup>7</sup>, K. Szántó<sup>2</sup>, A. Bálint<sup>2</sup>, Z. Szepes<sup>2</sup>, F. Nagy<sup>2</sup>, Á. Milassin<sup>2</sup>, A. Fábíán<sup>2</sup>, Á. Csontos<sup>3</sup>, P. Golovics<sup>3</sup>, L. Lakner<sup>8</sup>, K. Müllner<sup>3</sup>, M. Papp<sup>9</sup>, Á. Salamon<sup>10</sup>, K. Sarang<sup>8</sup>, Z. Vitális<sup>4</sup>, E. Schafer<sup>11</sup>, P. Sarló<sup>5</sup>, T. Molnár<sup>2</sup>  <sup>1</sup>University of Szeged, First Department of Medicine, Szeged, Hungary, <sup>2</sup>University of Szeged, First Department of Medicine, Szeged, Hungary, <sup>3</sup>Semmelweis University, 2<sup>nd</sup> Department of Medicine, Budapest, Hungary, <sup>4</sup>University of Debrecen, 2<sup>nd</sup> Department of Medicine, Debrecen, Hungary, <sup>5</sup>Hungarian Defence Force Military Hospital, Department of Gastroenterology, Budapest, Hungary, <sup>6</sup>University of Pécs, 1<sup>st</sup> Department of Medicine, Pécs, Hungary, <sup>7</sup>University of Szeged, First Department of Medicine, Szeged, Hungary, <sup>8</sup>Markusovszky Teaching Hospital, Szombathely, Hungary, <sup>9</sup>University of Debrecen, 2<sup>nd</sup> Department of Medicine, Szeged, Hungary, <sup>10</sup>Balassa János Hospital, Szekszárd, Hungary, <sup>11</sup>Semmelweis University, 2<sup>nd</sup> Department of Medicine, Szeged, Hungary</p>

Thursday, February 15, 2018, cont.

18:12 - 18:18	<p><b><i>DOP008: Safety of adalimumab in children and adolescents with Moderate to Severe Crohn's Disease: Interim results of the CAPE registry</i></b>                  D. Turner<sup>1</sup>, S. Koletzko<sup>2</sup>, H. Winter<sup>3</sup>, R. Baldassano<sup>4</sup>, M. Dubinsky<sup>5</sup>, W. Faubion<sup>6</sup>, J. Hyams<sup>7</sup>, S. Kugathasan<sup>8</sup>, J. Rosh<sup>9</sup>, J. Escher<sup>10</sup>, A. Griffiths<sup>11</sup>, J. Kierkus<sup>12</sup>, R. Russell<sup>13</sup>, G. Heap<sup>14</sup>, D. Arikian<sup>14</sup>, V. Kuehn<sup>15</sup>, J. Petersson<sup>14</sup>, A. Robinson<sup>16</sup>, <b>F. Ruemmele</b><sup>17</sup></p> <p><sup>1</sup>Institute of Pediatric Gastroenterology, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Jerusalem, Israel, <sup>2</sup>Dr. von Hauner Children's Hospital, University Medical Center, LMU Munich, Munich, Germany, <sup>3</sup>Department of Pediatrics, Massachusetts General Hospital, Boston, United States, <sup>4</sup>Pediatric Gastroenterology, The Children's Hospital of Philadelphia, Philadelphia, United States, <sup>5</sup>Department of Pediatrics, Division of Gastroenterology, Mount Sinai Medical Center, New York, United States, <sup>6</sup>Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States, <sup>7</sup>Division of Digestive Diseases, Connecticut Children's Medical Center, Hartford, United States, <sup>8</sup>Department of Pediatrics, Emory University School of Medicine &amp; Children's Healthcare of Atlanta, Atlanta, United States, <sup>9</sup>Division of Gastroenterology and Nutrition, Goryeb Children's Hospital, Morristown, United States, <sup>10</sup>Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands, <sup>11</sup>Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada, <sup>12</sup>Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Children's Memorial Health Institute, Warsaw, Poland, <sup>13</sup>Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, United Kingdom, <sup>14</sup>AbbVie Inc., North Chicago, United States, <sup>15</sup>AbbVie Deutschland GmbH &amp; Co. KG, Ludwigshafen, Germany, <sup>16</sup>Abbvie, Inc., North Chicago, United States, <sup>17</sup>Paediatric Gastroenterology, Hôpital Necker Enfants Malades, APHP, University Paris Descartes Sorbonne Paris Cité, Paris, France</p>
18:18 - 18:24	<p><b><i>DOP009: Comparative safety profile of vedolizumab and tumour necrosis factor – antagonist therapy for Inflammatory Bowel Disease: A multicentre consortium propensity score-matched analysis</i></b>                  D. Lukin<sup>1</sup>, A. Weiss<sup>1</sup>, S. Aniwan<sup>2</sup>, S. Kadire<sup>3</sup>, G. Tran<sup>3</sup>, M. Rahal<sup>3</sup>, D. Faleck<sup>4</sup>, A. Winters<sup>4</sup>, S. Chablaney<sup>4</sup>, J. Meserve<sup>5</sup>, G. Kochhar<sup>6</sup>, P. Shashi<sup>6</sup>, J.L. Koliani-Pace<sup>2</sup>, M. Bohm<sup>3</sup>, S. V Sagi<sup>3</sup>, M. Fischer<sup>3</sup>, B. Boland<sup>5</sup>, S. Singh<sup>5</sup>, R. Hirten<sup>4</sup>, E. Shmidt<sup>4</sup>, D. Hudesman<sup>5</sup>, S. Chang<sup>8</sup>, K. Sultan<sup>9</sup>, A. Swaminath<sup>10</sup>, N. Gupta<sup>11</sup>, S. Kane<sup>2</sup>, E.V. Loftus<sup>2</sup>, B. Shen<sup>6</sup>, B.E. Sands<sup>4</sup>, W.J. Sandborn<sup>5</sup>, J.-F. Colombel<sup>4</sup>, C.A. Siegel<sup>7</sup>, <b>P.S. Dulaj</b><sup>5</sup></p> <p><sup>1</sup>Montefiore Medical Center, New York, United States, <sup>2</sup>Mayo Clinic, Rochester, United States, <sup>3</sup>Indiana University, Indianapolis, United States, <sup>4</sup>Icahn School of Medicine at Mount Sinai, New York, United States, <sup>5</sup>University of California – San Diego, La Jolla, United States, <sup>6</sup>Cleveland Clinic Foundation, Cleveland, United States, <sup>7</sup>Dartmouth-Hitchcock Medical Center, Lebanon, United States, <sup>8</sup>New York University (NYU), New York, United States, <sup>9</sup>North Shore University Hospital, Manhasset, United States, <sup>10</sup>Lenox Hill Hospital, New York, United States, <sup>11</sup>University of Mississippi, Jackson, United States</p>

## Thursday, February 15, 2018, cont.

<b>Digital Oral Presentation Session 2 – IBD Genetics</b>	
Room: Strauss 1-2 Isabelle Cleynen, Leuven, Belgium Miles Parkes, Cambridge, United Kingdom	
<b>17:30 - 18:30</b>	
17:30 - 17:36	<p><b>DOP010: Activating PIK3CD mutations cause severe intestinal lymphonodular hyperplasia and an IBD-like phenotype</b> S. Farachi<sup>1</sup>, L. Werner<sup>2</sup>, L. Konnikova<sup>3</sup>, F. Rea<sup>1</sup>, I. Vardi<sup>4</sup>, E. Romeo<sup>1</sup>, O. Barel<sup>4</sup>, P. De Angelis<sup>1</sup>, L. Dall'Oglio<sup>1</sup>, G. Rechavi<sup>4</sup>, S. Snapper<sup>3</sup>, R. Somech<sup>2</sup>, B. Weiss<sup>2</sup>, C. Cancrini<sup>1</sup>, <b>D. Shouval<sup>2</sup></b></p> <p><sup>1</sup>Bambino Gesù Children Hospital, Department of Endoscopy, Rome, Italy, <sup>2</sup>Edmond and Lily Safra Children's Hospital, Pediatric Gastroenterology Unit, Tel Hashomer, Israel, <sup>3</sup>Boston Children's Hospital, Boston, United States, <sup>4</sup>Sheba Medical Center, Tel Hashomer, Israel, <sup>5</sup>Edmond and Lily Safra Children's Hospital, Tel Hashomer, Israel</p>
17:36 - 17:42	<p><b>DOP011: Genotype-Phenotype association analysis of Inflammatory Bowel Disease in 6,395 East Asian subjects: Results from the international IBD Genetics Consortium</b> <b>S. Abedian<sup>1</sup></b>, S.H. Wong<sup>2</sup>, S. Van Sommeren<sup>3</sup>, A. Takahashi<sup>4</sup>, J.H. Cheon<sup>5</sup>, W.H. Kim<sup>6</sup>, K. Yamazaki<sup>6</sup>, S.-K. Yang<sup>7</sup>, M. Kubo<sup>6</sup>, R.K. Weersma<sup>3</sup>, B.Z. Alizadeh<sup>1</sup>, S.C. Ng<sup>2</sup></p> <p><sup>1</sup>University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands, <sup>2</sup>The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Faculty of Medicine, Hong Kong, China, <sup>3</sup>University of Groningen, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands, <sup>4</sup>Riken, Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, Yokohama, Japan, <sup>5</sup>Yonsei University College of Medicine, Department of Gastroenterology and Hepatology, Seoul, South Korea, <sup>6</sup>Riken, Laboratory for Genotyping Development, Center for Integrative Medical Sciences, Yokohama, Japan, <sup>7</sup>Asan Medical Center, University of Ulsan College of Medicine, Department of Gastroenterology and Hepatology, Seoul, South Korea</p>
17:42 - 17:48	<p><b>DOP012: Disease demarcation in Ulcerative Colitis is associated with different patterns of gene expression</b> M. Suarez-Farinas<sup>1</sup>, R. Huang<sup>1</sup>, R. Kosoy<sup>1</sup>, A. Irizar<sup>1</sup>, B. Losic<sup>1</sup>, G. Wei<sup>1</sup>, L. Peters<sup>1</sup>, W.-M. Song<sup>1</sup>, A. Di Narzo<sup>1</sup>, W. Wang<sup>1</sup>, J. Perrigoue<sup>2</sup>, A. Castillo<sup>3</sup>, J. Rogers<sup>3</sup>, A. Atreja<sup>3</sup>, A. Hurley<sup>1</sup>, M. Mahajan<sup>1</sup>, B. Zhang<sup>1</sup>, A. Stojmirovic<sup>2</sup>, M. Curran<sup>2</sup>, R. Dobrin<sup>2,4</sup>, M. Dubinsky<sup>3</sup>, K. Hao<sup>1</sup>, J. Zhu<sup>1</sup>, E. Schadt<sup>1</sup>, S. Plevy<sup>2</sup>, J. Friedman<sup>2</sup>, C. Brodmerkel<sup>2</sup>, B. Sands<sup>3</sup>, A. Kasarskis<sup>1</sup>, R. Ungaro<sup>3</sup>, <b>C. Argmann<sup>1</sup></b>, J.-F. Colombel<sup>3</sup></p> <p><sup>1</sup>Icahn School of Medicine at Mount Sinai, Genetics and Genomics Sciences, New York, United States, <sup>2</sup>Janssen R&amp;D, Spring House, United States, <sup>3</sup>Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, <sup>4</sup>Bristo-Myers Squibb, Hopewell, United States</p>
17:48 - 17:54	<p><b>DOP013: An IBD associated variant in PTPN2 promotes inflammatory responses but enhances the anti-inflammatory effect of spermidine</b> <b>M. Butter</b>, N. Obialo, K. Bäbler, L. Van der Lely, S. Lang, C. Gottier, M. Scharl, M.R. Spalinger University Hospital of Zurich, University of Zurich, Clinic for Gastroenterology and Hepatology, Zurich, Switzerland</p>
17:54 - 18:00	<p><b>DOP014: Impact of genetic variation on gene and protein expression in Crohn's Disease</b> <b>A. Hart</b>, K. Hayden, E. Wadman, S. Bhagat, D. Jacobstein, C. Brodmerkel, J. Friedman, K. Li Janssen Research &amp; Development, LLC, Spring House, United States</p>

Thursday, February 15, 2018, cont.

18:00 - 18:06	<p><b>DOP015: Dysregulation of cell-type specific long ncRNA in the ileum of treatment naïve early onset Crohn Disease</b>  <b>Y. Haberman</b><sup>1,2</sup>, M. BenShoshan<sup>1</sup>, A. Di Segni<sup>1</sup>, P.J. Dexheimer<sup>3</sup>, T. Braun<sup>1</sup>, B. Weiss<sup>1</sup>, C. Avivi<sup>1</sup>, I. Barshack<sup>1</sup>, Y. Anikster<sup>1</sup>, B. Aronow<sup>3</sup>, J.S. Hyams<sup>4</sup>, S. Kugathasan<sup>5</sup>, L.A. Denson<sup>3</sup>, The Crohn's &amp; Colitis Foundation (CCF)-sponsored RISK study  <sup>1</sup>Sheba Medical Center, Tel Hashomer, Israel, <sup>2</sup>CCHMC, Cincinnati, United States, <sup>3</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States, <sup>4</sup>Connecticut Children's Medical Center, Hartford, United States, <sup>5</sup>Emory University, Atlanta, United States</p>
18:06 - 18:12	<p><b>DOP016: Metagenomic analysis of intestinal mucosa revealed an IBD-specific shift in the eukaryotic gut virome composition at early stages of gut inflammation</b>  <b>F. Ungaro</b><sup>1</sup>, L. Massimino<sup>2</sup>, S. D'Alessio<sup>1</sup>, S. Danese<sup>1</sup>  <sup>1</sup>Humanitas University, Biomedical Science, Milan, Italy, <sup>2</sup>San Raffaele Scientific Institute, Division of Neuroscience, Milan, Italy</p>
18:12 - 18:18	<p><b>DOP017: Increased intestinal aryl hydrocarbon receptor expression and pathway sensitivity in Crohn's Disease</b>  <b>P. Harrow</b><sup>1,2</sup>, N. McCarthy<sup>1</sup>, A. Stagg<sup>1</sup>, J. Lindsay<sup>1,2</sup>  <sup>1</sup>Blizard Institute, Immunobiology, London, United Kingdom, <sup>2</sup>Royal London Hospital, Gastroenterology, London, United Kingdom</p>
18:18 - 18:24	<p><b>DOP018: Baseline ILC1 distribution in blood predicts response to ustekinumab in patients with refractory Crohn's Disease</b>  <b>B. Creyns</b><sup>1</sup>, B. Verstockt<sup>2,3</sup>, J. Cremer<sup>1</sup>, M. Ferrante<sup>2,3</sup>, S. Vermeire<sup>2,3</sup>, C. Jan<sup>1</sup>, G. Van Assche<sup>2,3</sup>, C. Breyneart<sup>1</sup>  <sup>1</sup>KULeuven, Lab of Clinical Immunology, Leuven, Belgium, <sup>2</sup>University Hospital Gasthuisberg, Department of Gastroenterology, Leuven, Belgium, <sup>3</sup>KU Leuven, TARGID - Departement of Chronic Diseases, Metabolism and Aging, Leuven, Belgium</p>

Thursday, February 15, 2018, cont.

**Digital Oral Presentation Session 3 – Old and new immunomodulators**

17:30 - 18:30

Room: Strauss 3

Krisztina Gece, Amsterdam, The Netherlands

Ailsa Hart, London, United Kingdom

**DOP019: Immunomodulators reduce the risk of surgery and hospitalization in Crohn's Disease in a prospective European population-based inception cohort – the Epi-IBD cohort**

**J. Burisch<sup>1</sup>**, V. Andersen<sup>4,3</sup>, S. Čuković-Čavka<sup>4</sup>, P.L. Lakatos<sup>5</sup>, R. D'Inca<sup>6</sup>, F. Magro<sup>7,8,9</sup>, N. Arebi<sup>10</sup>, L. Kievit<sup>11</sup>, I. Kaimakliotis<sup>12</sup>, D. Valpiani<sup>13</sup>, K.H. Katsanos<sup>14</sup>, Z. Vegh<sup>5</sup>, J.F. Dahlerup<sup>15</sup>, M. Fumery<sup>16</sup>, N. Pedersen<sup>17</sup>, J. Halfvarson<sup>18</sup>, E. Belousova<sup>19</sup>, K.R. Nielsen<sup>20</sup>, S. Turcan<sup>21</sup>, P. Ellul<sup>22</sup>, L. Kupcinskas<sup>23</sup>, P. Oksanen<sup>24</sup>, D. Duricova<sup>25</sup>, M. Giannotta<sup>26</sup>, A. Goldis<sup>27</sup>, V. Hernandez<sup>28</sup>, R. Salupere<sup>29</sup>, S. Odes<sup>30</sup>, E. Langholz<sup>31</sup>, P. Munkholm<sup>1</sup>, Epi-IBD study group

<sup>1</sup>North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark, <sup>2</sup>Viborg Regional Hospital, Medical Department, Viborg, Denmark, <sup>3</sup>Hospital of Southern Jutland, Medical Department, Aabenraa, Denmark, <sup>4</sup>University Hospital Center Zagreb, University of Zagreb School of Medicine, Division of Gastroenterology and Hepatology, Zagreb, Croatia, <sup>5</sup>Semmelweis University, <sup>1st</sup> Department of Medicine, Budapest, Hungary, <sup>6</sup>Azienda Ospedaliera di Padova, Department of Surgery, Oncology and Gastroenterology, Padova, Italy, <sup>7</sup>University of Porto, Institute for molecular and cell biology, Porto, Portugal, <sup>8</sup>Hospital de São João, Department of Gastroenterology, Porto, Portugal, <sup>9</sup>Oporto Medical School, Institute of Pharmacology and Therapeutics, Porto, Portugal, <sup>10</sup>St Mark's Hospital, Gastroenterology, London, United Kingdom, <sup>11</sup>Herning Central Hospital, Department of Medicine, Herning, Denmark, <sup>12</sup>Nicosia Private practice, Nicosia Private practice, Nicosia, Cyprus, <sup>13</sup>Department of Gastroenterology and Digestive Endoscopy, Morgagni Hospital, Forlì, Italy, <sup>14</sup>University Hospital, Ioannina, <sup>1st</sup> Division of Internal Medicine and Hepato-Gastroenterology Unit, Ioannina, Greece, <sup>15</sup>Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark, <sup>16</sup>Amiens University and Hospital, Epimad Registry, Gastroenterology Unit, Amiens, France, <sup>17</sup>Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark, <sup>18</sup>Faculty of Medicine and Health, Örebro University, Department of Gastroenterology, Örebro, Sweden, <sup>19</sup>Moscow Regional Research Clinical Institute, Department of Gastroenterology, Moscow, Russian Federation, <sup>20</sup>The National Hospital of the Faroe Islands, Medical department, Tórshavn, Faroe Islands, <sup>21</sup>State University of Medicine and Pharmacy of the Republic of Moldova, Department of Gastroenterology, Chisinau, Moldova, Republic of, <sup>22</sup>Mater Dei Hospital, Division of Gastroenterology, L-Imnsida, Malta, <sup>23</sup>Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania, <sup>24</sup>Tampere University Hospital, Department of Gastroenterology and Alimentary Tract Surgery, Tampere, Finland, <sup>25</sup>Charles University, IBD Center ISCARE, Prague, Czech Republic, <sup>26</sup>AOU Careggi Regional Referral Center for Inflammatory Bowel Disease, Gastroenterology Department, Florence, Italy, <sup>27</sup>University of Medicine Victor Babes, Clinic of Gastroenterology, Timisoara, Romania, <sup>28</sup>Complejo Hospitalario Universitario de Vigo, Gastroenterology Department, Vigo, Spain, <sup>29</sup>Tartu University Hospital, Division of Endocrinology and Gastroenterology, Tartu, Estonia, <sup>30</sup>Soroka Medical Center and Ben Gurion University of the Negev, Department of Gastroenterology and Hepatology, Beer Sheva, Israel, <sup>31</sup>Gentofte Hospital, Department of Medical Gastroenterology, Copenhagen, Denmark

17:30 - 17:36

Thursday, February 15, 2018, cont.

17:36 - 17:42	<p><b>DOP020: Thiopurine monotherapy still has a place in the treatment of patients with Mild-to-Moderate Crohn's Disease in the biological era</b>  <b>B. Verstockt</b><sup>1,2</sup>, L. Boets<sup>1</sup>, G. Van Assche<sup>1,2</sup>, S. Vermeire<sup>1,2</sup>, M. Ferrante<sup>1,2</sup>  <sup>1</sup>University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, <sup>2</sup>KU Leuven, Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium</p>
17:42 - 17:48	<p><b>DOP021: Immunosuppressive and anti-TNF treatment is associated with a lower risk of migration from B1-to-B3-stage in Crohn's Disease: 10-year-follow-up data from the Swiss IBD cohort study</b>                  P. Cernoch<sup>1</sup>, N. Fournier<sup>2</sup>, M. Scharl<sup>1</sup>, J. Zeitz<sup>3</sup>, B. Morell<sup>1</sup>, T. Greuter<sup>1</sup>, P. Schreiner<sup>1</sup>, B. Misselwitz<sup>1</sup>, E. Safroneeva<sup>4</sup>, A. Schoepfer<sup>5</sup>, S.R. Vavricka<sup>6</sup>, G. Rogler<sup>1</sup>, <b>L. Biedermann</b><sup>7</sup>  <sup>1</sup>University Hospital Zurich, Division of Gastroenterology &amp; Hepatology, Zurich, Switzerland, <sup>2</sup>University of Lausanne, IUMSP, Lausanne, Switzerland, <sup>3</sup>Klinik Hirslanden, Department of Gastroenterology, Zurich, Switzerland, <sup>4</sup>University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, <sup>5</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Department of Gastroenterology, Lausanne, Switzerland, <sup>6</sup>Center of Gastroenterology and Hepatology, Zurich, Switzerland, <sup>7</sup>University Hospital Zurich, Gastroenterology &amp; Hepatology, Zurich, Switzerland</p>
17:48 - 17:54	<p><b>DOP022: Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: A randomised controlled trial</b>  <b>J.E. Kreijne</b><sup>1</sup>, M.R. Lie<sup>1</sup>, G. Dijkstra<sup>2</sup>, M. Löwenberg<sup>3</sup>, G. van Assche<sup>4</sup>, R.L. West<sup>5</sup>, D. van Noord<sup>5</sup>, A.A. van der Meulen-de Jong<sup>6</sup>, B.E. Hansen<sup>1,7</sup>, A.C. de Vries<sup>1</sup>, C.J. van der Woude<sup>1</sup>  <sup>1</sup>Erasmus MC, Gastroenterology and Hepatology, Rotterdam, The Netherlands, <sup>2</sup>University Medical Center Groningen and University of Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands, <sup>3</sup>Academic Medical Center Amsterdam, Gastroenterology and Hepatology, Amsterdam, The Netherlands, <sup>4</sup>University Hospitals Leuven, KU Leuven, Gastroenterology, Leuven, Belgium, <sup>5</sup>Franciscus Hospital &amp; Vlietland Hospital, Gastroenterology and Hepatology, Rotterdam, The Netherlands, <sup>6</sup>Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, The Netherlands, <sup>7</sup>Toronto General Hospital, Center for Liver Disease, Toronto, Canada</p>
17:54 - 18:00	<p><b>DOP023: Tofacitinib for the treatment of Ulcerative Colitis: Up to 4.4 years of safety data from global clinical trials</b>                  W.J. Sandborn<sup>1</sup>, <b>J. Panés</b><sup>2</sup>, G.R. D'Haens<sup>3</sup>, B.E. Sands<sup>4</sup>, C. Su<sup>5</sup>, M. Moscariello<sup>5</sup>, T.V. Jones<sup>5</sup>, R.D. Pedersen<sup>5</sup>, G.S. Friedman<sup>5</sup>, N. Lawendy<sup>5</sup>, G. Chan<sup>5</sup>  <sup>1</sup>University of California San Diego, Division of Gastroenterology, La Jolla, CA, United States, <sup>2</sup>Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, <sup>3</sup>Academic Medical Centre, Department of Gastroenterology, Amsterdam, The Netherlands, <sup>4</sup>Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, United States, <sup>5</sup>Pfizer Inc, Collegeville, PA, United States</p>

## Thursday, February 15, 2018, cont.

18:00 - 18:06	<p><b>DOP024: Tofacitinib achieves symptomatic improvement within three days in moderately to severely active Ulcerative Colitis, regardless of prior tumour necrosis factor inhibitor treatment status: Results from OCTAVE induction 1 &amp; 2</b>  S. Hanauer<sup>1</sup>, R. Panaccione<sup>2</sup>, S. Danese<sup>3</sup>, A. Cheifetz<sup>4</sup>, <b>W. Reinisch</b><sup>5</sup>, P.D.R. Higgins<sup>6</sup>, D.A. Woodworth<sup>7</sup>, H. Zhang<sup>7</sup>, G.S. Friedman<sup>7</sup>, N. Lawendy<sup>7</sup>, D. Quirk<sup>7</sup>, C.I. Nduaka<sup>7</sup>, C. Su<sup>7</sup></p> <p><sup>1</sup>Northwestern University, Evanston, IL, United States, <sup>2</sup>University of Calgary, Calgary, AB, Canada, <sup>3</sup>Humanitas Research Hospital, IBD Center, Department of Gastroenterology, Rozzano, Milan, Italy, <sup>4</sup>Beth Israel Deaconess Medical Center and Harvard Medical School, Department of Medicine and Division of Gastroenterology, Boston, MA, United States, <sup>5</sup>Medical University of Vienna, Dept Internal Medicine III, Vienna, Austria, <sup>6</sup>University of Michigan, Ann Arbor, MI, United States, <sup>7</sup>Pfizer Inc, Collegeville, PA, United States</p>
18:06 - 18:12	<p><b>DOP025: Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the OCTAVE clinical programme</b>  G.R. Lichtenstein<sup>1</sup>, M.A. Ciorba<sup>2</sup>, <b>G. Rogler</b><sup>3</sup>, D. Quirk<sup>4</sup>, C.I. Nduaka<sup>4</sup>, R.D. Pedersen<sup>4</sup>, N. Lawendy<sup>4</sup>, G. Chan<sup>4</sup>, C. Su<sup>4</sup>, J. Panés<sup>5</sup></p> <p><sup>1</sup>Perelman School of Medicine of the University of Pennsylvania, Division of Gastroenterology, Philadelphia, PA, United States, <sup>2</sup>Washington University in Saint Louis, Division of Gastroenterology, Saint Louis, MO, United States, <sup>3</sup>University of Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland, <sup>4</sup>Pfizer Inc, Collegeville, PA, United States, <sup>5</sup>Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain</p>
18:12 - 18:18	<p><b>DOP026: Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE open</b>  B.E. Sands<sup>1</sup>, A.C. Moss<sup>2</sup>, <b>A. Armuzzi</b><sup>3</sup>, J.K. Marshall<sup>4</sup>, J.O. Lindsay<sup>5</sup>, W.J. Sandborn<sup>6</sup>, S. Danese<sup>7</sup>, K. Tsilkos<sup>8</sup>, N. Lawendy<sup>9</sup>, H. Zhang<sup>9</sup>, G.S. Friedman<sup>9</sup>, G. Chan<sup>9</sup>, D.W. Krichbaum<sup>9</sup>, C. Su<sup>9</sup></p> <p><sup>1</sup>Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, United States, <sup>2</sup>Beth Israel Deaconess Medical Centre, Division of Gastroenterology, Boston, MA, United States, <sup>3</sup>Presidio Columbus Fondazione Policlinico Gemelli Università Cattolica, IBD Unit, Rome, Italy, <sup>4</sup>McMaster University, Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, Hamilton, ON, Canada, <sup>5</sup>The Royal London Hospital, Barts Health NHS Trust, Department of Gastroenterology, London, United Kingdom, <sup>6</sup>University of California San Diego, Division of Gastroenterology, La Jolla, CA, United States, <sup>7</sup>Humanitas Research Hospital, IBD Center, Department of Gastroenterology, Rozzano, Milan, Italy, <sup>8</sup>Pfizer Inc, New York, NY, United States, <sup>9</sup>Pfizer Inc, Collegeville, PA, United States</p>
18:18 - 18:24	<p><b>DOP027: Efficacy and safety of an additional eight weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib eight-week induction non-responders</b>  B.G. Feagan<sup>1</sup>, M.C. Dubinsky<sup>2</sup>, <b>M. Lukas</b><sup>3</sup>, D. Quirk<sup>4</sup>, C.I. Nduaka<sup>4</sup>, E. Maller<sup>4</sup>, N. Lawendy<sup>4</sup>, C. Kayhan<sup>4</sup>, W. Wang<sup>4</sup>, G. Chan<sup>4</sup>, C. Su<sup>4</sup></p> <p><sup>1</sup>Western University, Robarts Clinical Trials, London, ON, Canada, <sup>2</sup>Icahn School of Medicine at Mount Sinai Hospital, Department of Pediatrics and Medicine, New York, NY, United States, <sup>3</sup>Charles University, Prague, Czech Republic, <sup>4</sup>Pfizer Inc, Collegeville, PA, United States</p>

Thursday, February 15, 2018, cont.

**Digital Oral Presentation Session 4 – Practicalities of IBD patient care**

Room: Stolz 1-2

Joana Torres, Lisbon, Portugal

Stephan Vavricka, Zurich, Switzerland

17:30 - 18:30

17:30 - 17:36

**DOP028: 2<sup>nd</sup> N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn's Disease or Ulcerative Colitis**
**K. Kemp<sup>1</sup>**, L. Dibley<sup>2</sup>, U. Chauhan<sup>3</sup>, K. Greveson<sup>4</sup>, S. Jaghult<sup>5</sup>, K. Ashton<sup>6</sup>, S. Buckton<sup>7</sup>, J. Duncan<sup>8</sup>, P. Hartmann<sup>9</sup>, N. Ipenburg<sup>10</sup>, L. Moortgat<sup>11</sup>, R. Theeuwes<sup>12</sup>, M. Verway<sup>13</sup>, L. Younge<sup>14</sup>, P. Bager<sup>15</sup>
<sup>1</sup>Manchester Royal Infirmary / University of Manchester, Gastroenterology, Manchester, United Kingdom, <sup>2</sup>University of Greenwich / Barts Heath, School of Nursing / Gastroenterology, London, United Kingdom, <sup>3</sup>McMasterUniversity, Digestive Diseases, Hamilton, Canada, <sup>4</sup>Royal Free Hospital, Gastroenterology, London, United Kingdom, <sup>5</sup>Karolinska Institutet Danderyd Hospital, Stockholm Gastro Centre, Stockholm, Sweden, <sup>6</sup>Hull and East Yorkshire Hospitals, Gastroenterology, Hull, United Kingdom, <sup>7</sup>Coastal Digestive Health, IBD Clinic, Mountain Creek, Australia, <sup>8</sup>St Thomas' Hospital, Gastroenterology, London, United Kingdom, <sup>9</sup>Gastroenterologische Gemeinschaftspraxis, Gastroenterology, Minden, Germany, <sup>10</sup>Ijsselland Hospital, Dept of Surgery, ZC Capelle A/D Ijssel, The Netherlands, <sup>11</sup>AZ Delta Roeselare-Menen, Gastroenterology, Roeselare, Belgium, <sup>12</sup>LUMC, Gastroenterology, Leiden, The Netherlands, <sup>13</sup>Leiden University Medical Centre, Gastroenterology, Leiden, The Netherlands, <sup>14</sup>Barts and The London NHS Trust, Gastroenterology, London, United Kingdom, <sup>15</sup>Gastroenterology and Hepatology Aarhus University, Dept of Medicine, Aarhus, Denmark

17:36 - 17:42

**DOP029: Treatment and long-term outcomes of paediatric patients with penetrating Crohn's Disease**
**L. Kollen<sup>1</sup>**, A. Leroyer<sup>2</sup>, A. Breton<sup>3</sup>, M. Fumery<sup>4</sup>, G. Savoye<sup>5</sup>, J. Lemale<sup>6</sup>, D. Morin<sup>1</sup>, B. Pariente<sup>7</sup>, E. Mas<sup>3</sup>, D. Turck<sup>8</sup>, M. Al Khouri<sup>1</sup>, P. Blanc<sup>9</sup>, C. Gower<sup>2</sup>, **G. Pineton de Chambrun<sup>9</sup>**
<sup>1</sup>Montpellier University Hospital, Pediatric Gastroenterology and Nutrition, Montpellier, France, <sup>2</sup>Lille University Hospital, Epidemiology, Lille, France, <sup>3</sup>Toulouse University Hospital, Pediatric Gastroenterology and Nutrition, Toulouse, France, <sup>4</sup>Amiens University Hospital, Gastroenterology, Amiens, France, <sup>5</sup>Rouen University Hospital, Gastroenterology, Rouen, France, <sup>6</sup>Armand Trousseau University Hospital, Pediatric Gastroenterology and Nutrition, Paris, France, <sup>7</sup>Lille University Hospital, Gastroenterology, Lille, France, <sup>8</sup>Lille University Hospital, Pediatric Gastroenterology and Nutrition, Lille, France, <sup>9</sup>Montpellier University Hospital, Gastroenterology, Montpellier, France

## Thursday, February 15, 2018, cont.

17:42 - 17:48	<p><b><i>DOP030: The efficacy of home telemonitoring versus conventional follow-up: A randomised controlled trial among teenagers with Inflammatory Bowel Disease</i></b>  A. Heida<sup>1</sup>, A. Muller Kobold<sup>2</sup>, J. Rossen<sup>3</sup>, A. Kindermann<sup>4</sup>, F. Kokke<sup>5</sup>, T. Meij, De<sup>6</sup>, O. Norbruis<sup>7</sup>, R. Weersma<sup>8</sup>, M. Wessels<sup>9</sup>, T. Hummel<sup>10</sup>, H. Escher<sup>11</sup>, H. Wering, van<sup>12</sup>, D. Hendriks<sup>13</sup>, L. Mearin<sup>14</sup>, H. Groen<sup>15</sup>, H. Verkade<sup>1</sup>, <b>P. Van Rheenen<sup>1</sup></b></p> <p><sup>1</sup>University Medical Center Groningen, Paediatric Gastroenterology Hepatology &amp; Nutrition, Groningen, The Netherlands, <sup>2</sup>University Medical Center Groningen, Laboratory Medicine, Groningen, The Netherlands, <sup>3</sup>University Medical Center Groningen, Microbiology, Groningen, The Netherlands, <sup>4</sup>Academic Medical Center, Paediatric Gastroenterology Hepatology &amp; Nutrition, Amsterdam, The Netherlands, <sup>5</sup>Wilhemina Kinder Ziekenhuis, Paediatric Gastroenterology Hepatology &amp; Nutrition, Utrecht, The Netherlands, <sup>6</sup>VU Medical Center, Paediatric Gastroenterology Hepatology &amp; Nutrition, Amsterdam, The Netherlands, <sup>7</sup>Isala Clinic, Paediatrics, Zwolle, The Netherlands, <sup>8</sup>University Medical Center Groningen, Gastroenterology &amp; Hepatology, Groningen, The Netherlands, <sup>9</sup>Rijnstate Hospital, Paediatrics, Arnhem, The Netherlands, <sup>10</sup>Medisch Spectrum Twente, Paediatrics, Enschede, The Netherlands, <sup>11</sup>Erasmus Medical Center - Sophia Kinder Ziekenhuis, Paediatric Gastroenterology Hepatology &amp; Nutrition, Rotterdam, The Netherlands, <sup>12</sup>Amphia Ziekenhuis, Paediatrics, Breda, The Netherlands, <sup>13</sup>Haga Hospital, Paediatrics, The Hague, The Netherlands, <sup>14</sup>Leiden University Medical Center, Paediatric Gastroenterology Hepatology &amp; Nutrition, Leiden, The Netherlands, <sup>15</sup>University Medical Center Groningen, Epidemiology, Groningen, The Netherlands</p>
17:48 - 17:54	<p><b><i>DOP031: Individualised home-monitoring of disease activity in adult patients with Inflammatory Bowel Disease can be recommended implemented in clinical practice</i></b>  <b>D.V. Ankersen<sup>1</sup></b>, D. Marker, P. Weimers, J. Burisch, P. Munkholm North Zealand University Hospital, Frederikssund, Denmark</p>
17:54 - 18:00	<p><b><i>DOP032: Crohn's Disease patients' perspectives towards de-escalating immunosuppressive therapy: A comparative French and American survey</i></b>  <b>C.A. Siegel<sup>1</sup></b>, K.D. Thompson<sup>2</sup>, D. Walls<sup>3</sup>, J. Gollins<sup>4</sup>, A. Buisson<sup>5</sup>, A. Olympie<sup>5</sup>, L. Beaugerie<sup>6</sup>, J.-F. Colombel<sup>7</sup>, E. Louis on behalf of the BIOCYCLE group<sup>8</sup></p> <p><sup>1</sup>Dartmouth-Hitchcock Medical Center, Lebanon, United States, <sup>2</sup>Dartmouth-Hitchcock Medical Center, Medicine, Lebanon, United States, <sup>3</sup>BDJ Solutions, Boston, United States, <sup>4</sup>Delta Modelling, Chicago, United States, <sup>5</sup>Association François Aupetit, Paris, France, <sup>6</sup>Hôpital Saint-Antoine, Paris, France, <sup>7</sup>Icahn</p>
18:00 - 18:06	<p><b><i>DOP033: Trends in epidemiology of Inflammatory Bowel Disease among Jewish Israeli adolescents: A population based study</i></b>  <b>I. Ghersin<sup>1</sup></b>, L.H. Katz<sup>2</sup>, S. Daher<sup>3</sup>, R. Shamir<sup>4</sup>, A. Assa<sup>4</sup></p> <p><sup>1</sup>Rambam Health Care Campus, Haifa, Israel, <sup>2</sup>Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, <sup>3</sup>IDF Medical Corps, Tel Hashomer, Israel, <sup>4</sup>Schneider Children's Medical Center, Gastroenterology, Petach Tikva, Israel</p>

Thursday, February 15, 2018, cont.

18:06 - 18:12	<p><b>DOP034: Assessment of direct healthcare cost drivers of Crohn's Disease in a Dutch population-based cohort study shows a major shift</b>  <b>R. Lalisang<sup>1</sup></b>, D. Wintjens<sup>1,2</sup>, M. Romberg-Camps<sup>3</sup>, A. van Bodegraven<sup>3</sup>, L. Oostenbrug<sup>3</sup>, J. Haans<sup>1</sup>, A. Masclee<sup>1,2</sup>, D. Jonkers<sup>1,2</sup>, M. Pierik<sup>1,2</sup>  <sup>1</sup>Maastricht University Medical Centre +, Department of Internal medicine, Division of Gastroenterology and Hepatology, Maastricht, The Netherlands, <sup>2</sup>Maastricht University Medical Centre +, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands, <sup>3</sup>Zuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen/Heerlen, The Netherlands</p>
18:12 - 18:18	<p><b>DOP035: Beclomethasone dipropionaat is effective for microscopic colitis: Results of an open label multicentre study (COLCO)</b>                  T. De Corte<sup>1</sup>, <b>E. Janssens<sup>1</sup></b>, K. Thorrez<sup>2</sup>, A. D'Hondt<sup>1</sup>, K. Dejaegher<sup>3</sup>, F. D'Heygere<sup>4</sup>, B. van Besien<sup>2</sup>, L. Harlet<sup>1</sup>, H. Peeters<sup>5</sup>, W. Vanmoerkercke<sup>4</sup>, P. van Hooetegem<sup>6</sup>, F. Baert<sup>1</sup>  <sup>1</sup>AZ Delta Roeselare Menen, Department of Gastroenterology, Roeselare, Belgium, <sup>2</sup>Jan Yperman Hospital, Department of Gastroenterology, Ieper, Belgium, <sup>3</sup>Sint-Jozefskliniek, Department of Gastroenterology, Izegem, Belgium, <sup>4</sup>AZ Groeninge, Department of Gastroenterology, Kortrijk, Belgium, <sup>5</sup>AZ St. Lucas, Department of Gastroenterology, Ghent, Belgium, <sup>6</sup>AZ St. Lucas, Department of Gastroenterology, Brugge, Belgium</p>
18:18 - 18:24	<p><b>DOP036: Ustekinumab for Crohn's Disease: A nationwide real-life observational cohort study (ICC Case Series)</b>  <b>V. Biemans<sup>1,2</sup></b>, A. van der Meulen-de Jong<sup>3</sup>, C. van der Woude<sup>4</sup>, N. de Boer<sup>5</sup>, G. Dijkstra<sup>6</sup>, B. Oldenburg<sup>7</sup>, C. Ponsioen<sup>8</sup>, P. Maljaars<sup>3</sup>, J. Haans<sup>2</sup>, M. Pierik<sup>2</sup>, F. Hoentjen<sup>9</sup>, Dutch Initiative on Crohn and Colitis (ICC)  <sup>1</sup>Radboudumc, Nijmegen, The Netherlands, <sup>2</sup>Maastricht University Medical Center (MUMC), Maastricht, The Netherlands, <sup>3</sup>Leiden University Medical Center (LUMC), Department of Gastroenterology and Hepatology, Leiden, The Netherlands, <sup>4</sup>Erasmus Medical Center, Rotterdam, The Netherlands, <sup>5</sup>VU University Medical Centre Institute of Education, Department of Gastroenterology and Hepatology, Room J393, Amsterdam, The Netherlands, <sup>6</sup>University Medical Center Groningen, Groningen, The Netherlands, <sup>7</sup>University Medical Centre Utrecht, Utrecht, The Netherlands, <sup>8</sup>Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, <sup>9</sup>Radboudumc, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands</p>

Thursday, February 15, 2018, cont.

<b>Digital Oral Presentation Session 5 – Best surgical management of IBD</b>	
<b>17:30 - 18:30</b>	Room: Lehar 4 Antonino Spinelli, Milan, Italy Oded Zmora, Tel Aviv, Israel
17:30 - 17:36	<p><b>DOP037: Postoperative anti-TNF therapy is associated with a significant reduction of both endoscopic and clinical recurrence following surgery for ileocolonic Crohn's Disease: Results of a prospective nationwide cohort conducted by the GETAID chirurgie group</b></p> <p><b>L. Maggiori<sup>1</sup></b>, A. Brouquet<sup>2</sup>, P. Zerbib<sup>3</sup>, J. Lefevre<sup>4</sup>, Q. Denost<sup>5</sup>, A. Germain<sup>6</sup>, E. Cotte<sup>7</sup>, L. Beyer-Berjot<sup>8</sup>, N. Munoz-Bongrand<sup>9</sup>, V. Desfourneaux<sup>10</sup>, A. Rahili<sup>11</sup>, J.-P. Duffas<sup>12</sup>, K. Pautrat<sup>13</sup>, C. Denet<sup>14</sup>, V. Bridoux<sup>15</sup>, G. Meurette<sup>16</sup>, J.-L. Faucheron<sup>17</sup>, J. Loriau<sup>18</sup>, F. Guillon<sup>19</sup>, E. Vicaut<sup>20</sup>, Y. Panis<sup>1</sup>, S. Benoist<sup>2</sup></p> <p><sup>1</sup>Beaujon Hospital, APHP, Colorectal Surgery, Clichy, France, <sup>2</sup>CHU Bicetre, APHP, Department of Oncologic and Digestive Surgery, Le Kremlin-Bicetre, France, <sup>3</sup>CHRU Lille, Department of digestive surgery and transplantation, Lille, France, <sup>4</sup>St Antoine Hospital, APHP, Digestive surgery, Paris, France, <sup>5</sup>CHU Bordeaux, Digestive surgery, Bordeaux, France, <sup>6</sup>CHRU Nancy, Digestive Surgery, Nancy, France, <sup>7</sup>CHU Lyon-Sud, Digestive surgery, Lyon, France, <sup>8</sup>CHU Marseille-Nord, Digestive surgery, Marseille, France, <sup>9</sup>St Louis Hospital, APHP, Digestive surgery, Paris, France, <sup>10</sup>CHU Rennes, Digestive Surgery, Rennes, France, <sup>11</sup>CHU Nice, Digestive Surgery, Nice, France, <sup>12</sup>CHU Toulouse, Digestive surgery, Toulouse, France, <sup>13</sup>Lariboisière Hospital, APHP, Digestive Surgery, Paris, France, <sup>14</sup>Institut Mutualiste Montsouris, Digestive Surgery, Paris, France, <sup>15</sup>CHU Rouen, Digestive Surgery, Rouen, France, <sup>16</sup>CHU Nantes, Digestive Surgery, Nantes, France, <sup>17</sup>CHU Grenoble, Digestive Surgery, Grenoble, France, <sup>18</sup>Hopital St Joseph, Digestive Surgery, Paris, France, <sup>19</sup>CHU Montpellier, Digestive Surgery, Montpellier, France, <sup>20</sup>Lariboisière Hospital, APHP, Department of Clinical Research, Paris, France</p>
17:36 - 17:42	<p><b>DOP038: Postoperative outcome in 2890 patients following right hemicolectomy and ileo-cecal resection in colonic cancer and Crohn's Disease: Results from ESCP-S-ECCO snapshot prospective audit 2015</b></p> <p><b>S. Dich Grandt</b>, 2015 European Society of Coloproctology Collaborating Group</p>
17:42 - 17:48	<p><b>DOP039: Exploring stoma rates in Crohn's Disease in the biologic era: A population-based time trend analysis</b></p> <p><b>C. Ma</b>, P.G. Kotze, A. Almutairdi, D. Tanyngoh, C. Seow, K. Novak, C. Lu, R. Panaccione, G. Kaplan University of Calgary, IBD unit, Division of Gastroenterology and Hepatology, Calgary, Canada</p>
17:48 - 17:54	<p><b>DOP040: Five-year colectomy data from the Observational Postmarketing Ulcerative Colitis Study, a European registry for adults with Ulcerative Colitis treated with originator infliximab or conventional therapy</b></p> <p><b>J. Panés<sup>1</sup></b>, J.O. Lindsay<sup>2</sup>, N. Teich<sup>3,4</sup>, S. Lindgren<sup>5</sup>, J.-F. Colombel<sup>6</sup>, F. Cornillie<sup>7</sup>, H. Ann Flynn<sup>8</sup>, S. Huyck<sup>8</sup>, P. Stryszak<sup>8</sup>, R. Yao<sup>8</sup>, G. Philip<sup>8</sup>, W. Reinisch<sup>9</sup></p> <p><sup>1</sup>Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, <sup>2</sup>The Royal London, Barts Health NHS Trust, London, United Kingdom, <sup>3</sup>Internistische Gemeinschaftspraxis, Leipzig, Germany, <sup>4</sup>Faculty of Medicine, Jena University, Jena, Germany, <sup>5</sup>Lund University, Malmö, Sweden, <sup>6</sup>Icahn School of Medicine at Mount Sinai, New York, United States, <sup>7</sup>Merck Sharpe &amp; Dohme, Kriens, Switzerland, <sup>8</sup>Merck &amp; Co., Inc., Kenilworth, United States, <sup>9</sup>Universitätsklinik für Innere Medizin III, Vienna, Austria</p>

Thursday, February 15, 2018, cont.

17:54 - 18:00	<p><b>DOP041: Surgery and hospitalisation in patients with Inflammatory Bowel Disease; 10 years follow-up of a Danish population-based inception cohort</b>  <b>B. Lo<sup>1</sup></b>, I. Vind<sup>1</sup>, F. Bendtsen<sup>1</sup>, M. Vester-Andersen<sup>1,2</sup>, J. Burisch<sup>1</sup>  <sup>1</sup>Copenhagen University Hospital Hvidovre, The Gastro Unit, Medical Division, Hvidovre, Denmark, <sup>2</sup>Zealand University Hospital, Medical Department, Køge, Denmark</p>
18:00 - 18:06	<p><b>DOP042: Need for ileocaecal resections, but not ileo-colic resections, has decreased – a nationwide study of temporal trends in Crohn surgery in Sweden 1990-2014</b>  <b>D. Kalman<sup>1</sup></b>, C. Nordenvall<sup>2</sup>, A. Hallqvist Everhov<sup>3</sup>, M.C. Sachs<sup>4</sup>, J.F. Ludvigsson<sup>5</sup>, A. Ekblom<sup>6</sup>, P. Myrelid<sup>1</sup>, O. Olén<sup>7</sup>  <sup>1</sup>Division of surgery, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University and Department of Surgery, County Council of Östergötland, Linköping, Sweden, <sup>2</sup>Dept. of Molecular Medicine and Surgery, Karolinska Institutet; Center for Digestive Disease, Div. of Coloproctology, Karolinska University Hospital, Stockholm, Sweden, <sup>3</sup>Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, <sup>4</sup>Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, <sup>5</sup>Department Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA, Stockholm, Sweden, <sup>6</sup>Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, <sup>7</sup>Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of pediatric gastroenterology and nutrition, Sachs' Children and Youth Hospital, Stockholm, Sweden</p>
18:06 - 18:12	<p><b>DOP043: Comparative outcomes of ileal pouch revision vs. excision for pouch failure within the American College of Surgeon National Surgical Quality Improvement Programme</b>  <b>S. Holubar<sup>1</sup></b>, P. Neary<sup>2</sup>, S. Shawki<sup>2</sup>, A. Aiello<sup>2</sup>, C. Delaney<sup>2</sup>, S. Steele<sup>2</sup>, T. Hull<sup>2</sup>, L. Stocchi<sup>2</sup>  <sup>1</sup>Cleveland Clinic, Department of Colon &amp; Rectal Surgery, Cleveland, United States, <sup>2</sup>Cleveland Clinic, Clinical Transformation, Cleveland, United States</p>

Thursday, February 15, 2018, cont.

<p>18:12 - 18:18</p>	<p><b>DOP044: Efficacy, safety and long-term outcome of endoscopic dilation therapy for Crohn's Disease strictures of the upper gastrointestinal tract – an international multicentre cohort study including 99 patients with 129 dilation procedures</b>  <b>D. Bettenworth</b><sup>1,2</sup>, M. Mücke<sup>3</sup>, A. Singh<sup>4</sup>, R. Lopez<sup>5</sup>, M. Goetz<sup>6</sup>, T. Matsui<sup>7</sup>, J.G. Karstensen<sup>8</sup>, N.S. Ding<sup>9</sup>, T.B. Qiu<sup>9</sup>, J. Hampe<sup>10</sup>, K. Matthes<sup>10</sup>, P.V. Valli<sup>11</sup>, F. Guo<sup>12</sup>, W. Zhu<sup>13</sup>, G. Rogler<sup>11</sup>, F. Rieder<sup>14,15</sup></p> <p><sup>1</sup>University Hospital Münster, Department of Medicine B, Gastroenterology and Hepatology, Münster, Germany, <sup>2</sup>University Hospital Münster, Department of Medicine B, Münster, Germany, <sup>3</sup>University Hospital Frankfurt, Department of Internal Medicine 1, Frankfurt a.M., Germany, <sup>4</sup>Cleveland Clinic Foundation, Cleveland, Ohio, USA, Department of Hospital Medicine, Medicine Institute, Cleveland, United States, <sup>5</sup>Cleveland Clinic Foundation, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland, United States, <sup>6</sup>University Hospital Tübingen, First Department of Internal Medicine I, Tübingen, Germany, <sup>7</sup>Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, <sup>8</sup>Copenhagen University Hospital, Gastro Unit, Division of Endoscopy, Herlev, Denmark, <sup>9</sup>St. Vincent Hospital, Department of Gastroenterology, Melbourne, Australia, <sup>10</sup>University Hospital Dresden, Technical University Dresden, Medical Department 1, Dresden, Germany, <sup>11</sup>University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland, <sup>12</sup>Jinling Hospital, School of Medicine, Nanjing University, Department of General Surgery, Nanjing, China, <sup>13</sup>Jinling Hospital, School of Medicine Nanjing University, Department of General Surgery, Nanjing, China, <sup>14</sup>Cleveland Clinic Foundation, Department of Gastroenterology, Hepatology &amp; Nutrition, Digestive Diseases and Surgery Institut, Cleveland, United States, <sup>15</sup>Cleveland Clinic, Department of Pathobiology, Lerner Research Institute, Cleveland, United States</p>
<p>18:18 - 18:24</p>	<p><b>DOP045: Combination therapy with anti-TNF and immunosuppressive therapies is the most effective medication to prevent and treat endoscopic postoperative recurrence in patients with Crohn's Disease</b>  <b>A. Buisson</b><sup>1,2</sup>, L. Cannon<sup>3</sup>, K. Umanskiy<sup>3</sup>, R.D. Hurst<sup>3</sup>, N.H. Hyman<sup>3</sup>, A. Sakuraba<sup>4</sup>, J. Pekow<sup>4</sup>, S. Dalal<sup>4</sup>, R.D. Cohen<sup>4</sup>, B. Pereira<sup>5</sup>, D.T. Rubin<sup>4</sup></p> <p><sup>1</sup>University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, <sup>2</sup>UMR 1071 Inserm/Université d'Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France, <sup>3</sup>University of Chicago Medicine, Department of Surgery, Chicago, United States, <sup>4</sup>Inflammatory Bowel Disease Center University of Chicago Medicine, Chicago, United States, <sup>5</sup>University Hospital, Biostatistics Unit, DRCl, Clermont-Ferrand, France</p>

Friday, February 16, 2018

**Digital Oral Presentation Session 6 – Optimisation of biologic therapies**

Room: Lehar 1-3

Axel Dignass, Frankfurt, Germany

Paula Ministro, Viseu, Portugal

17:20 - 18:20

**DOP046: Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn's Disease: Data from the LOVE-CD trial**
**S. Berends**<sup>1,2</sup>, M. Löwenberg<sup>2</sup>, F. Baert<sup>3</sup>, R. Mathôt<sup>1</sup>, E. Clasquin<sup>2</sup>, C. Van Der Woude<sup>4</sup>, F. Hoentjen<sup>5</sup>, P. Bossuyt<sup>6</sup>, D. Franchimont<sup>7</sup>, T. Rispens<sup>8,9</sup>, A. De Vries<sup>9</sup>, S. Vermeire<sup>10</sup>, G. D'Haens<sup>2</sup>
<sup>1</sup>Academic Medical Center (AMC), Hospital Pharmacy, Amsterdam, The Netherlands, <sup>2</sup>Academic Medical Center (AMC), Gastroenterology and Hepatology, Amsterdam, The Netherlands, <sup>3</sup>AZ Delta Roeselare-Menen, Gastroenterology, Roeselare-Menen, Belgium, <sup>4</sup>Erasmus University Medical Center, Gastroenterology and Hepatology, Rotterdam, The Netherlands, <sup>5</sup>Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands, <sup>6</sup>Imelda GI Clinical Research Center, Gastroenterology, Bonheiden, Belgium, <sup>7</sup>Erasmus Hospital, Gastroenterology, Brussels, Belgium, <sup>8</sup>Sanquin Research and Landsteiner Laboratory, Immunopathology, Amsterdam, The Netherlands, <sup>9</sup>Sanquin Diagnostic Services, Biologicals Lab, Amsterdam, The Netherlands, <sup>10</sup>University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium

17:20 - 17:26

**DOP047: Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn's Disease: Pharmacokinetic-pharmacodynamic analysis of TAILORIX**
**E. Dreesen**<sup>1</sup>, G. D'Haens<sup>2</sup>, F. Baert<sup>3</sup>, B. Pariente<sup>4</sup>, Y. Bouhnik<sup>5</sup>, J. van der Woude<sup>6</sup>, J. Moreau<sup>7</sup>, D. Laharie<sup>8</sup>, S. Vermeire<sup>9,10</sup>, A. Gils<sup>1</sup>
<sup>1</sup>KU Leuven, Departement of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, <sup>2</sup>Academic Medical Centre, Amsterdam, The Netherlands, <sup>3</sup>AZ Delta, Roeselare, Belgium, <sup>4</sup>Hospital Claude Huriez, Lille, France, <sup>5</sup>Hospital Beaujon, Clichy, France, <sup>6</sup>Erasmus MC, Rotterdam, The Netherlands, <sup>7</sup>CHU, Toulouse, Belgium, <sup>8</sup>Hospital Haut-Lévêque, Bordeaux, France, <sup>9</sup>University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, <sup>10</sup>KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

17:26 - 17:32

**DOP048: Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with Inflammatory Bowel Disease**
**A. Yarur**<sup>1</sup>, A. Bruss<sup>1</sup>, C. Fox<sup>1</sup>, P. Beniwal-Patel<sup>1</sup>, A. Patel<sup>1</sup>, B. Berens<sup>1</sup>, S. Naik<sup>2</sup>, D. Stein<sup>1</sup>
<sup>1</sup>Medical College of Wisconsin, Gastroenterology and Hepatology, Milwaukee, United States, <sup>2</sup>Prometheus Laboratories, San Diego, United States

17:32 - 17:38

**DOP049: Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant Ulcerative Colitis patients: A prospective study**
**D. Tarabar**<sup>1</sup>, K. El Jurdi<sup>2</sup>, O. Yvellez<sup>2</sup>, Z. Milenkovic<sup>1</sup>, S. Petrovic<sup>1</sup>, B. Subotic<sup>1</sup>, T.P. Brocic<sup>1</sup>, I. Brcrevic<sup>1</sup>, O. Latinovic<sup>3</sup>, D.T. Rubin<sup>2</sup>
<sup>1</sup>Military Medical Academy, Belgrade, Serbia, <sup>2</sup>University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States, <sup>3</sup>Clinical Center Vojvodina, Novi Sad, Serbia

17:38 - 17:44

**DOP050: Influence of disease location on vedolizumab efficacy in Inflammatory Bowel Disease: A real-life multicentre experience**
**S. Nancey**<sup>1</sup>, A.L. Charlois<sup>2</sup>, B. Bonaz<sup>1</sup>, B. Flourie<sup>2</sup>, G. Boschetti<sup>2</sup>, N. Mathieu<sup>1</sup>
<sup>1</sup>Grenoble Alpes University Hospital, University Clinic of Hepato-Gastroenterology, Grenoble, France, <sup>2</sup>Lyon Sud University Hospital, Department of Gastroenterology, Lyon, France

17:44 - 17:50

## Friday, February 16, 2018, cont.

17:50 - 17:56	<p><b>DOP051: Shorter disease duration is associated with higher response rates to vedolizumab in Crohn's Disease but not Ulcerative Colitis: A multi-centre consortium analysis</b></p> <p>D. Faleck<sup>1</sup>, A. Winters<sup>1</sup>, S. Chablaney<sup>1</sup>, P. Shashi<sup>2</sup>, J. Meserve<sup>3</sup>, A. Weiss<sup>4</sup>, S. Aniwani<sup>5</sup>, J.L. Koliiani-Pace<sup>6</sup>, G. Kochhar<sup>2</sup>, B. Boland<sup>3</sup>, S. Singh<sup>3</sup>, R. Hirten<sup>1</sup>, E. Schmidt<sup>1</sup>, K. Lasch<sup>7</sup>, M. Luo<sup>7</sup>, M. Bohm<sup>8</sup>, S.V Sagi<sup>8</sup>, M. Fischer<sup>8</sup>, D. Hudesman<sup>9</sup>, S. Chang<sup>9</sup>, D. Lukin<sup>4</sup>, K. Sultan<sup>10</sup>, A. Swaminath<sup>11</sup>, N. Gupta<sup>12</sup>, C.A. Siegel<sup>6</sup>, B. Shen<sup>2</sup>, W.J. Sandborn<sup>3</sup>, S. Kane<sup>5</sup>, E.V. Loftus<sup>5</sup>, B.E. Sands<sup>1</sup>, J.-F. Colombel<sup>1</sup>, <b>P.S. Dulai<sup>3</sup></b>, R. Ungaro<sup>1</sup></p> <p><sup>1</sup>Icahn School of Medicine at Mount Sinai, New York, United States, <sup>2</sup>Cleveland Clinic Foundation, Cleveland, United States, <sup>3</sup>University of California - San Diego, La Jolla, United States, <sup>4</sup>Montefiore Medical Center, New York, United States, <sup>5</sup>Mayo Clinic, Rochester, United States, <sup>6</sup>Dartmouth-Hitchcock Medical Center, Lebanon, United States, <sup>7</sup>Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States, <sup>8</sup>Indiana University, Indianapolis, United States, <sup>9</sup>New York University (NYU), New York, United States, <sup>10</sup>North Shore University Hospital, Manhasset, United States, <sup>11</sup>Lenox Hill Hospital, New York, United States, <sup>12</sup>University of Mississippi, Jackson, United States</p>
17:56 - 18:02	<p><b>DOP052: Vedolizumab versus ustekinumab for Crohn's Disease: Comparative effectiveness in a real-life observational cohort study (ICC Case Series)</b></p> <p><b>V. Biemans<sup>1,2</sup></b>, C. van der Woude<sup>3</sup>, A. van der Meulen-de Jong<sup>4</sup>, G. Dijkstra<sup>5</sup>, N. de Boer<sup>6</sup>, B. Oldenburg<sup>7</sup>, C. Ponsioen<sup>8</sup>, A. de Vries<sup>3</sup>, D. Wintjens<sup>9</sup>, F. Hoentjen<sup>9</sup>, M. Pierik<sup>2</sup>, Dutch Initiative on Crohn and Colitis (ICC)</p> <p><sup>1</sup>Radboudumc, Nijmegen, The Netherlands, <sup>2</sup>Maastricht University Medical Center (MUMC), Maastricht, The Netherlands, <sup>3</sup>Erasmus Medical Center, Rotterdam, The Netherlands, <sup>4</sup>Leiden University Medical Center (LUMC), Department of Gastroenterology and Hepatology, Leiden, The Netherlands, <sup>5</sup>University Medical Center Groningen, Groningen, The Netherlands, <sup>6</sup>VU University Medical Centre Institute of Education, Department of Gastroenterology and Hepatology, Room J393, Amsterdam, The Netherlands, <sup>7</sup>University Medical Centre Utrecht, Utrecht, The Netherlands, <sup>8</sup>Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, <sup>9</sup>Radboudumc, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands</p>
18:02 - 18:08	<p><b>DOP053: Impact of concomitant immunomodulator use on vedolizumab effectiveness: A multicentre consortium propensity score-matched analysis</b></p> <p>D. Hudesman<sup>1</sup>, S. Chang<sup>1</sup>, P. Shashi<sup>2</sup>, A. Winters<sup>3</sup>, S. Chablaney<sup>3</sup>, J. Meserve<sup>4</sup>, A. Weiss<sup>5</sup>, S. Aniwani<sup>6</sup>, D. Faleck<sup>3</sup>, J.L. Koliiani-Pace<sup>7</sup>, G. Kochhar<sup>2</sup>, B. Boland<sup>4</sup>, S. Singh<sup>4</sup>, R. Hirten<sup>3</sup>, E. Schmidt<sup>3</sup>, K. Lasch<sup>8</sup>, M. Luo<sup>8</sup>, M. Bohm<sup>9</sup>, S. V Sagi<sup>9</sup>, M. Fischer<sup>9</sup>, D. Lukin<sup>5</sup>, K. Sultan<sup>10</sup>, A. Swaminath<sup>11</sup>, N. Gupta<sup>12</sup>, C.A. Siegel<sup>7</sup>, B. Shen<sup>2</sup>, S. Kane<sup>6</sup>, E.V. Loftus<sup>6</sup>, B.E. Sands<sup>3</sup>, W.J. Sandborn<sup>4</sup>, J.-F. Colombel<sup>3</sup>, <b>P.S. Dulai<sup>3</sup></b></p> <p><sup>1</sup>New York University (NYU), New York, United States, <sup>2</sup>Cleveland Clinic Foundation, Cleveland, United States, <sup>3</sup>Icahn School of Medicine at Mount Sinai, New York, United States, <sup>4</sup>University of California - San Diego, La Jolla, United States, <sup>5</sup>Montefiore Medical Center, New York, United States, <sup>6</sup>Mayo Clinic, Rochester, United States, <sup>7</sup>Dartmouth-Hitchcock Medical Center, Lebanon, United States, <sup>8</sup>Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States, <sup>9</sup>Indiana University, Indianapolis, United States, <sup>10</sup>North Shore University Hospital, Manhasset, United States, <sup>11</sup>Lenox Hill Hospital, New York, United States, <sup>12</sup>University of Mississippi, Jackson, United States</p>

Friday, February 16, 2018, cont.

18:08 - 18:14	<p><b>DOP054: Vedolizumab in combination with steroids for induction therapy in Crohn's Disease: An exploratory analysis of the GEMINI 2 and GEMINI 3 studies</b></p> <p>B.E. Sands<sup>1</sup>, <b>G. Van Assche</b><sup>2</sup>, D. Tudor<sup>3</sup>, T. Tan<sup>4</sup></p> <p><sup>1</sup>Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, <sup>2</sup>University Hospitals Leuven and TARGID, Division of Gastroenterology and Hepatology, Leuven, Belgium, <sup>3</sup>Takeda Pharmaceuticals International AG, Zurich, Switzerland, <sup>4</sup>Takeda Pharmaceuticals International AG, Global Medical Affairs, Zurich, Switzerland</p>
---------------	---

**Digital Oral Presentation Session 7 – Novel therapies**

Room: Strauss 3

Marc Ferrante, Leuven, Belgium

Peter Irving, London, United Kingdom

17:20 - 18:20

17:20 - 17:26	<p><b>DOP055: Luminal application of a GATA3-specific DNzyme ameliorates mucosal inflammation in a randomised trial with active Ulcerative Colitis patients</b></p> <p><b>R. Atreya</b><sup>1</sup>, T. Kühbacher<sup>2,3</sup>, H. Schmitt<sup>1</sup>, S. Hirschmann<sup>1</sup>, M.J. Waldner<sup>1</sup>, O. Drvarov<sup>2</sup>, S. Fischer<sup>1</sup>, M. Vetter<sup>1</sup>, B. Weigmann<sup>1</sup>, A. Turowska<sup>4</sup>, T. Mühl<sup>4</sup>, U. Homburg<sup>4</sup>, J. Renz<sup>4</sup>, M. Vieth<sup>5</sup>, H. Garn<sup>6</sup>, H. Renz<sup>6</sup>, M.F. Neurath<sup>1</sup></p> <p><sup>1</sup>Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine I, Erlangen, Germany, <sup>2</sup>Asklepios Westklinikum, Department of Internal Medicine/Gastroenterology, Hamburg, Germany, <sup>3</sup>Christian Albrechts University Kiel, Department of Internal Medicine/Gastroenterology, Kiel, Germany, <sup>4</sup>Sterna biologicals GmbH Co &amp; KG, Marburg, Germany, <sup>5</sup>Institute of Pathology, Bayreuth, Germany, <sup>6</sup>Philipps University Marburg, Marburg, Germany</p>
17:26 - 17:32	<p><b>DOP056: Efficacy and safety of anti-fractalkine monoclonal antibody, E6011, in patients with Crohn's Disease who had lost response to anti-TNFa agents: A multicentre, open-label, Phase 1/2 study</b></p> <p><b>K. Matsuoka</b><sup>1</sup>, M. Naganuma<sup>2</sup>, S. Tanida<sup>3</sup>, K. Kitamura<sup>4</sup>, T. Matsui<sup>5</sup>, M. Arai<sup>6</sup>, M. Fujiya<sup>7</sup>, N. Horiki<sup>8</sup>, H. Nebiki<sup>9</sup>, F. Kinjo<sup>10</sup>, T. Miyazaki<sup>11</sup>, T. Matsumoto<sup>12</sup>, M. Esaki<sup>13</sup>, K. Mitsuyama<sup>14</sup>, M. Saruta<sup>15</sup>, A. Ido<sup>16</sup>, S. Hojo<sup>17</sup>, O. Takenaka<sup>17</sup>, K. Oketani<sup>18</sup>, T. Imai<sup>19</sup>, H. Tsubouchi<sup>20</sup>, T. Hibi<sup>21</sup>, T. Kanai<sup>2</sup></p> <p><sup>1</sup>Tokyo Medical and Dental University, Gastroenterology and Hepatology, Tokyo, Japan, <sup>2</sup>Keio University School of Medicine, Internal Medicine, Gastroenterology and Hepatology, Tokyo, Japan, <sup>3</sup>Nagoya City University Graduate School of Medical Sciences, Gastroenterology and Metabolism, Aichi, Japan, <sup>4</sup>Kanazawa University Hospital, Gastroenterology, Ishikawa, Japan, <sup>5</sup>Fukuoka University Chikushi Hospital, Gastroenterology, Fukuoka, Japan, <sup>6</sup>Chiba University Hospital, Gastroenterology, Chiba, Japan, <sup>7</sup>Asahikawa Medical University, Gastroenterology and Hematology/Oncology, Hokkaido, Japan, <sup>8</sup>Mie University Hospital, Endoscopy, Mie, Japan, <sup>9</sup>Osaka City General Hospital, Gastroenterology, Osaka, Japan, <sup>10</sup>Urasoe General Hospital, Center for Gastroenterology, Okinawa, Japan, <sup>11</sup>Hyogo College of Medicine, Inflammatory Bowel Disease, Hyogo, Japan, <sup>12</sup>Iwate Medical University, Internal Medicine, School of Medicine, Gastroenterology, Iwate, Japan, <sup>13</sup>Kyushu University Graduate School of Medical Sciences, Medicine and Clinical Science, Fukuoka, Japan, <sup>14</sup>Kurume University School of Medicine, Inflammatory Bowel Disease Center, Fukuoka, Japan, <sup>15</sup>The Jikei University School of Medicine, Gastroenterology and Hepatology, Tokyo, Japan, <sup>16</sup>Kagoshima University Graduate School of Medicine and Dental Sciences, Digestive and Lifestyle Diseases, Kagoshima, Japan, <sup>17</sup>Eisai. Co., Ltd., Tokyo, Japan, <sup>18</sup>EA Pharma Co., Ltd., Tokyo, Japan, <sup>19</sup>KAN Research Institute, Hyogo, Japan, <sup>20</sup>Kagoshima City Hospital, Kagoshima, Japan, <sup>21</sup>Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan</p>

## Friday, February 16, 2018, cont.

17:32 - 17:38	<p><b>DOP057: ECCO-EBMT joint paper: Autologous haematopoietic stem cell transplantation (ÀHSCT) in severe Crohn's Disease: Summary of the ECCO-EBMT joint review</b></p> <p><b>J. Snowden<sup>1</sup></b>, J. Panes<sup>2</sup>, T. Alexander<sup>3</sup>, M. Allez<sup>4</sup>, S. Ardiszone<sup>5</sup>, D. Dierickx<sup>6</sup>, J. Finke<sup>7</sup>, P. Hasselblatt<sup>7</sup>, C. Hawkey<sup>8</sup>, M. Kazmi<sup>9</sup>, J. Lindsay<sup>10</sup>, F. Onida<sup>11</sup>, A. Salas<sup>2</sup>, R. Saccardi<sup>12</sup>, S. Vermeire<sup>13</sup>, M. Rovira<sup>14</sup>, E. Ricart<sup>2</sup></p> <p><sup>1</sup>Sheffield Teaching Hospitals NHS Foundation Trust, Haematology, Sheffield, United Kingdom, <sup>2</sup>Hospital Clinic, IDIBAPS, CIBERehd, Gastroenterology, Barcelona, Spain, <sup>3</sup>Charité – University Medicine Berlin, 1. Department of Rheumatology and Clinical Immunology, Berlin, Germany, <sup>4</sup>Hôpital Saint Louis, APHP, INSERM U1160, Paris Diderot, Sorbonne Paris-Cité University, Gastroenterology, Paris, France, <sup>5</sup>DIBIC-ASST Fatebenefratelli Sacco - University of Milan, Gastroenterology, Milan, Italy, <sup>6</sup>University Hospitals Leuven, Haematology, Leuven, Belgium, <sup>7</sup>Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Department of Medicine II, Freiburg, Germany, <sup>8</sup>University of Nottingham, Nottingham Digestive Diseases Centre, Nottingham, United Kingdom, <sup>9</sup>Guys &amp; St Thomas' NHS Foundation Trust, Haematology, London, United Kingdom, <sup>10</sup>The Royal London Hospital, Barts Health NHS Trust &amp; Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Gastroenterology, London, United Kingdom, <sup>11</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - University of Milan, Hematology-BMT Center, Milan, United Kingdom, <sup>12</sup>Careggi University Hospital, Department of Haematology, Firenze, Italy, <sup>13</sup>University hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, <sup>14</sup>IDIBAPS, Hospital Clinic, BMT Unit, Hematology Department &amp; Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain</p>
17:38 - 17:44	<p><b>DOP058: Combined stem cells and anticytokine therapy contributes to a more pronounced decrease in the degree of inflammation of the intestinal mucosa in Crohn's Disease</b></p> <p><b>N. Fadeeva<sup>1</sup></b>, O. Knyazev<sup>1</sup>, A. Kagramanova<sup>1</sup>, E. Dobroluybova<sup>1</sup>, I. Donchenko<sup>1</sup>, S. Khomeriki<sup>2</sup>, A. Babayan<sup>1</sup>, A. Lishchinskaya<sup>3</sup>, A. Konoplyannikov<sup>4</sup></p> <p><sup>1</sup>Moscow Clinical Research Center, Department of Inflammatory Bowel Disease, Moscow, Russian Federation, <sup>2</sup>Moscow Clinical Research Center, Department of Pathology, Moscow, Russian Federation, <sup>3</sup>Moscow Clinical Research Center, Moscow, Russian Federation, <sup>4</sup>Medical Radiological Scientific Center, Department of Stem Cells Therapy, Obninsk, Russian Federation</p>
17:44 - 17:50	<p><b>DOP059: Combined anticytokine and local mesenchymal stem cells therapy promotes longer healing of simple fistulas in patients with Crohn's Disease</b></p> <p><b>N. Belyakov<sup>1</sup></b>, O. Knyazev<sup>1</sup>, N. Fadeeva<sup>1</sup>, N. Orlova<sup>2</sup>, A. Konoplyannikov<sup>3</sup>, A. Parfenov<sup>1</sup></p> <p><sup>1</sup>Moscow Clinical Research Center, Department of Inflammatory Bowel Disease, Moscow, Russian Federation, <sup>2</sup>Moscow Clinical Research Center, Department of Radiology, Moscow, Russian Federation, <sup>3</sup>Medical Radiological Scientific Center, Department of Stem Cells Therapy, Obninsk, Russian Federation</p>
17:50 - 17:56	<p><b>DOP060: Human amnion epithelial cells and their conditioned media reduces intestinal inflammation and fibrosis in a murine model of chronic colitis</b></p> <p><b>N. Kuk<sup>1,2</sup></b>, J. Correia<sup>1,2</sup>, M. Alhomrani<sup>1,2,3</sup>, R. Lim<sup>3</sup>, W. Sievert<sup>1,2</sup>, A. Hodge<sup>1,2</sup>, G. Moore<sup>1,2</sup></p> <p><sup>1</sup>Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, <sup>2</sup>Gastroenterology and Hepatology Unit, Monash Medical Centre, Melbourne, Australia, <sup>3</sup>Hudson Institute for Medical Research, Melbourne, Australia</p>

Friday, February 16, 2018, cont.

17:56 - 18:02	<p><b>DOP061: Human amnion epithelial cells reduce intestinal inflammation in a 2,4,6-trinitrobenzene sulfonic acid induced model of Acute Colitis</b>  <b>N. Kuk<sup>1,2</sup>, J. Correia<sup>1,2</sup>, M. Alhomrani<sup>1,2,3</sup>, R. Lim<sup>3</sup>, W. Sievert<sup>1,2</sup>, A. Hodge<sup>1,2</sup>, G. Moore<sup>1,2</sup></b></p> <p><sup>1</sup>Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, <sup>2</sup>Gastroenterology and Hepatology Unit, Monash Medical Centre, Melbourne, Australia, <sup>3</sup>Hudson Institute for Medical Research, Melbourne, Australia</p>
18:02 - 18:08	<p><b>DOP062: The anti-MAdCAM antibody SHP647 in Crohn's Disease: Endoscopic effects of induction therapy</b>  <b>G.R. D'Haens<sup>1</sup>, K. Gorelick<sup>2</sup>, Y. Wang<sup>3</sup>, F. Cataldi<sup>3</sup>, W.J. Sandborn<sup>4</sup></b></p> <p><sup>1</sup>Academic Medical Centre, Amsterdam, The Netherlands, <sup>2</sup>Zymo Consulting Group, Newtown Square, United States, <sup>3</sup>Shire, Lexington, United States, <sup>4</sup>University of California San Diego, La Jolla, United States</p>
18:08 - 18:14	<p><b>DOP063: Inhibition of tyrosine kinase 2 signalling ameliorates T cell transfer colitis</b>  <b>L.C. De Vries<sup>1,2</sup>, M.E. Wildenberg<sup>1,2</sup>, R.A. Willemze<sup>1,2</sup>, H.P. van Hamersveld<sup>1</sup>, O. Welting<sup>1</sup>, C. Verseijden<sup>1</sup>, B. Strobl<sup>3</sup>, M. Mueller<sup>3</sup>, G.R. D'Haens<sup>2</sup>, W.J. De Jonge<sup>1</sup></b></p> <p><sup>1</sup>Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands, <sup>2</sup>Academic Medical Center, Gastroenterology &amp; Hepatology, Amsterdam, The Netherlands, <sup>3</sup>University of Veterinary Medicine, Institute of Animal Breeding and Genetics, Vienna, Austria</p>

**Digital Oral Presentation Session 8 – Treatment strategies**

17:20 - 18:20

 Room: Stolz 1-2  
 Antonio López-Sanromán, Madrid, Spain  
 Christian Maaser, Lüneburg, Germany

17:20 - 17:26	<p><b>DOP064: ECCO Expert Consensus and Topical Review on Treatment Exit Strategies in Inflammatory Bowel Disease</b>  <b>G. Doherty<sup>1</sup>, K. Katsanos<sup>2</sup>, J. Burisch<sup>3</sup>, M. Allez<sup>4</sup>, K. Papamichael<sup>5</sup>, A. Stallmach<sup>6</sup>, R. Mao<sup>7</sup>, I. Prytz Berset<sup>8</sup>, J. Gisbert<sup>9</sup>, S. Sebastian<sup>10</sup>, J. Kierkuš<sup>11</sup>, L. Lopetuso<sup>12</sup>, E. Szymanska<sup>11</sup>, E. Louis<sup>13</sup></b></p> <p><sup>1</sup>St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland, <sup>2</sup>University and Medical School of Ioannina, Ioannina, Greece, <sup>3</sup>North Zealand University Hospital, Frederikssund, Denmark, <sup>4</sup>Hôpital Saint-Louis, APHP, INSERM UMRS 1160, Université Denis Diderot, Paris, France, <sup>5</sup>Beth Israel Deaconess Medical Center, Department of Gastroenterology, Boston, United States, <sup>6</sup>University Hospital Jena, Department of Medicine, Jena, Germany, <sup>7</sup>The First Affiliated Hospital Of Sun Yat-sen University, Guangzhou, China, <sup>8</sup>alesund Hospital, Department of Gastroenterology, Alesund, Norway, <sup>9</sup>Hospital Universitario de La Princesa, Department of Gastroenterology, Madrid, Spain, <sup>10</sup>Hull &amp; East Yorkshire NHS Trust, Hull &amp; York Medical School, Hull, United Kingdom, <sup>11</sup>Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Warsaw, Poland, <sup>12</sup>Catholic University of Rome - A. Gemelli Hospital, Department of Internal Medicine and Gastroenterology, Rome, Italy, <sup>13</sup>CHU Liege, Sart Tilman, Department of Pediatric Gastroenterology, Liege, Belgium</p>
---------------	---

## Friday, February 16, 2018, cont.

17:26 - 17:32	<p><b>DOP065: Long term cost effectiveness of tight control for Crohn's Disease with adalimumab-based treatment: Economic evaluation beyond 48 weeks of CALM trial</b>  <b>R. Panaccione</b><sup>1</sup>, J.-F. Colombel<sup>2</sup>, P. Bossuyt<sup>3</sup>, F. Baert<sup>4</sup>, T. Vanasek<sup>5</sup>, A. Danalioglu<sup>6</sup>, G. Novacek<sup>7</sup>, A. Armuzzi<sup>8</sup>, W. Reinisch<sup>7</sup>, S. Johnson<sup>9</sup>, M. Buessing<sup>9</sup>, E. Neimark<sup>10</sup>, J. Petersson<sup>10</sup>, A.M. Robinson<sup>10</sup>, R.B. Thakkar<sup>10</sup>, W.-J. Lee<sup>10</sup>, M. Skup<sup>10</sup>, G. D'Haens<sup>11</sup></p> <p><sup>1</sup>University of Calgary, Calgary, Canada, <sup>2</sup>Icahn School of Medicine at Mount Sinai, New York, United States, <sup>3</sup>Imelda General Hospital, Bonheiden, Belgium, <sup>4</sup>AZ Delta Roeselare-Menen, Roeselare-Menen, Belgium, <sup>5</sup>Hepato-Gastroenterologie HK, s.r.o., Hradec Králové, Czech Republic, <sup>6</sup>Bezmialem Vakif University, Istanbul, Turkey, <sup>7</sup>Medical University of Vienna, Vienna, Austria, <sup>8</sup>Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, <sup>9</sup>Medicus Economics LLC, Boston, United States, <sup>10</sup>AbbVie Inc., North Chicago, United States, <sup>11</sup>IBD Unit, Academic Medical Center, Amsterdam, The Netherlands</p>
17:32 - 17:38	<p><b>DOP066: Developing a Core Outcome Set for Fistulising Perianal Crohn's Disease</b>  <b>K. Sahnan</b><sup>1</sup>, P.J. Tozer<sup>1</sup>, S.O. Adegbola<sup>1</sup>, M.J. Lee<sup>2</sup>, N. Heywood<sup>3</sup>, A.G.K. McNair<sup>4</sup>, D. Hind<sup>5</sup>, N. Yassin<sup>6</sup>, A.J. Lobo<sup>7</sup>, S.R. Brown<sup>2</sup>, S. Sebastian<sup>8</sup>, R.K. Phillips<sup>1</sup>, P.F. Lung<sup>9</sup>, O.D. Faiz<sup>1</sup>, K. Crook<sup>10</sup>, S. Blackwell<sup>11</sup>, A. Verjee<sup>12</sup>, A.L. Hart<sup>13</sup>, N.S. Fearnhead<sup>14</sup></p> <p><sup>1</sup>St Mark's Hospital, Colorectal Surgery, London, United Kingdom, <sup>2</sup>Sheffield Teaching Hospitals NHS Trust, Northern General Hospital, Department of Colorectal Surgery, Sheffield, United Kingdom, <sup>3</sup>University Hospital South Manchester, Department of Colorectal Surgery, Manchester, United Kingdom, <sup>4</sup>Bristol, School of Social and Community Medicine, Bristol, United Kingdom, <sup>5</sup>Clinical Trials Research Unit, School of Health and Related Research, Sheffield, UK, Sheffield, United Kingdom, <sup>6</sup>Birmingham University Hospitals NHS Trust, Birmingham, United Kingdom, <sup>7</sup>Sheffield Teaching Hospitals NHS Trust, Northern General Hospital, Department of Gastroenterology, Sheffield, United Kingdom, <sup>8</sup>Hull Royal Infirmary, Hull &amp; East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, United Kingdom, <sup>9</sup>St Mark's Hospital, Gastrointestinal Imaging, London, United Kingdom, <sup>10</sup>St Mark's Hospital, Department of IBD, London, United Kingdom, <sup>11</sup>Patient representative, Liverpool, United Kingdom, <sup>12</sup>Patient representative, London, United Kingdom, <sup>13</sup>St Mark's Hospital, IBD/Physiology, London, United Kingdom, <sup>14</sup>Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Department of Colorectal Surgery, Cambridge, United Kingdom</p>
17:38 - 17:44	<p><b>DOP067: Treatment discontinuation, flares and hospitalisations among biologic-naïve patients with IBD over the first year of treatment: A comparative effectiveness study of vedolizumab versus infliximab</b>  M. Raluy-Callado<sup>1</sup>, A. Berger<sup>2</sup>, J.M. Khalid<sup>3</sup>, <b>H. Patel</b><sup>3</sup></p> <p><sup>1</sup>Evidera, Real-World Evidence, London, United Kingdom, <sup>2</sup>Evidera, Real World Evidence, Waltham, MA, United States, <sup>3</sup>Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom</p>
17:44 - 17:50	<p><b>DOP068: Crohn's Disease decision aid leads to more patients choosing combination therapy in a cluster randomised controlled trial</b>  <b>C.A. Siegel</b><sup>1</sup>, K.D. Thompson<sup>1</sup>, L.S. Siegel<sup>2</sup>, T. MacKenzie<sup>3</sup>, M.C. Dubinsky<sup>4</sup></p> <p><sup>1</sup>Dartmouth-Hitchcock Medical Center, Lebanon, United States, <sup>2</sup>Climate Interactive, Hanover, United States, <sup>3</sup>Geisel School of Medicine at Dartmouth, Hanover, United States, <sup>4</sup>Icahn School of Medicine at Mount Sinai, New York, United States</p>

Friday, February 16, 2018, cont.

17:50 - 17:56	<p><b>DOP069: Improved quality of care &amp; quality of life for IBD patients using mobile based remote monitoring platform: A randomised control trial</b>  <b>A. Atreja<sup>1</sup></b>, E. Otobo<sup>1</sup>, E. Szigethy<sup>2</sup>, H. Shroff<sup>1</sup>, H. Chang<sup>1</sup>, L. Keefer<sup>1</sup>, J. Rogers<sup>1</sup>, T. Ullman<sup>1</sup>, J.F. Marion<sup>1</sup>, B. Cohen<sup>1</sup>, E. Maser<sup>1</sup>, S. Itzkowitz<sup>1</sup>, J.-F. Colombel<sup>1</sup>, B. Sands<sup>1</sup>  <sup>1</sup>Icahn School of Medicine at Mount Sinai, New York, United States, <sup>2</sup>University of Pittsburgh, Pittsburgh, United States</p>
17:56 - 18:02	<p><b>DOP070: Development and pilot of an index to identify young people with Inflammatory Bowel Disease at risk of psychological morbidity</b>  <b>R.T. Lees<sup>1</sup></b>, A.J. Brooks<sup>1</sup>, G. Rowse<sup>2</sup>, P. Narula<sup>3</sup>, P. Norman<sup>4</sup>, A.J. Lobo<sup>1</sup>  <sup>1</sup>Sheffield Teaching Hospitals, Department of Gastroenterology, Sheffield, United Kingdom, <sup>2</sup>University of Sheffield, Clinical Psychology Unit, Sheffield, United Kingdom, <sup>3</sup>Sheffield Children's Hospital, Gastroenterology Department, Sheffield, United Kingdom, <sup>4</sup>University of Sheffield, Department of Psychology, Sheffield, United Kingdom</p>
18:02 - 18:08	<p><b>DOP071: Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn's Disease: Data from CALM</b>  <b>R. Panaccione<sup>1</sup></b>, J.-F. Colombel<sup>2</sup>, P. Bossuyt<sup>3</sup>, F. Baert<sup>4</sup>, T. Vanasek<sup>5</sup>, A. Danaliloglu<sup>6</sup>, G. Novacek<sup>7</sup>, A. Armuzzi<sup>8</sup>, W. Reinisch<sup>7</sup>, E. Neimark<sup>9</sup>, J. Petersson<sup>9</sup>, A.M. Robinson<sup>9</sup>, R.B. Thakkar<sup>9</sup>, N. Chen<sup>9</sup>, M. Skup<sup>9</sup>, W.-J. Lee<sup>9</sup>, G. D'Haens<sup>10</sup>  <sup>1</sup>University of Calgary, Calgary, Canada, <sup>2</sup>Icahn School of Medicine at Mount Sinai, New York, United States, <sup>3</sup>Imelda General Hospital, Bonheiden, Belgium, <sup>4</sup>AZ Delta Roeselare-Menen, Roeselare-Menen, Belgium, <sup>5</sup>Hepato-Gastroenterologie HK, s.r.o., Hradec Králové, Czech Republic, <sup>6</sup>Bezmialem Vakif University, Istanbul, Turkey, <sup>7</sup>Medical University of Vienna, Vienna, Austria, <sup>8</sup>Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, <sup>9</sup>AbbVie Inc., North Chicago, United States, <sup>10</sup>IBD Unit, Academic Medical Center, Amsterdam, The Netherlands</p>
18:08 - 18:14	<p><b>DOP072: Achieving biochemical remission with adalimumab therapy using therapeutic drug monitoring: Results of a large prospective Crohn's Disease cohort</b>  <b>N. Plevis<sup>1</sup></b>, P. Jenkinson, C.S. Chuah, M. Lyons, R. Hall, G. Jones, E. Watson, I. Arnott, C. Lees      NHS Lothian, Gastroenterology, Edinburgh, United Kingdom</p>

Friday, February 16, 2018, cont.

**Digital Oral Presentation Session 9 – Advances in IBD Pathophysiology**

Room: Strauss 1-2

Jesús Rivera-Nieves, San Diego, United States

TBC

17:20 - 18:20

**DOP073: Results of the sixth ECCO Scientific Workshop: The pathogenesis of inflammatory extraintestinal manifestations of Inflammatory Bowel Disease – implications for research, diagnosis and therapy**

**C.R.H. Hedin<sup>1</sup>**, S.R. Vavricka<sup>2</sup>, A.J. Stagg<sup>3</sup>, A. Schoepfer<sup>4</sup>, T. Raine<sup>5</sup>, L. Puig<sup>6</sup>, U. Pleyer<sup>7</sup>, A. Navarini<sup>8</sup>, A.E. van der Meulen-de Jong<sup>9</sup>, J. Maul<sup>10</sup>, K.H. Katsanos<sup>11</sup>, A. Kagramanova<sup>12</sup>, T. Greuter<sup>13,14</sup>, Y. Gonzalez Lama<sup>15</sup>, F.A. van Gaalen<sup>16</sup>, P. Ellul<sup>17</sup>, J. Burisch<sup>18</sup>, D. Bettenworth<sup>19</sup>, M. Becker<sup>20</sup>, G. Bamias<sup>21</sup>, F. Rieder<sup>22</sup>

<sup>1</sup>Karolinska University Hospital, Gastroenterology unit, Patient Area Gastroenterology, Dermatovenereology and Rheumatology, Stockholm, Sweden, <sup>2</sup>Centre for Gastroenterology and Hepatology, Zurich, Switzerland, <sup>3</sup>Barts and The London, Queen Mary's School of Medicine and Dentistry, Centre for Immunobiology, London, United Kingdom, <sup>4</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Department of Gastroenterology, Lausanne, Switzerland, <sup>5</sup>University of Cambridge, Department of Medicine, Cambridge, United Kingdom, <sup>6</sup>Universitat Autònoma de Barcelona, Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, <sup>7</sup>Charité - University Hospital Berlin, University Eye Clinic, Uveitis Center, Berlin, Germany, <sup>8</sup>University Hospital Zurich, Department of Dermatology, Zurich, Switzerland, <sup>9</sup>Leiden University Medical Center (LUMC), Department of Gastroenterology and Hepatology, Leiden, The Netherlands, <sup>10</sup>Gastroenterologie am Bayerischen Platz, Berlin, Germany, <sup>11</sup>University and Medical School of Ioannina, Department of Internal Medicine I, Division of Gastroenterology and Hepatology, Ioannina, Greece, <sup>12</sup>The Loginov Moscow Clinical Scientific Centre, IBD Department, Moscow, Russian Federation, <sup>13</sup>Mayo Clinic, Gastroenterology Research Unit, Rochester, MN, United States, <sup>14</sup>University of Zurich, Department of Gastroenterology and Hepatology, USZ, Zurich, Switzerland, <sup>15</sup>Hospital Universitario Puerta De Hierro, Intestinal Inflammatory Disease Unit / IBD Unit, Gastroenterology and Hepatology Service/Gastroenterology and Hepatology Department, Madrid, Spain, <sup>16</sup>Leiden University Medical Center (LUMC), Department of Rheumatology, Leiden, The Netherlands, <sup>17</sup>Mater Dei Hospital, Department of Medicine, Division of Gastroenterology, Triq Dun Karm, L-Imnsida, Malta, <sup>18</sup>North Zealand University Hospital, Department of Gastroenterology and Hepatology, Frederikssund, Denmark, <sup>19</sup>University Hospital Münster, Department of Medicine B, Gastroenterology and Hepatology, Münster, Germany, <sup>20</sup>Triemli Hospital, Department of Ophthalmology, Zurich, Switzerland, <sup>21</sup>Sotiria Hospital, National and Kapodistrian University of Athens, GI Unit, <sup>22</sup>rd Academic Dpt. of Internal Medicine, Athens, Greece, <sup>22</sup>Cleveland Clinic Foundation, Department of Gastroenterology and Hepatology, Cleveland, United States

17:20 - 17:26

**DOP074: IL-33 promotes gut mucosal wound healing by inducing miRNA-320 to stimulate epithelial restitution and repair**

**L.R. Lopetuso<sup>1,2</sup>**, C. De Salvo<sup>2</sup>, L. Di Martino<sup>2</sup>, N. Rana<sup>2</sup>, W. Goodman<sup>2</sup>, F. Scaldaferrì<sup>1</sup>, A. Armuzzi<sup>1</sup>, A. Gasbarrini<sup>1</sup>, T.T. Pizarro<sup>2</sup>

<sup>1</sup>Catholic University of Sacred Heart, Internal Medicine Department, Gastroenterology Division, Rome, Italy, <sup>2</sup>Case Western Reserve University, Pathology, Cleveland, United States

17:26 - 17:32

Friday, February 16, 2018, cont.

17:32 - 17:38	<p><b>DOP075: Colonic gamma delta t-cells respond innately to NKG2D ligands and are grossly dysregulated in active Inflammatory Bowel Disease</b>  <b>R.J. Dart</b><sup>1,2,3</sup>, P. Vantourout<sup>1,2</sup>, A. Laing<sup>1,2</sup>, J. Digby-Bell<sup>3</sup>, N. Powell<sup>3,4</sup>, P. Irving<sup>3</sup>, A. Hayday<sup>1,2</sup>  <sup>1</sup>Francis Crick Institute, Immunosurveillance Lab, London, United Kingdom, <sup>2</sup>King's College London, DIIID, London, United Kingdom, <sup>3</sup>Guy's and St Thomas Foundation Trust, Department of Gastroenterology, London, United Kingdom, <sup>4</sup>King's College London, DTIMB, London, United Kingdom</p>
17:38 - 17:44	<p><b>DOP076: IL-3 drives IL-10-secreting Tr1 cells to counteract experimental colitis</b>  <b>S. Zundler</b>, M. Spocinska, V. Popp, E. Becker, R. Atreya, C. Neufert, I. Atreya, B. Weigmann, M.F. Neurath                  University of Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany</p>
17:44 - 17:50	<p><b>DOP077: Deep Immunophenotyping reveals a role for Mucosal Associated Invariant T (MAIT) cells in the response to anti-TNF treatment in Crohn's Disease</b>  <b>M. Walshe</b>, L.A. Elliott, D. Danso-Abeam, G. Cullen, J. Sheridan, H. Mulcahy, E. Ryan, G. Doherty                  Centre for Colorectal Disease, St. Vincent's University Hospital, University College Dublin, Dublin, Ireland</p>
17:50 - 17:56	<p><b>DOP078: Visceral and subcutaneous adipose tissues of Crohn's Disease patients contains bacteria</b>  <b>C. Serena</b><sup>1</sup>, M. Terrón-Puig<sup>1</sup>, E. Maymó-Masip<sup>1</sup>, M. Queipo-Ortuño<sup>2</sup>, J. Sabadell-Basallote<sup>1</sup>, M.M. Rodríguez<sup>1</sup>, C. Nuñez-Roa<sup>1</sup>, M. Menacho<sup>3</sup>, E. Espin<sup>4</sup>, A. Zorzano<sup>5</sup>, M. Millan<sup>6</sup>, S. Fernández-Veledo<sup>1</sup>, J. Vendrell<sup>1</sup>  <sup>1</sup>Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, Tarragona, Spain, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain, Tarragona, Spain, <sup>2</sup>Servicio de Endocrinología y Nutrición, Campus Teatinos s/n, Hospital Clínico Universitario Virgen de la Victoria, 29010, Málaga, Spain, CIBEROBN, Instituto de Salud Carlos III, Madrid, Spain, Málaga, Spain, <sup>3</sup>Hospital Joan XIII, Digestive Unit, Tarragona, Spain, <sup>4</sup>Colorectal Surgery Unit, General Surgery Service, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, Barcelona, Spain, <sup>5</sup>Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain, CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Barcelona, Spain, Departamento de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain, <sup>6</sup>Hospital Joan XIII, Colorectal Surgery Unit, Tarragona, Spain</p>
17:56 - 18:02	<p><b>DOP079: Heat shock protein GP96 is essential for self-renewal of the intestinal epithelial barrier</b>  <b>M. Schwarzfischer</b><sup>1</sup>, Y. Morsy<sup>1</sup>, K. Atrott<sup>1</sup>, C. Stanzel<sup>1</sup>, S. Lang<sup>1</sup>, G. Rogler<sup>1,2</sup>, M. Scharl<sup>1</sup>, M. Spalinger<sup>1</sup>  <sup>1</sup>University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, <sup>2</sup>University Hospital Zurich, Zurich, Switzerland</p>
18:02 - 18:08	<p><b>DOP080: Endoplasmic reticulum stress in bordering epithelium of Crohn's Disease patients with intestinal fibrosis</b>  <b>S. Hu</b><sup>1</sup>, N. Bletard<sup>2</sup>, C. Massot<sup>1,3</sup>, N. Pierre<sup>1</sup>, F. Quesada Calvo<sup>1</sup>, G. Paulissen<sup>1</sup>, N. Smargiasso<sup>4</sup>, G. Mazzucchielli<sup>4</sup>, D. Baiwir<sup>5</sup>, E. De Pauw<sup>4</sup>, P. Delvenne<sup>2</sup>, M.-A. Meuwis<sup>1,3</sup>, E. Louis<sup>1,3</sup>  <sup>1</sup>GIGA-R, Uliège, Translational Gastroenterology, Liège, Belgium, <sup>2</sup>CHU de Liège, Pathological anatomy, Liège, Belgium, <sup>3</sup>CHU de Liège, Hepato-gastroenterology and digestive oncology, Liège, Belgium, <sup>4</sup>Uliège, Laboratory of mass spectrometry, Chemistry, Liège, Belgium, <sup>5</sup>GIGA proteomic facility, Uliège, GIGA, Liège, Belgium</p>

Friday, February 16, 2018, cont.

18:08 - 18:14	<p><b>DOP081: Genital granulomatosis in Crohn's Disease: Results of the ECCO CONFER study</b>  <b>F. Dederichs<sup>1</sup></b>, I. Iesalnieks<sup>2</sup>, M. Sladek<sup>3</sup>, C. Tzivinikos<sup>4</sup>, R. Hansen<sup>5</sup>, C. Muñoz<sup>6</sup>, P. Pavli<sup>7</sup>, M. Cavicchi<sup>8</sup>, V. Abitbol<sup>9</sup>, J.-F. Rahier<sup>10</sup>, S. Vavricka<sup>11</sup>, K. Katsanos<sup>12</sup>, E. Domènech<sup>13,14</sup></p> <p><sup>1</sup>Kath. Krankenhaus Hagen, Hagen, Germany, <sup>2</sup>Klinikum Bogenhausen, München, Germany, <sup>3</sup>Jagiellonian University Medical College, Krakow, Poland, <sup>4</sup>Royal London Hospital, London, United Kingdom, <sup>5</sup>Royal Hospital for Children, Glasgow, United Kingdom, <sup>6</sup>Villafranca del Hospital Universitario de Basurto, Bilbao, Spain, <sup>7</sup>Canberra Hospital, Canberra, Australia, <sup>8</sup>Cabinet Medical Créteil, Paris, France, <sup>9</sup>Cochin Hospital, Paris, France, <sup>10</sup>CHU Dinant-Godinne, Department of Gastroenterology, Yvoir, Belgium, <sup>11</sup>Triemli Hospital, Zurich, Switzerland, <sup>12</sup>University and Medical School of Ioannina, Ioannina, Greece, <sup>13</sup>Hospital Universitari Germans Trias I Pujol, Badalona, Spain, <sup>14</sup>CIBEREHD, Madrid, Spain</p>
---------------	--

**Digital Oral Presentation Session 10 – Microbes, food and cancer in IBD**  
 Room: Lehar 4  
 Gionata Fiorino, Milan, Italy  
 Arie Levine, Tel Aviv, Israel

17:20 - 17:26	<p><b>DOP082: Potential diagnostic biomarkers of Ulcerative Colitis-associated colorectal dysplasia</b>  <b>A.-M. Merli<sup>1</sup></b>, C. Massot<sup>1,2</sup>, N. Bletard<sup>3</sup>, F. Quesada Calvo<sup>1</sup>, D. Baiwir<sup>4</sup>, G. Mazzucchelli<sup>5</sup>, N. Smargiasso<sup>5</sup>, L. Servais<sup>6</sup>, C. Oury<sup>6</sup>, M.-C. De Pauw-Gillet<sup>7</sup>, E. De Pauw<sup>8</sup>, C. Coimbra Marques<sup>8</sup>, A. Colard<sup>9</sup>, A. Vijverman<sup>10</sup>, P. Delvenne<sup>3</sup>, M.-A. Meuwis<sup>1,2</sup>, E. Louis<sup>1,2</sup></p> <p><sup>1</sup>GIGA-R, ULiège, Translational Gastroenterology, Liège, Belgium, <sup>2</sup>CHU de Liège, Hepato-Gastroenterology and Digestive oncology, Liège, Belgium, <sup>3</sup>CHU de Liège, Pathological anatomy and cytology, Liège, Belgium, <sup>4</sup>GIGA proteomic facility, ULiège, Liège, Belgium, <sup>5</sup>ULiège, Laboratory of mass spectrometry, Chemistry, Liège, Belgium, <sup>6</sup>GIGA-R, ULiège, Laboratory of Thrombosis and Hemostasis, Liège, Belgium, <sup>7</sup>ULiège, Mammalian cell culture laboratory, Liège, Belgium, <sup>8</sup>CHU de Liège, Abdominal Surgery Department, Liège, Belgium, <sup>9</sup>CHC de Liège, Gastroenterology, Liège, Belgium, <sup>10</sup>CHR Citadelle de Liège, Gastroenterology and Digestive oncology, Liège, Belgium</p>
17:26 - 17:32	<p><b>DOP083: The association of appendectomy and colorectal cancer in Ulcerative Colitis patients: A systematic review and meta-analysis</b>  <b>M.E. Stellingwerf</b>, M.A. de Koning, W.A. Bemelman, G.R. D'Haens, C.J. Buskens          Academic Medical Center (AMC), Department of Surgery, Amsterdam, The Netherlands</p>
17:32 - 17:38	<p><b>DOP084: Toll-interacting protein promotes colitis-associated cancer by regulating immune cell infiltration</b>  <b>C. Begka<sup>1</sup></b>, S. Ragusa<sup>2</sup>, Y. Pu<sup>3</sup>, C. Mooser<sup>4</sup>, K. McCoy<sup>4</sup>, T. Petrova<sup>2</sup>, M.H. Maillard<sup>1</sup></p> <p><sup>1</sup>Service of Gastroenterology and Hepatology, CHUV, University of Lausanne, Lausanne, Switzerland, <sup>2</sup>Department of Oncology, CHUV, University of Lausanne, Lausanne, Switzerland, <sup>3</sup>Institute of Pathology, CHUV, Lausanne, Switzerland, <sup>4</sup>Clinic for Visceral Surgery and Medicine, Department of Gastroenterology; University Hospital Bern Inselspital, Bern, Switzerland</p>
17:38 - 17:44	<p><b>DOP085: Innate mesenchymal MyD88 signals promote spontaneous intestinal tumorigenesis</b>  <b>V. Koliarakis<sup>1</sup></b>, A. Henriques<sup>1</sup>, N. Chalkidi<sup>1</sup>, A. Polykratis<sup>2</sup>, M. Pasparakis<sup>2</sup>, G. Kollias<sup>1,3</sup></p> <p><sup>1</sup>BSRC „Alexander Fleming“, Vari, Greece, <sup>2</sup>University of Cologne, Institute of Genetics, Cologne, Germany, <sup>3</sup>University of Athens, School of Medicine, Athens, Greece</p>


Friday, February 16, 2018, cont.

17:44 - 17:50	<p><b>DOP086: Low FODMAP diet improves functional-like gastrointestinal symptoms but reduces bifidobacteria and faecalibacterium prausnitzii in Quiescent Inflammatory Bowel Disease: A randomised controlled trial and metagenomic analysis</b>  <b>S. Cox<sup>1</sup></b>, A. Stagg<sup>2</sup>, S. Fromentin<sup>3</sup>, D. Ehrlich<sup>3,4</sup>, N. McCarthy<sup>2</sup>, N. Galleron<sup>3</sup>, F. Levenez<sup>2</sup>, M. Lomer<sup>1,5</sup>, J. Lindsay<sup>2,6</sup>, P. Irving<sup>7</sup>, K. Whelan<sup>1</sup></p> <p><sup>1</sup>King's College London, Nutritional Sciences, London, United Kingdom, <sup>2</sup>Queen Mary University of London, Centre for Immunobiology, London, United Kingdom, <sup>3</sup>Institut National de la Recherche Agronomique, Microbiology, Paris, France, <sup>4</sup>King's College London, Dental Institute, London, United Kingdom, <sup>5</sup>Guy's and St Thomas' NHS Foundation Trust, Nutrition and dietetics, London, United Kingdom, <sup>6</sup>Barts Health NHS Trust, Gastroenterology, London, United Kingdom, <sup>7</sup>Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom</p>
17:50 - 17:56	<p><b>DOP087: The gut microbiota of pregnant women with Crohn's Disease and their babies is associated with abnormalities in the adaptive immune system – results from the MECONIUM study</b>  <b>J. Torres<sup>1,2</sup></b>, A. Seki<sup>3</sup>, L. Tarassishin<sup>4</sup>, J. Hu<sup>4</sup>, C. Eisele<sup>4</sup>, N. Nair<sup>4</sup>, G.J. Britton<sup>3,5</sup>, Q. Mao<sup>4</sup>, I. Mogno<sup>3,5</sup>, J.C. Clemente<sup>3,4</sup>, J. Faith<sup>4</sup>, J.-F. Colombel<sup>1</sup>, S. Mehandru<sup>1,3</sup>, I. Peter<sup>4</sup></p> <p><sup>1</sup>Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States, <sup>2</sup>Hospital Beatriz Angelo, Gastroenterology, Loures, Portugal, <sup>3</sup>Icahn School of Medicine at Mount Sinai, Precision Immunology Institute, New York, United States, <sup>4</sup>Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences, New York, United States, <sup>5</sup>Icahn School of Medicine at Mount Sinai, Institute for Genomics and Multiscale Biology, New York, United States</p>
17:56 - 18:02	<p><b>DOP088: Microbial dysbiosis increases experimental colitis by interfering with short-chain fatty acid dependent mucosal Reg3B expression</b>  <b>D. Bajic<sup>1</sup></b>, A. Su<sup>1</sup>, K. Hillmer<sup>1</sup>, R. Mejias-Luque<sup>2</sup>, S. Bluemel<sup>3</sup>, M. Docampo<sup>4</sup>, R. Schmid<sup>1</sup>, B. Schnabl<sup>3</sup>, M. van den Brink<sup>4</sup>, M. Gerhard<sup>2</sup>, <b>C. Stein-Thoeringer<sup>1,4</sup></b></p> <p><sup>1</sup>Klinikum rechts der Isar, II. Med. Klinik, Munich, Germany, <sup>2</sup>Institute of Med. Microbiology, TUM, Munich, Germany, <sup>3</sup>University of California, San Diego, San Diego, United States, <sup>4</sup>Memorial Sloan Kettering Cancer Center, New York, United States</p>
18:02 - 18:08	<p><b>DOP089: Individualised variations in the gut microbiota during remission precede Crohn's Disease flares</b>  <b>T. Braun<sup>1</sup></b>, A. Di Segni<sup>1</sup>, S. Neuman<sup>1</sup>, N. Levhar<sup>1</sup>, M. Bubis<sup>1</sup>, O. Picard<sup>1</sup>, M. Ben-Shoshan<sup>1</sup>, G. Efroni<sup>1</sup>, S. Farage Barhom<sup>1</sup>, E. Glick Saar<sup>1</sup>, A. Lahad<sup>1</sup>, D. Shouval<sup>1</sup>, B. Weiss<sup>1</sup>, A. Lahat<sup>1</sup>, R. Eliakim<sup>1</sup>, S. Ben-Horin<sup>1</sup>, U. Kopylov<sup>1</sup>, The Leona M. and Harry B. Helmsley Charitable Trust supported Israeli IBD Research Nucleus (IIRN), <b>Y. Haberman<sup>1,2</sup></b></p> <p><sup>1</sup>Sheba Medical Center, Tel Hashomer, Israel, <sup>2</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States</p>
18:08 - 18:14	<p><b>DOP090: Risk factors for bacteremia in hospitalised patients with Inflammatory Bowel Disease</b>  <b>I. Goren<sup>1,2</sup></b>, A. Israel<sup>3</sup>, A. Brom<sup>4</sup>, G. Segal<sup>4</sup></p> <p><sup>1</sup>Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel, <sup>2</sup>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, <sup>3</sup>Clalit health services, Jerusalem, Israel, <sup>4</sup>Sheba Medical Center affiliated with Sackler faculty of medicine Tel Aviv University, Internal Medicine T, Ramat Gan, Israel</p>



European  
Crohn's and Colitis  
Organisation

# New ECCO Guidelines & Topical Reviews



Stay tuned with JCC online 2018

## ECCO Guidelines

- ECCO - ESGAR Consensus Guidelines on Diagnostic Techniques and Monitoring

## ECCO Topical Reviews

- Complementary Medicine and Psychotherapy
- Perioperative Dietary Therapy

ECCO is looking forward to your visit to JCC online, which also provides free access to all Guideline and Topical Review publications!

Christian Maaser  
ECCO GuiCom Chair

Laurence Egan  
JCC Editor-in-Chief

Scan and contact the ECCO Office  
[www.ecco-ibd.eu](http://www.ecco-ibd.eu)



# Hard copy poster presentations/Poster exhibition

## Opening hours

<i>Industry and Poster exhibition</i>	
Thursday, February 15, 2018	<b>10:30 - 18:00</b>
Friday, February 16, 2018	<b>09:30 - 18:00</b>
Saturday, February 17, 2018	<b>09:30 - 13:00</b>

### *Guided poster session*

The guided poster session is scheduled on Friday, February 16, 2018 from 12:30 to 13:30 in the exhibition hall in Hall C at Messe Wien.

At least one of the authors of the abstracts will be present to give a 1-2 minute summary of the major findings described in the poster. Poster session chairs will guide through the poster exhibition in pairs. Congress delegates present during that time will enjoy the opportunity to engage in poster discussions.

Please choose one of the below listed poster groups and follow the respective poster chairs (they will carry a button with the words "ECCO Poster Chair" as well as a sign indicating the poster group number and the topic). The starting poster of each group is indicated below – please make sure to be there at 12:30.

## Guided poster sessions are chaired by:

### (i) **Basic Science:**

- Group 1** (starts at **P001**): Paula Borralho Nunes, Lisbon, Portugal  
Michael Scharl, Zurich, Switzerland
- Group 2** (starts at **P033**): Isabelle Cleynen, Leuven, Belgium  
Gerhard Rogler, Zurich, Switzerland
- Group 3** (starts at **P064**): Hannah Gordon, London, United Kingdom  
Charlotte Hedin, Solna, Sweden
- Group 4** (starts at **P095**): Pieter Hindryckx, Ghent, Belgium  
Monika Tripathi, Cambridge, United Kingdom

### (ii) **Clinical: Diagnosis & outcome:**

- Group 5** (starts at **P126**): Laurent Beaugerie, Paris, France  
Christiane Buskens, Amsterdam, The Netherlands
- Group 6** (starts at **P156**): Lissy de Ridder, Rotterdam, The Netherlands  
David Wilson, Edinburgh, United Kingdom
- Group 7** (starts at **P185**): Gert De Hertogh, Leuven, Belgium  
Janneke van der Woude, Rotterdam, The Netherlands
- Group 8** (starts at **P214**): Emma Calabrese, Rome, Italy  
Mihai Diculescu, Bucharest, Romania

- Group 9** (starts at **P243**): Marina Aloï, Rome, Italy  
TBC
- Group 10** (starts at **P272**): Tim Raine, Cambridge, United Kingdom  
Murat Toruner, Ankara, Turkey
- Group 11** (starts at **P301**): Gerassimos Mantzaris, Athens, Greece  
Andreas Sturm, Berlin, Germany
- Group 12** (starts at **P330**): Christian Maaser, Lüneburg, Germany  
Patrick van Rheenen, Groningen, The Netherlands

**(iii) Clinical: Therapy and observation:**

- Group 13** (starts at **P359**): Raja Atreya, Erlangen, Germany  
Daniel Hommes, Los Angeles, United States
- Group 14** (starts at **P390**): Michel Adamina, Winterthur, Switzerland  
Krisztina Gecse, Amsterdam, The Netherlands
- Group 15** (starts at **P421**): Miquel Gassull, Barcelona, Spain  
Paula Ministro, Viseu, Portugal
- Group 16** (starts at **P451**): Vito Annese, Florence, Italy  
Dino Tarabar, Belgrade, Serbia
- Group 17** (starts at **P481**): Willem Bemelman, Amsterdam, The Netherlands  
Herbert Tilg, Innsbruck, Austria
- Group 18** (starts at **P511**): Laurence Egan, Galway, Ireland  
Janindra Warusavitarne, London, United Kingdom
- Group 19** (starts at **P541**): Franck Carbonnel, Paris, France  
Marcus Harbord, London, United Kingdom
- Group 20** (starts at **P571**): Paolo Gionchetti, Bologna, Italy  
John Mansfield, Newcastle, United Kingdom
- Group 21** (starts at **P601**): TBC  
Edyta Zagorowicz, Warsaw, Poland
- Group 22** (starts at **P631**): Ailsa Hart, London, United Kingdom  
Milan Lukas, Prague, Czech Republic
- Group 23** (starts at **P661**): Peter Irving, London, United Kingdom  
Joana Torres, Lisbon, Portugal
- Group 24** (starts at **P691**): Konstantinos Katsanos, Ioannina, Greece  
Boris Vucelic, Zagreb, Croatia
- Group 25** (starts at **P721**): Jaroslaw Kierkus, Warsaw, Poland  
Fernando Magro, Porto, Portugal
- Group 26** (starts at **P751**): Anil Asthana, Melbourne, Australia  
Shaji Sebastian, Hull, United Kingdom

**(iv) Epidemiology:**

- Group 27** (starts at **P781**): Tine Jess, Copenhagen, Denmark  
Jimmy Limdi, Manchester, United Kingdom
- Group 28** (starts at **P811**): Naila Arebi, London, United Kingdom  
Peter Lakatos, Budapest, Hungary; Montreal, Canada

**(v) Genetics:**

- Group 29** (starts at **P841**): Richard Russell, Glasgow, United Kingdom  
Magali Svrcek, Paris, France

**(vi) Microbiology:**

- Group 30** (starts at **P851**): James Lindsay, London, United Kingdom  
Harry Sokol, Paris, France

## Poster exhibition

In order to view the list with abstracts presented at ECCO'18 as hard copy posters, please follow the links stated or scan the QR-codes in each category.

(i) **Basic Science**

Poster P001-P095

[ecco-ibd.eu/bs](http://ecco-ibd.eu/bs)



(ii) **Clinical: Diagnosis & outcome**

Poster P096-P358

[ecco-ibd.eu/cd](http://ecco-ibd.eu/cd)



(iii) **Clinical: Therapy and observation**

Poster P359-P780

[ecco-ibd.eu/ct](http://ecco-ibd.eu/ct)



(iv) **Epidemiology**

Poster P781-P840

[ecco-ibd.eu/epi](http://ecco-ibd.eu/epi)



- (v) **Genetics**  
Poster P841-P850  
[ecco-ibd.eu/gen](http://ecco-ibd.eu/gen)



- (vi) **Microbiology**  
Poster P851-P884  
[ecco-ibd.eu/mb](http://ecco-ibd.eu/mb)



- (vii) **Nurses abstracts**  
Poster N001-N037  
[ecco-ibd.eu/np](http://ecco-ibd.eu/np)



# Educational programme

One of ECCO's aims is to promote education in the field of IBD and to improve the quality of care for IBD patients throughout Europe. Thus, prior to and during the 13<sup>th</sup> Congress of ECCO in Vienna, ECCO offers the following educational activities:

## 16<sup>th</sup> IBD Intensive Advanced Course

<b>Date:</b>	February 14-15, 2018
<b>Time:</b>	February 14: 08:45-16:45 February 15: 07:45-12:00
<b>Organisation:</b>	EduCom
<b>Target audience:</b>	Junior gastroenterologists
<b>Registration:</b>	Upon invitation
<b>CME accreditation:</b>	9 CME credits, upon return of an evaluation form filled in online

### Wednesday, February 14, 2018

*Programme overview (as of January 15, 2018)*

*Strauss 3, Congress Centre, Messe Wien*

<b>08:45 - 09:00</b>	<b>Arrival &amp; distribution of voting pads</b>
<b>09:00 - 09:10</b>	<b>1: Welcome</b> Julián Panés, Barcelona, Spain James Lindsay, London, United Kingdom
<b>09:10 - 10:05</b>	<b>Session 1: Pathogenesis</b> Lead discussant: James Lindsay, London, United Kingdom
09:10 - 09:25	<b>2: Exosome</b> Jonas Halfvarson, Örebro, Sweden
09:25 - 09:40	<b>3: Genetics</b> Miles Parkes, Cambridge, United Kingdom
09:40 - 09:55	<b>4: Inflammatory pathways</b> Yehuda Chowers, Haifa, Israel
09:55 - 10:05	Discussion / Questions
<b>10:05 - 10:20</b>	<b>Coffee break</b>
<b>10:20 - 11:35</b>	<b>Session 2: Drug management sessions. Part I: Conventional drugs</b> Lead discussant: Antonio López-Sanromán, Madrid, Spain
10:20 - 10:40	<b>5: 5-ASA compounds</b> Gerhard Rogler, Zurich, Switzerland
10:40 - 11:00	<b>6: Thiopurines</b> Peter Irving, London, United Kingdom
11:00 - 11:15	<b>7: Methotrexate</b> Pascal Juillerat, Bern, Switzerland
11:15 - 11:35	<b>8: Steroids</b> Stephan Vavricka, Zurich, Switzerland

## Wednesday, February 14, 2018, cont.

*Programme overview (as of January 15, 2018)*

*Strauss 3, Congress Centre, Messe Wien*

<b>11:35 - 12:55</b>		<b>Session 2: Drug management sessions. Part II: Biologics</b> Lead discussant: Séverine Vermeire, Leuven, Belgium
	11:35 - 11:55	<b>9: Anti-TNF agents</b> Filip Baert, Roeselare, Belgium
	11:55 - 12:10	<b>10: Vedolizumab</b> James Lindsay, London, United Kingdom
	12:10 - 12:25	<b>11: Ustekinumab</b> Marc Ferrante, Leuven, Belgium
	12:25 - 12:40	<b>12: Tofacitinib</b> Séverine Vermeire, Leuven, Belgium
	12:40 - 12:55	Discussion / Questions
<b>12:55 - 13:30</b>		<b>Lunch break</b>
<b>13:30 - 15:00</b>		<b>Session 3: Seminars: Part I: Special clinical situations</b>
	13:30 - 14:15	<b>EITHER:</b> <b>13a. Managing IBD and pregnancy</b> (Strauss 3, Congress Centre, Messe Wien) Iris Dotan, Petah Tikva, Israel Janneke van der Woude, Rotterdam, The Netherlands <b>OR</b> <b>13b. Managing extraintestinal manifestations of IBD</b> (Schubert 6, Congress Centre, Messe Wien) Peter Lakatos, Budapest, Hungary; Montreal, Canada Stephan Vavricka, Zurich, Switzerland
	14:15 - 15:00	<b>EITHER:</b> <b>14a. Managing IBD and pregnancy</b> (Schubert 6, Congress Centre, Messe Wien) Iris Dotan, Petah Tikva, Israel Janneke van der Woude, Rotterdam, The Netherlands <b>OR</b> <b>14b. Managing extraintestinal manifestations of IBD</b> (Strauss 3, Congress Centre, Messe Wien) Peter Lakatos, Budapest, Hungary; Montreal, Canada Stephan Vavricka, Zurich, Switzerland
<b>15:00 - 15:15</b>		<b>Coffee break</b>
<b>15:15 - 16:45</b>		<b>Session 3: Seminars: Part II: Long term management</b>
	15:15 - 16:00	<b>EITHER:</b> <b>15a. Managing complications associated with anti-TNF therapy</b> (Strauss 3, Congress Centre, Messe Wien) Shomron Ben-Horin, Ramat Gan, Israel Axel Dignass, Frankfurt, Germany <b>OR</b> <b>15b. Endoscopy in IBD incl. chromo-endoscopy, balloon dilatation</b> (Schubert 6, Congress Centre, Messe Wien) Marc Ferrante, Leuven, Belgium Pierre Michetti, Lausanne, Switzerland
	16:00 - 16:45	<b>EITHER:</b> <b>16a. Managing complications associated with anti-TNF therapy</b> (Schubert 6, Congress Centre, Messe Wien) Shomron Ben-Horin, Ramat Gan, Israel Axel Dignass, Frankfurt, Germany <b>OR</b> <b>16b. Endoscopy in IBD incl. chromo-endoscopy, balloon dilatation</b> (Strauss 3, Congress Centre, Messe Wien) Marc Ferrante, Leuven, Belgium Pierre Michetti, Lausanne, Switzerland

## Thursday, February 15, 2018

*Programme overview (as of January 15, 2018)*

*Strauss 3, Congress Centre, Messe Wien*

<b>07:45 - 09:25</b>		<b>Session 4: Interactive case discussions</b> Lead discussant: Ailsa Hart, London, United Kingdom
07:45 - 08:30	<b>17: Case-based discussion: Fistulising Crohn's Disease: Medical and surgical approaches</b> Paulo Kotze, Curitiba, Brazil; Calgary, Canada Antonio López-Sanromán, Madrid, Spain	
08:30 - 08:35	Discussion	
08:35 - 09:20	<b>18: Case-based discussion: Optimal management of patient with severe Crohn's Disease treated with anti-TNF agents</b> Case presentation: Michael Fitzpatrick, Oxford, United Kingdom Discussion: Simon Travis, Oxford, United Kingdom	
09:20 - 09:25	Discussion/Questions	
<b>09:25 - 09:45</b>		<b>Coffee break</b>
<b>09:45 - 11:50</b>		<b>Session 5: Special cases scenarios</b> Lead discussant: Gerassimos Mantzaris, Athens, Greece
09:45 - 10:15	<b>19: Medical management of Acute Severe Ulcerative Colitis</b> Corey Siegel, Lebanon, United States	
10:15 - 10:45	<b>20: Management of refractory pouchitis</b> Iris Dotan, Petah Tikva, Israel	
10:45 - 11:15	<b>21: Pre- and postoperative management of Crohn's Disease</b> Glen Doherty, Dublin, Ireland	
11:15 - 11:50	<b>22: Case based discussion: Investigation and management of mild/moderate Crohn's Disease</b> Case presentation: Tim Raine, Cambridge, United Kingdom Discussion: Laurence Egan, Galway, Ireland	
<b>11:50 - 12:00</b>		<b>Feedback and closing remarks</b> Pascal Juillerat, Bern, Switzerland

9<sup>th</sup> N-ECCO School

<b>Date:</b>	Wednesday, February 14, 2018
<b>Time:</b>	08:30-16:15
<b>Organisation:</b>	N-ECCO
<b>Target audience:</b>	IBD nurses, Dietitians
<b>Registration:</b>	Upon invitation
<b>CME accreditation:</b>	n.a.

## Wednesday, February 14, 2018

*Programme overview (as of January 15, 2018) –  
Schubert 1-2, Congress Centre, Messe Wien*

<b>08:30 - 08:45</b>	<b>1: Welcome &amp; Introduction</b> Usha Chauhan, Hamilton, Canada
<b>08:45 - 12:15</b>	<b>Session 1: Diagnosis and assessment</b> Usha Chauhan, Hamilton, Canada Nicolette Wierdsma, Amsterdam, The Netherlands
08:45 - 09:30	<b>2: Diagnosis, anatomy and physiology in IBD</b> Marc Ferrante, Leuven, Belgium
09:30 - 10:00	<b>3: Psychosocial implications of living with IBD</b> Kay Greveson, London, United Kingdom
10:00 - 10:30	<b>4: Nutritional assessment in IBD</b> Konstantinos Gerasimidis, Glasgow, United Kingdom
<b>10:30 - 10:45</b>	<b>Coffee break</b>
10:45 - 11:15	<b>5: Surgery in IBD</b> Michel Adamina, Winterthur, Switzerland
11:15 - 11:45	<b>6: Medical treatment</b> Konstantinos Katsanos, Ioannina, Greece
11:45 - 12:15	<b>7: Adherence</b> Palle Bager, Aarhus, Denmark
<b>12:15 - 13:15</b>	<b>Lunch break</b>

## Wednesday, February 14, 2018, cont.

*Programme overview (as of January 15, 2018) –*

*Schubert 1-2, Congress Centre, Messe Wien*

<b>13:15 - 14:50</b>	<b>Session 2: Case studies – disease management</b> Kay Greveson, London, United Kingdom Nicolette Wierdsma, Amsterdam, The Netherlands	
13:15 - 14:05	<b>EITHER:</b> <b>8a: Workshop 1 – UC Management (Group A)</b> Schubert 1-2, Congress Centre, Messe Wien Nik Sheng Ding, Melbourne, Australia <b>OR:</b> <b>8b: Workshop 2 – CD Management (Group B)</b> Schubert 3, Congress Centre, Messe Wien Pieter Hindryckx, Ghent, Belgium	
14:05 - 14:50	<b>EITHER:</b> <b>9a: Workshop 1 – UC Management (Group B)</b> Schubert 3, Congress Centre, Messe Wien Nik Sheng Ding, Melbourne, Australia <b>OR:</b> <b>9b: Workshop 2 – CD Management (Group A)</b> Schubert 1-2, Congress Centre, Messe Wien Pieter Hindryckx, Ghent, Belgium	
<b>14:50 - 15:05</b>	<b>Coffee break</b>	
<b>15:05 - 16:05</b>	<b>Session 3: Multidisciplinary management in IBD</b> Kay Greveson, London, United Kingdom Nicolette Wierdsma, Amsterdam, The Netherlands	
15:05 - 15:35	<b>10: Nutritional management in IBD</b> Rotem Sigall-Boneh, Tel Aviv, Israel	
15:35 - 16:05	<b>11: Nursing roles in IBD management</b> Liesbeth Moortgat, Roeselare, Belgium	
<b>16:05 - 16:15</b>	<b>12: Closing remarks</b> Usha Chauhan, Hamilton, Canada	



European  
Crohn's and Colitis  
Organisation

# ECCO Educational Workshops 2018

## ECCO Workshops



**56<sup>th</sup>** ECCO Workshop  
Athens, **Greece** - April 28, 2018



**57<sup>th</sup>** ECCO Workshop  
Helsinki, **Finland** - September 5, 2018



**58<sup>th</sup>** ECCO Workshop  
Montevideo, **Uruguay** - September 9, 2018



**59<sup>th</sup>** ECCO Workshop  
Antwerp, **Belgium** - September 28, 2018



**60<sup>th</sup>** ECCO Workshop  
Santa Cruz de Tenerife, **Spain** - November 16, 2018



Spreading standards in IBD:  
Your presence counts!

Scan and contact the ECCO Office  
[www.ecco-ibd.eu](http://www.ecco-ibd.eu)



# 3<sup>rd</sup> ECCO Endoscopy Workshop

<b>Date:</b>	February 14, 2018
<b>Time:</b>	13:00-18:00
<b>Organisation:</b>	EduCom
<b>Target audience:</b>	Physicians, Surgeons, Paediatricians
<b>Registration:</b>	For registered participants only. No onsite registration
<b>CME accreditation:</b>	4 CME credits, upon return of an evaluation form filled in online

## Wednesday, February 14, 2018

*Programme overview (as of January 15, 2018) –  
Lehar 4, Congress Centre, Messe Wien*

<b>13:00 - 13:15</b>	<b>1: Welcome &amp; Introduction</b> James Lindsay, London, United Kingdom <b>2: Pre-course test</b>
<b>13:15 - 14:15</b>	<b>3: Session 1: Endoscopic scores in UC: UCEIS vs Mayo</b> Chair: James Lindsay, London, United Kingdom Speaker: Simon Travis, Oxford, United Kingdom
<b>14:15 - 15:15</b>	<b>4: Session 2: Endoscopic surveillance</b> Chair: Matthieu Allez, Paris, France Speaker: Raf Bisschops, Leuven, Belgium
<b>15:15 - 15:45</b>	<b>Coffee break</b>
<b>15:45 - 16:45</b>	<b>5: Session 3: Endoscopic therapy in IBD</b> Chair: Massimo Fantini, Rome, Italy Speaker: Raja Atreya, Erlangen, Germany
<b>16:45 - 17:45</b>	<b>6: Session 4: Small bowel and pouch assessment</b> Chair: Peter Lakatos, Budapest, Hungary; Montreal, Canada Speaker: Peter Irving, London, United Kingdom
<b>17:45 - 18:00</b>	<b>7: Post-course test &amp; concluding remarks</b> Peter Irving, London, United Kingdom

5<sup>th</sup> N-ECCO Research Forum

<b>Date:</b>	Wednesday, February 14, 2018
<b>Time:</b>	14:00-18:00
<b>Organisation:</b>	N-ECCO
<b>Target audience:</b>	IBD nurses and Allied health professionals
<b>Registration:</b>	For registered participants only. No onsite registration
<b>CME accreditation:</b>	n.a.

## Wednesday, February 14, 2018

*Programme overview (as of January 15, 2018) –  
Lehar 1, Congress Centre, Messe Wien*

<b>14:00 - 14:10</b>	<b>1: Welcome &amp; Introduction</b> Susanna Jäghult, Stockholm, Sweden
<b>14:10 - 15:10</b>	<b>Session 1: Practical issues in research</b> Palle Bager, Aarhus, Denmark Susanna Jäghult, Stockholm, Sweden
	14:10 - 14:30 <b>2: Funding</b> Christine Norton, London, United Kingdom
	14:30 - 14:50 <b>3: Publication</b> Shomron Ben-Horin, Ramat Gan, Israel
	14:50 - 15:10 <b>4: How to develop guidelines</b> Karen Kemp, Manchester, United Kingdom
<b>15:10 - 17:45</b>	<b>Session 2: International IBD nursing research projects</b> Palle Bager, Aarhus, Denmark Susanna Jäghult, Stockholm, Sweden
	15:10 - 15:25 <b>5: Status on: Fatigue and physical function in IBD</b> Dawn Farrell, Cork, Ireland
	15:25 - 15:40 <b>6: Status on: Fatigue in Europe</b> Wladzia Czuber-Dochan, London, United Kingdom
	15:40 - 16:00 <b>7: Medication adherence, worries and concerns in IBD</b> Susanna Jäghult, Stockholm, Sweden
<b>16:00 - 16:30</b>	<b>Coffee break</b>
	16:30 - 17:30 <b>8: Workshops</b> Susanna Jäghult, Stockholm, Sweden Dawn Farrell, Cork, Ireland Wladzia Czuber-Dochan, London, United Kingdom
	17:30 - 17:45 <b>9: Short presentation of status from the workshops</b>
<b>17:45 - 18:00</b>	<b>10: Learning from today: How to proceed?</b> Susanna Jäghult, Stockholm, Sweden Palle Bager, Aarhus, Denmark

# 4<sup>th</sup> Basic ECCO: EduCational COurse for Industry

<b>Date:</b>	Wednesday, February 14, 2018
<b>Time:</b>	10:00-17:00
<b>Organisation:</b>	ClinCom
<b>Target audience:</b>	Corporate & Non-Corporate Members
<b>Registration:</b>	For registered participants only. No onsite registration
<b>CME accreditation:</b>	n.a.

## Wednesday, February 14, 2018

*Programme overview (as of January 15, 2018 –  
Stolz 1, Congress Centre, Messe Wien*

<b>10:00 - 10:05</b>	<b>1: Welcome</b> Julián Panés, Barcelona, Spain
<b>10:05 - 12:00</b>	<b>Session 1</b> Javier Gisbert, Madrid, Spain
10:05 - 10:20	<b>2: What is IBD, and what is the difference between Ulcerative Colitis and Crohn's Disease?</b> John Mansfield, Newcastle upon Tyne, United Kingdom
10:20 - 10:35	<b>3: What causes IBD?</b> Isabelle Cleynen, Leuven, Belgium
10:35 - 10:45	<b>Question time</b>
10:45 - 11:00	<b>4: How is IBD diagnosed?</b> Edyta Zagorowicz, Warsaw, Poland
11:00 - 11:15	<b>5: What are risk factors for complicated IBD outcome?</b> Krisztina Gecse, Amsterdam, The Netherlands
11:15 - 11:30	<b>6: How is IBD care organised?</b> Jonas Halfvarson, Örebro, Sweden
11:30 - 11:45	<b>7: What do IBD nurses do?</b> Patricia Geens, Leuven, Belgium
11:45 - 12:00	<b>Question time</b>
<b>12:00 - 13:00</b>	<b>Lunch break</b>

## Wednesday, February 14, 2018, cont.

*Programme overview (as of January 15, 2018 –  
Stolz 1, Congress Centre, Messe Wien)*

<b>13:00 - 14:30</b>	<b>Session 2</b> John Mansfield, Newcastle upon Tyne, United Kingdom
13:00 - 13:15	<b>8: What is the role of 5-ASA?</b> Gerassimos Mantzaris, Athens, Greece
13:15 - 13:30	<b>9: What is the role of immunomodulators?</b> Javier Gisbert, Madrid, Spain
13:30 - 13:45	<b>10: What about biological therapy?</b> Marc Ferrante, Leuven, Belgium
13:45 - 14:00	<b>11: Is there a role for dietary treatment?</b> Arie Levine, Tel Aviv, Israel
14:00 - 14:15	<b>12: How to choose between treatment modalities?</b> Filip Baert, Roeselare, Belgium
14:15 - 14:30	<b>Question time</b>
<b>14:30 - 15:00</b>	<b>Coffee break</b>
<b>15:00 - 16:30</b>	<b>Session 3</b> Krisztina Gecse, Amsterdam, The Netherlands
15:00 - 15:15	<b>13: Surgery for perianal and fistulising CD: When and how?</b> Paulo Kotze, Curitiba, Brazil; Calgary, Canada
15:15 - 15:30	<b>14: Surgery for luminal CD: When and how?</b> Oded Zmora, Tel Aviv, Israel
15:30 - 15:45	<b>15: How to prevent postoperative CD recurrence?</b> Antonio López-Sanròman, Madrid, Spain
15:45 - 16:00	<b>16: Surgery for UC: When and how?</b> Antonino Spinelli, Milan, Italy
16:00 - 16:15	<b>17: What happens after a pouch operation?</b> Nik Sheng Ding, Melbourne, Australia
16:15 - 16:30	<b>Question time</b>
<b>16:30 - 17:00</b>	<b>Session 4</b> Julián Panés, Barcelona, Spain
16:30 - 16:45	<b>18: The IBD quiz for the industry</b> Marc Ferrante, Leuven, Belgium
16:45 - 17:00	<b>19: Where is the unmet need for patients with IBD?</b> Ailsa Hart, London, United Kingdom

# 4<sup>th</sup> Y-ECCO Basic Science Workshop

<b>Date:</b>	Wednesday, February 14, 2018
<b>Time:</b>	13:30-16:30
<b>Organisation:</b>	Y-ECCO
<b>Target audience:</b>	Basic scientists, Physicians, Paediatricians, Surgeons, IBD nurses
<b>Registration:</b>	For registered participants only. No onsite registration
<b>CME accreditation:</b>	2 CME credits, upon return of an evaluation form filled in online

## Wednesday, February 14, 2018

*Programme overview (as of January 15, 2018) –  
Schubert 4-5, Congress Centre, Messe Wien*

<b>13:30 - 13:35</b>	<b>1: Introduction</b> Isabelle Cleynen, Leuven, Belgium
<b>13:35 - 14:50</b>	<b>Session 1: In vivo perils in IBD</b> Dominik Bettenworth, Münster, Germany Claudio Fiocchi, Cleveland, United States
13:35 - 14:05	<b>2: Application and relevance of in vivo models in IBD</b> Claudio Fiocchi, Cleveland, United States
14:05 - 14:20	<b>3: Abstract 1: Consequences of an IL2RA locus duplication in a very early onset Inflammatory Bowel Disease patient</b> Linda Joosse, Rotterdam, The Netherlands
14:20 - 14:35	<b>4: Abstract 2: Gene expression profiles in inflamed colonic biopsies from newly diagnosed Crohn's Disease and Ulcerative Colitis patients differ depending on the age at diagnosis</b> Sare Verstockt, Leuven, Belgium
14:35 - 14:50	<b>5: Abstract 3: TIGIT expression identifies circulating CD38 effector T cells with immune regulatory properties whose frequencies at diagnosis predict disease course of paediatric IBD patients</b> Linda Joosse, Rotterdam, The Netherlands
<b>14:50 - 15:10</b>	<b>Meet the speakers break</b>
<b>15:10 - 16:25</b>	<b>Session 2: Ex vivo promises in IBD</b> Britta Siegmund, Berlin, Germany Nuha Yassin, London, United Kingdom
15:10 - 15:40	<b>6: Promises and perils of ex vivo models in IBD</b> Britta Siegmund, Berlin, Germany
15:40 - 15:55	<b>7: Abstract 4: Validation of a novel xenograft mouse model for intestinal fistulas</b> Ramona Bruckner, Zurich, Switzerland
15:55 - 16:10	<b>8: Abstract 5: Targeting fibroblast activation protein in Crohn's Disease intestinal strictures restores balanced deposition of extracellular matrix and reduces fibrosis</b> Marta Truffi, Milan, Italy
16:10 - 16:25	<b>9: Abstract 6: CCL20 and CCR6 on peripheral blood mononuclear cells (PBMC) in Inflammatory Bowel Disease (IBD): A more potent chemokine in Ulcerative Colitis?</b> Helene Skovdahl, Trondheim, Norway
<b>16:25 - 16:30</b>	<b>10: Closing remarks and Y-ECCO best abstract awards</b> Isabelle Cleynen, Leuven, Belgium

4<sup>th</sup> EpiCom Workshop

<b>Date:</b>	Wednesday, February 14, 2018
<b>Time:</b>	13:30-17:00
<b>Organisation:</b>	EpiCom
<b>Target audience:</b>	Physicians, Surgeons, Paediatricians, IBD nurses
<b>Registration:</b>	For registered participants only. No onsite registration
<b>CME accreditation:</b>	3 CME credits, upon return of an evaluation form filled in online

## Wednesday, February 14, 2018

*Programme overview (as of January 15, 2018) –  
Lehar 2, Congress Centre, Messe Wien*

<b>An introduction to pharmacoepidemiology: How to interpret real world data for clinical practice</b>	
<b>13:30 - 13:40</b>	<b>1: Welcome &amp; Introduction</b> Ebbe Langholz, Hellerup, Denmark
<b>13:40 - 15:40</b>	<b>Session 1: Basic principles pharmacoepidemiology</b> Laurent Beaugerie, Paris, France Ebbe Langholz, Hellerup, Denmark
13:40 - 14:00	<b>2: An introduction to pharmacoepidemiology</b> Laurent Peyrin-Biroulet, Vandoeuvre-les-Nancy, France
14:00 - 14:20	<b>3: Real world data</b> Jonas Halfvarson, Örebro, Sweden
14:20 - 14:40	<b>4: The role of pharmacoepidemiology in regulatory agencies</b> Valerie Straßmann, Bonn, Germany
14:40 - 15:10	<b>5: Central threats to the validity</b> Marieke Pierik, Maastricht, The Netherlands
15:10 - 15:30	<b>6: Propensity scores and other approaches to overcome potential biases</b> Julien Kirchgerner, Paris, France
15:30 - 15:40	<b>Q&amp;A Session</b>
<b>15:40 - 16:00</b>	<b>Coffee break</b>
<b>16:00 - 17:00</b>	<b>Session 2: Pharmacoepidemiology and IBD</b> Naïla Arebi, London, United Kingdom Marieke Pierik, Maastricht, The Netherlands
16:00 - 16:20	<b>7: Pharmacoepidemiology of distinct populations: A focus on ageing and ethnic populations</b> Naïla Arebi, London, United Kingdom
16:20 - 16:50	<b>8: Pharmacoepidemiological studies on IBD using various data sources</b> Laurent Beaugerie, Paris, France
16:50 - 17:00	<b>Q&amp;A Session</b>
<b>17:00</b>	<b>9: Closure &amp; Farewell</b> Ebbe Langholz, Hellerup, Denmark

# 7<sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP

**Date:** February 15, 2018  
**Time:** 08:15-17:15  
**Organisation:** S-ECCO in collaboration with ESCP  
**Target audience:** Surgeons, Physicians, IBD nurses  
**Registration:** For registered participants only. No onsite registration  
**CME accreditation:** 6 CME credits, upon return of an evaluation form filled in online



## Thursday, February 15, 2018

*Programme overview (as of January 15, 2018) –  
 Stolz 1-2, Congress Centre, Messe Wien*

<i>Cutting edge IBD Surgery</i>	
<b>08:15 - 08:25</b>	<b>1: Welcome</b> Oded Zmora, Tel Aviv, Israel
<b>08:25 - 10:15</b>	<b>Session 1: Salt and grain of IBD Surgery</b> Glen Doherty, Dublin, Ireland Yves Panis, Clichy, France
<b>08:25 - 09:05</b>	<b>Debate 1: Short stricturing terminal ileum</b>
08:25 - 08:35	<b>2: Resection – best outcome, why change</b> Antonino Spinelli, Milan, Italy
08:35 - 08:45	<b>3: Save the TI – side to side strictureplasty</b> Gianluca Sampietro, Milan, Italy
08:45 - 08:55	<b>4: Advanced endoscopy will solve – dilatation and stenting</b> Matthieu Allez, Paris, France
08:55 - 09:05	<b>Discussion</b>
<b>09:05 - 10:00</b>	<b>Debate 2: The role of the mesentery in IBD</b>
09:05 - 09:20	<b>5: Hot cells in IBD</b> Manon Wildenberg, Amsterdam, The Netherlands
09:20 - 09:35	<b>6: The mesentery in ileocolic resection</b> Calvin Coffey, Limerick, Ireland
09:35 - 09:50	<b>7: The mesentery in proctectomy</b> Christianne Buskens, Amsterdam, The Netherlands
09:50 - 10:00	<b>Discussion</b>
<b>10:00 - 10:15</b>	<b>8: Sexual function before and after surgery for IBD</b> Janneke van der Woude, Rotterdam, The Netherlands
<b>10:15 - 10:45</b>	<b>Coffee break</b>

## Thursday, February 15, 2018, cont.

*Programme overview (as of January 15, 2018) –  
Stolz 1-2, Congress Centre, Messe Wien*

<b>10:45 - 12:15</b>	<b>Session 2: The scientific IBD Surgeon</b> Willem Bemelman, Amsterdam, The Netherlands Oded Zmora, Tel Aviv, Israel
10:45 - 10:55	<b>9: Abstract 1: Developing a colorectal cancer risk prediction tool for patients with Ulcerative Colitis and low grade dysplasia</b> Misha Kabir, London, United Kingdom Presented as P127 at the poster exhibition
10:55 - 11:05	<b>10: Abstract 2: Intra-abdominal sepsis following ileocolic resection for Crohn's Disease: What are the risk factors and are they consistent internationally?</b> Amy Lightner, Rochester, United States Presented as P157 at the poster exhibition
11:05 - 11:15	<b>11: Abstract 3: Meta-analysis of endorectal advancement flap versus ligation of the intersphincteric fistula tract for Crohn's and cryptoglandular high perianal fistulas</b> Merle E. Stellingwerf, Amsterdam, The Netherlands Presented as P426 at the poster exhibition
11:15 - 11:25	<b>12: Abstract 4: Therapy refractory Ulcerative Colitis patients may benefit from appendectomy; long-term clinical results from a multicentre prospective cohort series</b> Merle E. Stellingwerf, Amsterdam, The Netherlands Presented as P578 at the poster exhibition
11:25 - 11:35	<b>13: The use of stem cell based therapy for Crohn's Disease in clinical trials: An update from a single institution's experience</b> Amy Lightner, Rochester, United States
11:35 - 11:45	<b>14: Risk of small bowel obstruction after laparoscopic pouch surgery</b> Diane Mège, Clichy, France
11:45 - 12:00	<b>15: Patient reported outcomes in IBD Surgery – what does it mean</b> Séverine Vermeire, Leuven, Belgium
12:00 - 12:15	<b>16: Keynote lecture: Unmet needs in IBD surgery: Surgical research</b> André D'Hoore, Leuven, Belgium
<b>12:15 - 13:15</b>	<b>Lunch break</b>
<b>13:15 - 15:15</b>	<b>Session 3: Cutting edge IBD Surgery</b> Michel Adamina, Winterthur, Switzerland Amy Lightner, Rochester, United States
<b>13:15 - 13:45</b>	<b>The big debate: Low grade dysplasia of the colon</b>
13:15 - 13:25	<b>17: Watchful waiting</b> Iris Dotan, Petah Tikva, Israel
13:25 - 13:35	<b>18: In the bucket</b> Yves Panis, Clichy, France
13:35 - 13:45	<b>Discussion</b>

## Thursday, February 15, 2018, cont.

*Programme overview (as of January 15, 2018) –  
Stolz 1-2, Congress Centre, Messe Wien*

<b>13:45 - 14:35</b>		<b>The debate: The high perianal fistula</b>
13:45 - 13:55	<b>19: Biologics all the way</b>	Paulo Kotze, Curitiba, Brazil; Calgary, Canada
13:55 - 14:05	<b>20: Fistulotomy, LIFT or advancement: Their only chance</b>	Nadav Haim, Tel Aviv, Israel
14:05 - 14:15	<b>21: Glues and plugs</b>	Philip Tozer, London, United Kingdom
14:15 - 14:25	<b>22: Stem cells: The holy grail?</b>	Julián Panés, Barcelona, Spain
14:25 - 14:35	<b>Discussion</b>	
<b>14:35 - 15:15</b>		<b>My ileoanal pouch</b>
14:35 - 14:45	<b>23: Tips and tricks to prevent a leak</b>	Oded Zmora, Tel Aviv, Israel
14:45 - 14:55	<b>24: Salvage of the acute and chronic anastomotic leak</b>	Willem Bemelman, Amsterdam, The Netherlands
14:55 - 15:05	<b>25: Does size matter? How long should the pouch be?</b>	Francesco Colombo, Milan, Italy
15:05 - 15:15	<b>Discussion</b>	
<b>15:15 - 15:45</b>		<b>Coffee break</b>
<b>15:45 - 16:15</b>		<b>Session 4: It takes two to tango</b> Ailsa Hart, London, United Kingdom Paulo Kotze, Curitiba, Brazil; Calgary, Canada
15:45 - 16:00	<b>26: Perioperative dietary therapy (Tandem talk)</b>	Rotem Sigall-Boneh, Tel Aviv, Israel Michel Adamina, Winterthur, Switzerland
16:00 - 16:15	<b>27: Stomas in IBD (Tandem talk)</b>	Karen Kemp, Manchester, United Kingdom Janindra Warusavitarne, London, United Kingdom
<b>16:15 - 17:05</b>		<b>Session 5: Decision making on the edge – Consultants' corner</b> Miguel Blas Franco, Tlalpan, Mexico Miguel Regueiro, Pittsburgh, United States André D'Hoore, Leuven, Belgium Antonino Spinelli, Milan, Italy
		<b>Challenging cases</b>
16:15-16:32	<b>28: Acute Colitis</b>	Léon Maggiori, Clichy, France
16:32-16:49	<b>29: Perforating intestinal Crohn's Disease</b>	Christian Gingert, Winterthur, Switzerland
16:49-17:05	<b>30: Septic shock in Crohn's Disease</b>	Chaya Shwaartz, Tel Aviv, Israel
<b>17:05 - 17:15</b>		<b>Closing remarks</b> Yves Panis, Clichy, France

# 12<sup>th</sup> N-ECCO Network Meeting

<b>Date:</b>	Thursday, February 15, 2018
<b>Time:</b>	09:00-17:00
<b>Organisation:</b>	N-ECCO
<b>Target audience:</b>	IBD nurses - advanced level
<b>Registration:</b>	For registered participants only. No onsite registration
<b>CME accreditation:</b>	n.a.

## Thursday, February 15, 2018

*Programme overview (as of January 15, 2018) –  
Strauss 1-2, Congress Centre, Messe Wien*

<b>09:00 - 09:15</b>	<b>1: Welcome &amp; Introduction</b> Palle Bager, Aarhus, Denmark
<b>09:15 - 10:30</b>	<b>Session 1: Hot topics IBD nursing</b> Kay Greveson, London, United Kingdom Rita Lindenthaler, Schwarzach, Austria
09:15 - 10:00	<b>2: Demonstrating the value of the IBD nurse</b> Isobel Mason, London, United Kingdom
10:00 - 10:30	<b>3: Sexual dysfunction in IBD</b> Konstantinos Katsanos, Ioannina, Greece
<b>10:30 - 11:00</b>	<b>Coffee break</b>
<b>11:00 - 12:30</b>	<b>Session 2: From bench to bedside – practical IBD</b> Usha Chauhan, Hamilton, Canada Tobias Kasa, Vienna, Austria
11:00 - 11:30	<b>4: Iron-deficiency, anaemia and fatigue</b> Palle Bager, Aarhus, Denmark
11:30 - 12:00	<b>5: Interpreting blood results (TGN, IGRA, TNF levels abnormal LFT, importance of TDM)</b> Peter Irving, London, United Kingdom
12:00 - 12:30	<b>6: IBD and elderly</b> Nienke Ipenburg, Leiden, The Netherlands
<b>12:30 - 14:00</b>	<b>Lunch break</b>
<b>12:45 - 13:45</b>	<b>N-ECCO Network Meeting Lunch Satellite Symposium</b> Please refer to page xx

## Thursday, February 15, 2018, cont.

Programme overview (as of January 15, 2018) –

Strauss 1-2, Congress Centre, Messe Wien

<b>Session 3: Abstracts</b> Susanna Jäghult, Stockholm, Sweden Rita Lindenthaler, Schwarzach, Austria	
14:00 - 14:45	<p><b>7: NO001: Cognitive behavioural therapy for the management of Inflammatory Bowel Disease-fatigue: A pilot randomised controlled trial</b>  <b>M. Artom</b>, W. Czuber-Dochan, J. Sturt, H. Proudfoot, C. Norton                      King's College London, Florence Nightingale Faculty of Nursing &amp; Midwifery, London, United Kingdom</p>
14:15 - 14:30	<p><b>8: NO002: The quality of care questionnaire – development of a valid measure for persons with Inflammatory Bowel Disease</b>  <b>K. Pihl Lesnovska</b><sup>1</sup>, S. Börjesson<sup>2</sup>, G. Hollman Frisman<sup>3</sup>, H. Hjortswang<sup>4</sup>, M. Wenemark<sup>5</sup>  <sup>1</sup>University hospital of Linköping, Gastroenterology and hepatology, Linköping, Sweden, <sup>2</sup>Faculty of Medicine, Linköping University, Department of Medical and Health Sciences, Linköping, Sweden, <sup>3</sup>Department of Medical and Health Sciences, Linköping University, Department of Anaesthesiology and Intensive Care, Linköping, Sweden, <sup>4</sup>Clinical and Experimental Medicine, Linköping University, Department of Gastroenterology and Department, Linköping, Sweden, <sup>5</sup>Department of Medical and Health Sciences, Linköping University, Centre for Organisational support and Development, Linköping, Sweden</p>
14:30 - 14:45	<p><b>9: NO003: Increasing research capacity of IBD nurses across Europe – a case study of Inflammatory Bowel Disease Fatigue (IBD-F) scale translation and validation</b>  <b>W. Czuber-Dochan</b><sup>1</sup>, M. Artom<sup>1</sup>, C. Norton<sup>1</sup>, A. Andonova<sup>2</sup>, M. Pencova<sup>2</sup>, V. Cluzeau<sup>3</sup>, M. Chalabreysee<sup>3</sup>, R. Barkan<sup>4</sup>, I. Goren<sup>4</sup>, L. Shpoker<sup>5</sup>, S. Radice<sup>6</sup>, E. Schiavoni<sup>7</sup>, A. Cocchieri<sup>8</sup>, D. Napolitano<sup>9</sup>, L. Turchini<sup>9</sup>, M. Zega<sup>9</sup>, L.P. Jelsness-Jørgensen<sup>10</sup>, A. Giner-Agudo<sup>11</sup>, R. Barastegui<sup>11</sup>, C. Fernández-Fernández<sup>12</sup>, M. Gallego<sup>11</sup>, F. Murciano<sup>13</sup>, E. Navarro<sup>14</sup>, A. Rivera<sup>15</sup>, A. Vara-Hernández<sup>16</sup>, S. Jäghult<sup>17</sup>, K. Pihl Lesnovska<sup>17</sup>, A. der Heer-Damen<sup>18</sup>, A. Heil<sup>18</sup>, L. Moortgat<sup>19</sup>  <sup>1</sup>King's College London, Faculty of Life Sciences &amp; Medicine, Department of Nutritional Sciences, London, United Kingdom, <sup>2</sup>Trakia University, Faculty of Medicine, Stara Zagora, Bulgaria, <sup>3</sup>Hôpital Archet2-4èmeB-CHU de Nice, Pôle digestif- Nutrition Clinique, Nice, France, <sup>4</sup>Rabin Medical Center - Beilinson Hospital, Department of Gastroenterology, Petah Tikva, Israel, <sup>5</sup>Bnai Zion Medical Center, Gastroenterology Department, Haifa, Israel, <sup>6</sup>Instituto Clinico Humanitas, Rozzano, Italy, <sup>7</sup>Fondazione Policlinico Universitario Agostino Gemelli, Gastroenterology and Hepatology Group, Roma, Italy, <sup>8</sup>Fondazione Policlinico Universitario Agostino Gemelli, Gastroenterology and Hepatology, Rome, Italy, <sup>9</sup>Fondazione Policlinico Universitario Agostino Gemelli, Gastroenterology and Hepatology, Roma, Italy, <sup>10</sup>Ostfold University College, Halden, Norway, <sup>11</sup>Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain, <sup>12</sup>Hospital Ramón y Cajal, Gastroenterology, Madrid, Spain, <sup>13</sup>Hospital del Mar, IBD and Digestology Department, Barcelona, Spain, <sup>14</sup>Vall Hebron University Hospital, IBD Unit Gastroenterology Department, Barcelona, Spain, <sup>15</sup>Hospital San Juan de Dios del Aljarafe, Internal Medicine, Seville, Spain, <sup>16</sup>Hospital Clinic de Barcelona, IBD Unit Gastroenterology Department, Barcelona, Spain, <sup>17</sup>Stockholm Gastro Center, Stockholm, Sweden, <sup>18</sup>Elisabeth-TweeSteden Ziekenhuis, Gastroenterology and Hepatology, Tilburg, The Netherlands, <sup>19</sup>Az Delta Hospital, Roeselare, Belgium</p>
14:45 - 15:15	<b>Coffee break</b>

## Thursday, February 15, 2018, cont.

*Programme overview (as of January 15, 2018) –*

*Strauss 1-2, Congress Centre, Messe Wien*

<b>15:15 - 16:30</b>	<b>Session 4: Debate timing of surgery in Acute Severe Colitis: Save the colon or save the patient</b> Tobias Kasa, Vienna, Austria Liesbeth Moortgat, Roeselare, Belgium
15:15 - 15:45	<b>10: Save the patient – medical treatments</b> Pieter Hindryckx, Ghent, Belgium
15:45 - 16:15	<b>11: Save the colon – early surgery</b> Yves Panis, Clichy, France
16:15 - 16:30	<b>Q&amp;A</b>
<b>16:30 - 17:00</b>	<b>Closing remarks, N-ECCO in 2018 and beyond</b> Palle Bager, Aarhus, Denmark



European  
Crohn's and Colitis  
Organisation

Vienna  
Austria

# ECCO IBD Curriculum



## ECCO's Framework of Education

- Concise yet complete: What gastroenterologists need to know to develop expertise in the IBD field
- Developed in part by ECCO Officers and ECCO National Representatives
- Provides a future framework for ECCO Educational Activities
- Close to 500 items from the e-CCO Learning Platform are already mapped to the ECCO IBD Curriculum
  - e-Courses
  - Talking Heads
  - Educational Podcasts
  - Webcasts from the ECCO Congress Scientific Programme and Educational Activities



Scan and visit

[www.e-learning.ecco-ibd.eu](http://www.e-learning.ecco-ibd.eu)



6<sup>th</sup> ClinCom Workshop

<b>Date:</b>	Thursday, February 15, 2018
<b>Time:</b>	08:00-11:40
<b>Organisation:</b>	ClinCom
<b>Target audience:</b>	Physicians, Surgeons, Paediatricians, Clinical researchers, Industry
<b>Registration:</b>	For registered participants only. No onsite registration
<b>CME accreditation:</b>	3 CME credits, upon return of an evaluation form filled in online

## Thursday, February 15, 2018

*Programme overview (as of January 15, 2018) –  
Lehar 1, Congress Centre, Messe Wien*

<b>08:00 - 08:05</b>	<b>1: Welcome &amp; Introduction</b> Marc Ferrante, Leuven, Belgium
<b>08:05 - 09:45</b>	<b>Session 1: Evolving endpoints in IBD clinical trials</b> Javier Gisbert, Madrid, Spain
08:05 - 08:25	<b>2: Patient reported outcomes</b> Laurent Peyrin-Biroulet, Vandoeuvre-les-Nancy, France
08:25 - 08:45	<b>3: Defining endoscopic endpoints</b> Krisztina Gecse, Amsterdam, The Netherlands
08:45 - 09:05	<b>4: Cross-sectional imaging</b> Andrea Laghi, Latina, Italy
09:05 - 09:25	<b>5: Histologic remission</b> Roger Feakins, London, United Kingdom
09:25 - 09:45	<b>6: How endpoints can influence trial design?</b> Walter Reinisch, Vienna, Austria
<b>09:45 - 10:15</b>	<b>Coffee break</b>
<b>10:15 - 11:30</b>	<b>Session 2: Comparative effectiveness research (CER)</b> John Mansfield, Newcastle upon Tyne, United Kingdom
10:15 - 10:30	<b>7: General principle</b> Jean-Frédéric Colombel, New York, United States
10:30 - 10:50	<b>8: What is the value of retrospective CER?</b> Pieter Hindryckx, Ghent, Belgium
10:50 - 11:10	<b>9: Head-to-head trials</b> Simon Travis, Oxford, United Kingdom
11:10 - 11:30	<b>10: Setting priorities for IBD (discussion)</b> Jean-Frédéric Colombel, New York, United States Pieter Hindryckx, Ghent, Belgium John Mansfield, Newcastle upon Tyne, United Kingdom Elmer Schabel, Bonn, Germany Simon Travis, Oxford, United Kingdom
<b>11:30 - 11:40</b>	<b>11: Summary &amp; Closing remarks</b> Marc Ferrante, Leuven, Belgium

# 5<sup>th</sup> ECCO-ESGAR Ultrasound-MRI Workshop

**Date:** Thursday, February 15, 2018  
**Time:** 07:30-12:15  
**Organisation:** EduCom in collaboration with ESGAR  
**Target audience:** Physicians, Radiologists, Surgeons, Paediatricians  
**Registration:** For registered participants only. No onsite registration  
**CME accreditation:** 3 CME credits, upon return of an evaluation form filled in online



## Thursday, February 15, 2018

*Programme overview (as of January 15, 2018) –  
 Lehar 3, Congress Centre, Messe Wien*

07:30 - 07:40	<b>1: Welcome &amp; Introduction</b> Andrea Laghi, Latina, Italy Giovanni Maconi, Milan, Italy
07:40 - 08:40	<b>2: Introductory lecture</b> Ultrasound: Torsten Kucharzik, Lüneburg, Germany MRI: Jordi Rimola, Barcelona, Spain
08:40 - 11:40	<b>3: Hands-on bowel ultrasonography and interactive discussion of cases, in small groups, guided by tutors (with US simulators and MRI workstations)</b> Anil Asthana, Melbourne, Australia Emma Calabrese, Rome, Italy Arun Gupta, Harrow, United Kingdom Christian Maaser, Lüneburg, Germany Francesca Maccioni, Rome, Italy Kerri Novak, Calgary, Canada Pasquale Paolantonio, Rome, Italy Jordi Rimola, Barcelona, Spain Jaap Stoker, Amsterdam, The Netherlands Michael Torkzad, Godalming, United Kingdom Stephan Vavricka, Zurich, Switzerland Rune Wilkens, Aarhus, Denmark
11:40 - 12:00	<b>Question &amp; Answer session</b> All participating tutors
12:00 - 12:15	<b>4: Post-Course test</b> <b>Concluding remarks</b> Andrea Laghi, Latina, Italy Giovanni Maconi, Milan, Italy

# 6<sup>th</sup> SciCom Workshop: Fat in IBD – Much more than an innocent bystander

<b>Date:</b>	Thursday, February 15, 2018
<b>Time:</b>	08:45-11:55
<b>Organisation:</b>	SciCom
<b>Target audience:</b>	Basic scientists and interested clinicians
<b>Registration:</b>	For registered participants only. No onsite registration
<b>CME accreditation:</b>	2 CME credits, upon return of an evaluation form filled in online

## Thursday, February 15, 2018

*Programme overview (as of January 15, 2018) –  
Lehar 4, Congress Centre, Messe Wien*

<i>Fat in IBD – Much more than an innocent bystander</i>	
<b>08:45 - 10:25</b>	<b>Session 1</b> Gerhard Rogler, Zurich, Switzerland Sebastian Zeissig, Dresden, Germany
	08:45 - 08:55 <b>1: Welcome &amp; Introduction</b> Britta Siegmund, Berlin, Germany
	08:55 - 09:25 <b>2: Fat and inflammation in obesity</b> Annette Schürmann, Nuthetal, Germany
	09:25 - 09:55 <b>3: Working with lipids in basic science – pitfalls and opportunities</b> Sebastian Zeissig, Dresden, Germany
	09:55 - 10:25 <b>4: Mesenteric fat and immune regulation – can abdominal fat control intestinal inflammation</b> Britta Siegmund, Berlin, Germany
<b>10:25 - 10:45</b>	<b>Coffee break</b>
<b>10:45 - 11:55</b>	<b>Session 2</b> Shomron Ben-Horin, Ramat Gan, Israel Britta Siegmund, Berlin, Germany
	10:45 - 11:05 <b>5: Angiogenesis and lymphangiogenesis in mesenteric adipose tissue in IBD</b> Silvio Danese, Milan, Italy
	11:05 - 11:25 <b>6: Fat and mesenchymal cell interactions – role in fibrosis and creeping fat formation</b> Ren Mao, Cleveland, United States
	11:25 - 11:45 <b>7: Fat: Unsuspected modulator of response to therapy</b> Sreedhar Subramanian, Liverpool, United Kingdom
	11:45 - 11:55 <b>8: Closing remarks</b> Britta Siegmund, Berlin, Germany

# 5<sup>th</sup> P-ECCO Educational Course

<b>Date:</b>	Thursday, February 15, 2018
<b>Time:</b>	10:00-12:00
<b>Organisation:</b>	P-ECCO
<b>Target audience:</b>	Paediatricians, Physicians, Surgeons, IBD nurses
<b>Registration:</b>	For registered participants only. No onsite registration
<b>CME accreditation:</b>	2 CME credits, upon return of an evaluation form filled in online

## Thursday, February 15, 2018

*Programme overview (as of January 15, 2018) –  
Schubert 4-5, Congress Centre, Messe Wien*

<b>10:00 - 12:00</b>	<b>Tackling the continuing challenges in PIBD patients</b> Patrick van Rheenen, Groningen, The Netherlands Richard Russell, Glasgow, United Kingdom	
10:00 - 10:05	<b>1: Welcome &amp; Introduction</b>	Richard Russell, Glasgow, United Kingdom
10:05 - 10:25	<b>2: Trans-mural healing: A desirable and achievable goal for children?</b>	Richard Russell, Glasgow, United Kingdom
10:25 - 10:50	<b>3: Monogenic very early onset IBD – case-based discussion</b>	Neil Shah, London, United Kingdom
10:50 - 11:15	<b>4: When approved drugs don't work</b>	David Wilson, Edinburgh, United Kingdom
11:15 - 11:40	<b>5: Childhood onset PSC: A distinct IBD phenotype?</b>	Patrick van Rheenen, Groningen, The Netherlands
11:40 - 12:00	<b>6: Stopping drugs in children – case-based discussion</b>	Jarosław Kierkuś, Warsaw, Poland



European  
Crohn's and Colitis  
Organisation

# We keep you informed at all times!

More reasons to join the ECCO Family!

## JCC

- 2016 Impact Factor: 5.813
- ECCO Guidelines and Topical Reviews
- ECCO Scientific Workshop Reviews
- JCC online only (website)
- Printed copies to be purchased at OUP

## ECCO Website

- ECCO Activities & Events
- Congress abstracts

## ECCO News

- All the inside stories of ECCO
- ECCO Calls, Elections and Activities
- Literature Reviews

## e-CO Learning

- e-Courses
- e-Library
- Abstracts
- Documents, images
- Webcasts, podcasts
- ECCO IBD Curriculum

Scan and contact the ECCO Office  
[www.ecco-ibd.eu](http://www.ecco-ibd.eu)



# 3<sup>rd</sup> H-ECCO IBD Masterclass

<b>Date:</b>	February 15-16, 2018
<b>Time:</b>	February 15: 13:30-17:15 February 16: 08:00-12:00
<b>Organisation:</b>	H-ECCO Working Group
<b>Target audience:</b>	Histopathologists, Clinicians
<b>Registration:</b>	For registered participants only. No onsite registration
<b>CME accreditation:</b>	6 CME credits, upon return of an evaluation form filled in online

## Thursday, February 15, 2018

*Programme overview (as of January 15, 2018) –  
Schubert 4-5, Congress Centre, Messe Wien*

<b>13:30 - 13:35</b>	<b>1: Welcome &amp; Introduction</b> Roger Feakins, London, United Kingdom
<b>13:35 - 15:15</b>	<b>Session 1: IBD diagnosis and IBD unclassified</b> Peter Irving, London, United Kingdom Vincenzo Villanacci, Brescia, Italy
13:35 - 13:55	<b>2: Biopsy diagnosis and classification of IBD</b> Paula Borralho, Lisbon, Portugal
13:55 - 14:15	<b>3: UC vs CD in resections and "Indeterminate Colitis"</b> Roger Feakins, London, United Kingdom
14:15 - 14:30	<b>4: IBD subclassification and IBDU: A gastroenterologist's perspective</b> Peter Irving, London, United Kingdom
14:30 - 14:45	<b>5: IBDU/"Indeterminate Colitis" and its management: A surgeon's perspective</b> Antonino Spinelli, Milan, Italy
14:45 - 15:05	<b>6: The appendix and periappendiceal mucosa in IBD</b> Neil Shepherd, Cheltenham, United Kingdom
15:05 - 15:15	<b>7: Slide seminar case 1</b> Paula Borralho, Lisbon, Portugal
<b>15:15 - 15:45</b>	<b>Coffee break</b>
<b>15:45 - 17:20</b>	<b>Session 2: Diagnostic precision</b> Paula Borralho, Lisbon, Portugal Magali Svrcek, Paris, France
15:45 - 16:00	<b>8: Granulomas and giant cells and their value</b> Roger Feakins, London, United Kingdom
16:00 - 16:20	<b>9: Ileitis: Crohn's Disease, "Backwash" and other types</b> Paula Borralho, Lisbon, Portugal
16:20 - 16:35	<b>10: Effects of chronicity on IBD pathology</b> Roger Feakins, London, United Kingdom
16:35 - 16:50	<b>11. Eosinophils in IBD and related conditions</b> Vincenzo Villanacci, Brescia, Italy
16:50 - 17:10	<b>12: Dysplasia vs reactive: A practical approach</b> Magali Svrcek, Paris, France
17:10 - 17:20	<b>13: Slide seminar case 2</b> Vincenzo Villanacci, Brescia, Italy

## Friday, February 16, 2018

*Programme overview (as of January 15, 2018) –  
Schubert 4-5, Congress Centre, Messe Wien*

<b>08:00 - 09:45</b>	<b>Session 3: Recent advances</b> Roger Feakins, London, United Kingdom Joana Torres, Lisbon, Portugal	
08:00 - 08:20	<b>14: Microbiota: Their role in the pathogenesis and progression of IBD</b>	Harry Sokol, Paris, France
08:20 - 08:45	<b>15: Hot topics in IBD research</b>	Magali Svrcek, Paris, France
08:45 - 09:05	<b>16: Liver disease in IBD</b>	Joana Torres, Lisbon, Portugal
09:05 - 09:25	<b>17: Liver pathology in IBD</b>	Dina Tiniakos, Newcastle, United Kingdom
09:25 - 09:45	<b>18: Colorectal neoplasia in IBD</b>	Magali Svrcek, Paris, France
<b>09:45 - 10:15</b>	<b>Coffee break</b>	
<b>10:15 - 11:55</b>	<b>Session 4: Scoring and grading; optimising the pathology report</b> Paula Borralho, Lisbon, Portugal Magali Svrcek, Paris, France	
10:15 - 10:30	<b>19: Clinical grades and scores in IBD</b>	James Lindsay, London, United Kingdom
10:30 - 10:50	<b>20: Histological scores – can we agree, and do they have a role?</b>	Jean-François Flejou, Paris, France
10:50 - 11:05	<b>21: CMV: Identification and quantification</b>	Vincenzo Villanacci, Brescia, Italy
11:05 - 11:15	<b>22: Biopsy Report: New and established disease</b>	Roger Feakins, London, United Kingdom
11:15 - 11:25	<b>23: Resection report in IBD</b>	Vincenzo Villanacci, Brescia, Italy
11:25 - 11:35	<b>24: Datasets for IBD: Could they be useful?</b>	Roger Feakins, London, United Kingdom
11:35 - 11:55	<b>25: Slide seminar cases 3 and 4</b>	Paula Borralho, Lisbon, Portugal Vincenzo Villanacci, Brescia, Italy
<b>11:55 - 12:00</b>	<b>26: Closing remarks</b> Roger Feakins, London, United Kingdom	

# 3<sup>rd</sup> D-ECCO Workshop

<b>Date:</b>	Friday, Feb. 16, 2018
<b>Time:</b>	08:30-12:25
<b>Organisation:</b>	D-ECCO Working Group
<b>Target audience:</b>	Dietitians, IBD nurses, physicians
<b>Registration:</b>	For registered participants only. No onsite registration
<b>CME accreditation:</b>	3 CME credits, upon return of an evaluation form filled in online

## Friday, February 16, 2018

*Programme overview (as of January 15, 2018) –  
Lehar 4, Congress Centre, Messe Wien*

<b>08:30 - 08:36</b>	<b>1: Welcome</b> Rotem Sigall-Boneh, Tel Aviv, Israel
<b>08:36 - 09:40</b>	<b>Session 1: Case-based presentations</b> Gerassimos Mantzaris, Athens, Greece Rotem Sigall-Boneh, Tel Aviv, Israel
08:36 - 08:52	<b>2: Obesity in IBD</b> Miranda Lomer, London, United Kingdom
08:52 - 09:08	<b>3: Nutritional assessment</b> Konstantinos Gerasimidis, Glasgow, United Kingdom
09:08 - 09:24	<b>4: Management of stoma</b> Nicolette Wierdsma, Amsterdam, The Netherlands
09:24 - 09:40	<b>5: Complications arising out of (mal)nutritionally induced Refractory Disease</b> Gerassimos Mantzaris, Athens, Greece
<b>09:40 - 10:00</b>	<b>Coffee break</b>
<b>10:00 - 11:00</b>	<b>Session 2: Diet and Ulcerative Colitis</b> Miranda Lomer, London, United Kingdom Nicolette Wierdsma, Amsterdam, The Netherlands
10:00 - 10:20	<b>6: Dietary pathogenesis in Ulcerative Colitis</b> Chen Sarbagili, Tel Aviv, Israel
10:20 - 10:40	<b>7: From pharma to farma in IBD</b> Arie Levine, Tel Aviv, Israel
10:40 - 11:00	<b>8: Probiotics and Ulcerative Colitis</b> Ailsa Hart, London, United Kingdom
<b>11:00 - 11:20</b>	<b>Coffee break</b>

## Friday, February 16, 2018, cont.

*Programme overview (as of January 15, 2018) –*

*Lehar 4, Congress Centre, Messe Wien*

<b>11:20 - 12:00</b>	<b>Session 3: Supplements in IBD</b> Konstantinos Gerasimidis, Glasgow, United Kingdom Arie Levine, Tel Aviv, Israel	
	11:20 - 11:40	<b>9: Dietary supplements in IBD</b> Rotem Sigall-Boneh, Tel Aviv, Israel
	11:40 - 12:00	<b>10: A case for and against oral iron in IBD: Tandem talk</b> Charlie Lees, Edinburgh, United Kingdom Richard Russell, Glasgow, United Kingdom
<b>12:00 - 12:20</b>	<b>11: Panel discussion/Q &amp; A</b> Ailsa Hart, London, United Kingdom Charlie Lees, Edinburgh, United Kingdom Gerassimos Mantzaris, Athens, Greece Richard Russell, Glasgow, United Kingdom Chen Sarbagili, Tel Aviv, Israel	
<b>12:20 - 12:25</b>	<b>12: Closing remarks</b> Nicolette Wierdsma, Amsterdam, The Netherlands	



European  
Crohn's and Colitis  
Organisation

Vienna  
Austria

# ECCO UR-CARE Training Centre

Stop by for a  
try next to the  
ECCO Booth



The IBD Database for your patient records and your research studies

- Visit the UR-CARE Training Centre in the entrance hall
- Test the database and discover all of the functionalities
- Open during Congress opening hours on Wednesday through Saturday
- Ask questions and get answers directly from the UR-CARE team
- Meet our official UR-CARE Trainers and ask your medical questions

Scan and visit

[www.ecco-ibd.eu/ur-care](http://www.ecco-ibd.eu/ur-care)



# Industry sponsored satellite symposia

Industry sponsored satellite symposia are organised by pharmaceutical companies. These symposia are open to all congress participants. Responsibility for the programme content remains with the sponsor.

ECCO has scheduled parallel satellite symposia on Thursday, February 15, 2018 at 11:00-12:00 and at 18:45-19:45, and on Friday, February 16, 2018 at 07:15-08:15 and at 18:35-19:35. Furthermore, parallel educational lunchtime satellite symposia are scheduled for Friday, February 16, 2018 at 12:40-13:20. Satellite symposia are held in the main Plenary hall in Hall D, respectively in the Parallel hall (Hall C) as well as in Rooms Lehar 1-3 and Strauss 1-2 (Congress Centre) on the ground level of Messe Wien. The programmes of satellite symposia are not affiliated with ECCO. Please note that due to compliance reasons, non-prescribing delegates might not have access to industry sponsored satellite symposia.

## Industry sponsored satellite symposia – Scientific programme Thursday, February 15, 2018

<b>Satellite symposium 1a – Organiser:</b>		<b>AbbVie</b>
<b>Meeting room:</b>		<b>Plenary hall, Hall D, Messe Wien</b>
<b>11:00 - 12:00</b>	<b>Keep CALM and use biomarkers in IBD</b> Remo Panaccione, Calgary, Canada	
abbvie	11:00 - 11:05	<b>Welcome and Introduction</b> Remo Panaccione, Calgary, Canada
	11:05 - 11:20	<b>The story of biomarkers so far</b> Jonas Halfvarson, Orebro, Sweden
	11:20 - 11:35	<b>Can we trust biomarkers when treating to a target?</b> Peter Bossuyt, Bonheiden, Belgium
	11:35 - 11:50	<b>Reducing patient burden and societal cost</b> Remo Panaccione, Calgary, Canada
	11:50 - 12:00	<b>Q&amp;A and Discussion</b> All
	12:00	<b>Closing remarks</b> Remo Panaccione, Calgary, Canada

## Industry sponsored satellite symposia – Scientific programme

Thursday, February 15, 2018, cont.

<b>Satellite symposium 1b – Organiser:</b>		<b>Sandoz</b>
<b>Meeting room:</b>		<b>Parallel hall, Hall C, Messe Wien</b>
<b>11:00 - 12:00</b>	<b>Delivering precision medicine and patient-centred care through a multidisciplinary approach</b> Krisztina Gecse, Amsterdam, The Netherlands	

<b>SANDOZ</b> <small>A Novartis Division</small>	11:00 - 11:15	<b>Optimising multidisciplinary care in IBD</b> Krisztina Gecse, Amsterdam, The Netherlands Antonino Spinelli, Milan Italy
	11:15 - 11:30	<b>Managing comorbidities – lessons learned from rheumatology</b> Frank Behrens, Frankfurt, Germany
	11:30 - 11:45	<b>New multidisciplinary approaches: What does the future look like?</b> Claudio Fiocchi, Cleveland, United States
	11:45 - 12:00	<b>Precision medicine: Current and future considerations – a panel discussion</b> Luisa Avedano (EFCCA), Brussels, Belgium Frank Behrens, Frankfurt, Germany Claudio Fiocchi, Cleveland, United States Krisztina Gecse, Amsterdam, The Netherlands Antonino Spinelli, Milan, Italy

<b>Satellite symposium 2a – Organiser:</b>		<b>Pfizer</b>
<b>Meeting room:</b>		<b>Plenary hall, Hall D, Messe Wien</b>
<b>18:45 - 19:45</b>	<b>Maximizing outcomes in UC care: both today and tomorrow</b>	



18:45 - 18:50	<b>Welcome and Introduction</b> Matthieu Allez, Paris, France
18:50 - 19:05	<b>Physician realities: Optimising treatment in today's patients</b> Matthieu Allez, Paris, France
19:05 - 19:30	<b>Novel approaches for an evolving treatment landscape</b> Marc Ferrante, Leuven, Belgium
19:30 - 19:40	<b>Q&amp;A</b>
19:40 - 19:45	<b>Closing remarks</b> Marc Ferrante, Leuven, Belgium

<b>Satellite symposium 2b – Organiser:</b>		<b>Biogen</b>
<b>Meeting room:</b>		<b>Parallel hall, Hall C, Messe Wien</b>
<b>18:45 - 19:45</b>	<b>Anti-TNF in IBD – inventory and outlook</b> Gert van Assche, Leuven, Belgium	



18:45 - 18:50	<b>Welcome and Introduction</b> Gert van Assche, Leuven, Belgium	
18:50 - 19:40	<b>Interactive discussion</b> Gert van Assche, Leuven, Belgium <b>The Erlangen case</b> Raya Atreya, Erlangen, Germany <b>The Paris case</b> Yoram Bouhnik, Paris, France <b>The Southampton case</b> Fraser Cummings, Southampton, United Kingdom <b>The role of TDM pre- and post-switch</b> Geert D'Haens, Amsterdam, The Netherlands	
	19:40 - 19:45	<b>Closing remarks</b> Gert van Assche, Leuven, Belgium

## Industry sponsored satellite symposia – Scientific programme

Thursday, February 15, 2018, cont.

<b>Satellite symposium 2c – Organiser:</b>		<b>Celltrion</b>
<b>Meeting room:</b>		<b>Lehar 1-3, Congress Centre, Messe Wien</b>
<b>18:45 - 19:45</b>	<b>Therapeutic Drug Monitoring: The value of biosimilar infliximab beyond evidence in IBD</b> Walter Reinisch, Vienna, Austria	
	18:45 - 18:50	<b>Opening</b> Walter Reinisch, Vienna, Austria
	18:50–19:05	<b>Accumulated experience with biosimilars from EFCCA</b> Salvo Leone, Milan, Italy
	19:05 – 19:20	<b>Personalised anti-TNF therapy in Crohn’s Disease study: PANTS</b> Tariq Ahmad, Exeter, United Kingdom
	19:20 – 19:35	<b>Early-on optimisation: Therapeutic drug monitoring for personalised treatment</b> Walter Reinisch, Vienna, Austria
	19:35 – 19:45	<b>Panel discussion</b> All

## Industry sponsored satellite symposia – Scientific programme

Friday, February 16, 2018

<b>Satellite symposium 3a – Organiser:</b>		<b>Takeda</b>
<b>Meeting room:</b>		<b>Plenary hall, Hall D, Messe Wien</b>
<b>07:15 - 08:15</b>	<b>Entering a new era of patient-reported outcomes in IBD: Past, present, and future</b> Peter Higgins, Ann Arbor, United States	
	07:15 - 07:30	<b>Why do patient-reported outcomes matter in Inflammatory Bowel Disease?</b> Peter Higgins, Ann Arbor, United States
	07:30 - 07:50	<b>Optimising biological therapies with patient-reported outcomes in mind</b> Brian Feagan, London, Canada
	07:50 - 08:05	<b>Continuing development of patient-reported outcomes in Inflammatory Bowel Disease</b> Peter Irving, London, United Kingdom
	08:05 - 08:15	<b>Panel discussion and Q&amp;A</b> Peter Higgins, Ann Arbor, United States

<b>Satellite symposium 3b – Organiser:</b>		<b>Samsung Bioepis</b>
<b>Meeting room:</b>		<b>Parallel hall, Hall C, Messe Wien</b>
<b>07:15 - 08:15</b>	<b>Biosimilars in IBD: Accompanying along with physicians, nurses and patients</b> Alessandro Armuzzi, Rome, Italy	
	07:15 - 07:20	<b>Welcome &amp; Introduction</b> Alessandro Armuzzi, Rome, Italy
	07:20 - 07:25	<b>Biosimilars to physicians: Credible agents</b> Alessandro Armuzzi, Rome, Italy
	07:25 - 07:40	<b>Biosimilars to patients: Information needs</b> Luisa Avedano, Brussels, Belgium
	07:40 - 07:55	<b>Biosimilars to nurses: Critical communication</b> Kay Greveson, London, United Kingdom
	07:55 - 08:05	<b>HCPs’ roles for optimised patients care by biosimilars</b> Alessandro Armuzzi, Rome, Italy
	08:05 - 08:15	<b>Panel discussion</b> All

## Lunchtime Satellite symposia – Scientific programme

Friday, February 16, 2018, cont.

<b>Satellite symposium 3c – Organiser:</b> <b>Pfizer</b>	
<b>Meeting room:</b> <b>Lehar 1-3, Congress Centre, Messe Wien</b>	
<b>07:15 - 08:15</b>	<b>Tackling today's challenges in managing IBD: A practical guide</b> Remo Panaccione, Calgary, Canada
	07:15 - 07:20 <b>Welcome &amp; Introduction</b> Remo Panaccione, Calgary, Canada
	07:20 - 07:35 <b>Addressing comorbid psychosocial risk factors in IBD: Why, what and how?</b> Iris Dotan, Petah Tikva, Israel
	07:35 - 07:50 <b>Rising to the loss of response challenge with anti-TNFs</b> Marla Dubinsky, New York, United States
	07:50 - 08:05 <b>Closing the access gap to biologics: Realising the biosimilar opportunity</b> Charlie Lees, Edinburgh, United Kingdom
	08:05 - 08:15 <b>Q&amp;A/Discussions</b>
<b>Satellite symposium LS1 – Organiser:</b> <b>AbbVie</b>	
<b>Meeting room:</b> <b>Plenary hall, Hall D, Messe Wien</b>	
<b>12:40 - 13:20</b>	<b>Patient First – the reality of extra-intestinal manifestations in IBD – an expert discussion</b> Tim Orchard, London, United Kingdom Stephan Vavricka, Zurich, Switzerland
	12:40 - 12:45 <b>In their own words – the patient perspective</b>
	12:45 - 13:10 <b>EIMs: An expert discussion on the factors that matter</b> Tim Orchard, London, United Kingdom Stephan Vavricka, Zurich, Switzerland
	13:10 - 13:20 <b>Key take aways and Q&amp;A</b> Tim Orchard, London, United Kingdom Stephan Vavricka, Zurich, Switzerland
<b>Lunch symposium LS2 – Organiser:</b> <b>Celgene</b>	
<b>Meeting room:</b> <b>Parallel hall, Hall C, Messe Wien</b>	
<b>12:40 - 13:20</b>	<b>What's your gut feeling about IBD clinical practice today and tomorrow? Interactive case-based discussions</b> Jean-Frédéric Colombel, New York, United States
	12:40 - 12:45 <b>Welcome &amp; Introduction</b> Jean-Frédéric Colombel, New York, United States
	12:45 - 13:00 <b>Case study 1: Current and future approaches to the management of Mild to Moderate Ulcerative Colitis</b> Panel discussion with: Jean-Frédéric Colombel, New York, United States Edouard Louis, Liège, Belgium Remo Panaccione, Calgary, Canada
	13:00 - 13:15 <b>Case study 2: Current and future approaches to the management of Moderate to Severe Crohn's Disease</b> Panel discussion with: Jean-Frédéric Colombel, New York, United States Edouard Louis, Liège, Belgium Remo Panaccione, Calgary, Canada
	13:15 - 13:20 <b>Closing remarks</b> Jean-Frédéric Colombel, New York, United States

## Lunchtime Satellite symposia – Scientific programme

Friday, February 16, 2018, cont.

<b>Lunch symposium LS3 – Organiser:</b>		<b>MSD</b>
<b>Meeting room:</b>		<b>Lehar 1-3, Congress Centre, Messe Wien</b>
<b>12:40 - 13:20</b>	<b>PROs, biomarkers and e-Health tools in UC practice</b> Glen Doherty, Dublin, Ireland	
	12:40 - 12:50	<b>Welcome &amp; Instruction</b> <b>Why Do We Need to Monitor UC Patients Treated With Conventional and Biological Therapies?</b> Glen Doherty, Dublin, Ireland
	12:50 - 13:20	<b>Interactive discussion:</b> <b>The Practical Aspects of UC Patient Monitoring: Benefits and Challenges</b> <b>What Further Improvements Should We Aim to Implement in Real-World Practice?</b> Glen Doherty, Dublin, Ireland Marieke Pierik, Maastricht, The Netherlands

<b>Lunch symposium LS4 – Organiser:</b>		<b>Tillotts</b>
<b>Meeting room:</b>		<b>Strauss 1-2, Congress Centre, Messe Wien</b>
<b>12:40 - 13:20</b>	<b>Physician: Sherlock and Saviour. Quality of life in IBD and insights into microscopic colitis</b> Axel Dignass, Frankfurt, Germany	
	12:40 - 12:45	<b>Welcome &amp; Introduction</b> Axel Dignass, Frankfurt, Germany
	12:45 - 13:00	<b>Psychiatric and psychological burden of IBD on quality of life</b> Yoram Inspector, London, United Kingdom
	13:00 - 13:15	<b>Microscopic colitis: It is all about quality of life!</b> Andreas Münch, Linköping, Sweden
	13:15 - 13:20	<b>Final remarks</b> All

## Industry sponsored satellite symposia – Scientific programme

Friday, February 16, 2018

<b>Satellite symposium 4a – Organiser:</b>		<b>Takeda</b>
<b>Meeting room:</b>		<b>Plenary hall, Hall D, Messe Wien</b>
<b>18:35 - 19:35</b>	<b>Individualised care for Crohn's Disease: Evolving approaches for a progressive disease</b> Jean-Frédéric Colombel, New York, United States	
	18:35 - 18:45	<b>Introduction: Evolving approaches for managing progressive Crohn's Disease</b> Jean-Frédéric Colombel, New York, United States
	18:45 - 19:00	<b>Maximising outcomes with early effective pharmacologic treatment of Crohn's Disease</b> Stefan Schreiber, Kiel, Germany
	19:00 - 19:15	<b>Fistulising Crohn's Disease: Current treatment challenges</b> Gert van Assche, Leuven, Belgium
	19:15 - 19:30	<b>Transforming treatment of Fistulising Crohn's Disease: New data on stem-cell based approaches</b> Damián García-Olmo, Madrid, Spain
	19:30 - 19:35	<b>Panel discussion and audience Q&amp;A</b> All Faculty

# International Symposia and Workshops

*Scientific Dialogue  
in the Interest of  
Therapeutic Progress*



Workshop  
**Liver-Gut-Microbiome Interactions**  
Hamburg, Germany  
January 25 – 26, 2018



Symposium 212  
**IBD and Liver: East Meets West**  
Kyoto, Japan  
September 7 – 8, 2018



Symposium 210  
**Crossing New Borders in IBD:  
Thoughts and Demands –  
From Mechanisms to Treatment**  
Lisbon, Portugal  
April 20 – 21, 2018



Symposium 213  
**Tailored Therapies for IBD:  
A Look into the Future**  
Milan, Italy  
October 5 – 6, 2018



Symposium 211  
**XXV International Bile Acid Meeting:  
Bile Acids in Health and Disease 2018**  
Dublin, Ireland  
July 6 – 7, 2018

FALK FOUNDATION e.V.



Leinenweberstr. 5  
79108 Freiburg  
Germany

Congress Department  
Tel.: +49 (0)761/1514-125  
Fax: +49 (0)761/1514-359  
E-Mail: [symposia@falk-foundation-symposia.org](mailto:symposia@falk-foundation-symposia.org)  
[www.falk-foundation-symposia.org](http://www.falk-foundation-symposia.org)

# 2018

## Lunchtime Satellite symposia – Scientific programme

Friday, February 16, 2018, cont.

<b>Satellite symposium 4c – Organiser:</b> <i>Janssen</i>	
<b>Meeting room:</b> <i>Lehar 1-3, Congress Centre, Messe Wien</i>	
<b>18:35 - 19:35</b>	<b><i>The road ahead: Advancing treatment strategies for Crohn's Disease</i></b> Séverine Vermeire, Leuven, Belgium
	18:35 - 18:40 <b><i>Welcome &amp; Introduction</i></b> Séverine Vermeire, Leuven, Belgium
	18:40 - 18:50 <b><i>Targeting IL-12/23 in Crohn's Disease: Update on evidence</i></b> Iris Dotan, Petah Tikva, Israel
	18:50 - 19:30 <b><i>Patient-case-based discussion: Making optimal choices to improve patient outcomes in Crohn's Disease</i></b> Matthieu Allez, Paris, France Iris Dotan, Petah Tikva, Israel Séverine Vermeire, Leuven, Belgium
	19:30 - 19:35 <b><i>Conclusions and close of meeting</i></b> Séverine Vermeire, Leuven, Belgium

<b>Satellite symposium 4d – Organiser:</b> <i>Ferring</i>	
<b>Meeting room:</b> <i>Strauss 1-2, Congress Centre, Messe Wien</i>	
<b>18:35 - 19:35</b>	<b><i>Change management in IBD, are we mastering it?</i></b> Subrata Ghosh, Birmingham, United Kingdom
	18:35 - 18:50 <b><i>Keynote opening address</i></b> Subrata Ghosh, Birmingham, United Kingdom
	18:50 - 19:10 <b><i>Treat-to-target in Mild to Moderate IBD – what do we know from clinical studies</i></b> Paolo Gionchetti, Bologna, Italy
	19:10 - 19:30 <b><i>Real world data in IBD management – learnings from The Netherlands</i></b> Bas Oldenburg, Utrecht, The Netherlands
	19:30 - 19:35 <b><i>Discussions and Q&amp;A</i></b>

## Industry sponsored satellite symposia – Educational programme

Thursday, February 15, 2018 – N-ECCO Network Meeting

<b>Satellite symposium Organiser:</b> <i>Takeda</i>	
<b>Meeting room:</b> <i>Strauss 1-2, Congress Centre, Messe Wien</i>	
<b>12:45 - 13:45</b>	<b><i>Treating-to-target in IBD – are you ready?</i></b> Chair: Catherine Stansfield, Salford, United Kingdom
	12:45 - 12:55 <b><i>Why patient empowerment is more important than ever!</i></b> Catherine Stansfield, Salford, United Kingdom
	12:55 - 13:05 <b><i>Treating-to-target in IBD: Goals, challenges and treatment planning</i></b> Pieter Hindryckx, Ghent, Belgium
	13:05 - 13:35 <b><i>Trio-talk: Making treat-to-target work in IBD</i></b> Desmond Glancy, Manchester, United Kingdom Pieter Hindryckx, Ghent, Belgium Catherine Stansfield, Salford, United Kingdom
	13:35 - 13:40 <b><i>Ask the experts: Treating-to-target in clinical practice</i></b> Chair-moderated Q&A with all speakers
	13:40 - 13:45 <b><i>Summary</i></b> Catherine Stansfield, Salford, United Kingdom



# Congress information

## *Badges*

Badges must be worn at all times throughout the entire congress and during social events. The coloured stripes on the name badges have the following significance:

- Congress delegates, Faculty members, Press
- Exhibitors, Participants of educational activities only
- Congress day ticket holders
- Congress Organiser, Staff

## *Banks and ATM*

Most banks in Vienna are open from Monday to Friday from 08:00 to 12:30 and from 13:30 to 15:00, and until 17:30 on Thursdays. In the city centre (first district), almost all banks are open over lunchtime. There will be ATMs in and nearby to the Congress centre and all over the city of Vienna. At the airport and main station and along the main streets you will find currency exchange offices.

## *Certificate of attendance*

All registered delegates can download and print their certificate of attendance in their individual user area in the online registration system after the congress.

## *Cloakroom*

The cloakroom can be found in the exhibition hall (Hall C) of Messe Wien. Neither Messe Wien nor the congress organisers may be held liable for any loss of belongings dropped off at the cloakroom.

## *Congress bags*

All registered delegates with a badge and a bag voucher are entitled to receive an ECCO'18 congress bag. With the fair trade bags by Township, ECCO supports their mission in creating a sustainable economic opportunity for women in South Africa's township communities. Please note that exhibitors are not entitled to receive a bag.

## *Coffee breaks*

Coffee breaks are always served in the exhibition hall (Hall C) at Messe Wien. ECCO offers coffee and pastries free of charge, snacks and lunch are served at cash catering stations. Attendees of the educational lunchtime symposia on Friday will be offered lunch prior to or after the symposium. Water fountains are available throughout the congress venue.

## Congress documentation

### Abstract USB drives

The ECCO'18 Final Programme booklet, which can be found in the congress bags, includes a voucher for the abstract USB drive with all abstracts. To obtain abstracts on an ECCO USB drive, please visit the ECCO Booth in the entrance hall.

### Abstracts – Online access

All abstracts can be found online ([www.ecco-ibd.eu](http://www.ecco-ibd.eu)) and the digital & website edition of JCC – Journal of Crohn's and Colitis. Further, computer access points will be available at the Internet Lounge in the exhibition hall (Hall C) for looking up abstracts online.

### Online streaming (post-event)

Members of ECCO can access the presentations of the 13<sup>th</sup> Congress of ECCO after the event - online at [www.ecco-ibd.eu](http://www.ecco-ibd.eu) in the e-Library of the e-CCO Learning platform. Presentation availability is subject to speaker authorisation.

## Congress organiser

OCEAiN – Organisation, Congress, Emotion, Association, iNnovation GmbH\*

ECCO Office

Ungargasse 6/13

1030 Vienna, Austria

Phone: +43-(0) 1-710 22 42

Fax: +43-(0) 1-710 22 42-001

E-mail: [ecco-congress@ecco-ibd.eu](mailto:ecco-congress@ecco-ibd.eu)

Web: [www.ecco-ibd.eu/ecco18](http://www.ecco-ibd.eu/ecco18)

\*service provider fully owned by European Crohn's and Colitis Organisation



European  
Crohn's and Colitis  
Organisation

## Congress venue

Messe Wien

Trabrennstraße 7

1021 Vienna, Austria

[www.messecongress.at](http://www.messecongress.at)



## Credit cards

All major cards are widely accepted in restaurants, hotels, shopping centres and stores, though in some small shops or hotels, there might occur an extra charge (2-6%).

## Currency

The Austrian currency is the Euro (EUR). You can exchange your currency at all banks as well as many exchange offices in Vienna. When you are exchanging your currency, you need your passport or official ID card. If you do not have it with you, the bank may refuse to exchange your currency.

## Disclaimer

Please note that in the event of a cancellation of the congress by the organisers in case of force majeure, the registration fee, hotel deposit and any other service ordered through the registration will be partially refunded or forfeited, subject to the commitments of the congress organiser at that time. You may wish to insure yourself directly against such a risk.

## *ECCOlogical*

At ECCO, we believe that our commitment to more eco-friendly & sustainable meetings will benefit our host destinations by leaving a minimum ecological footprint and will elevate the delegate experience.

Traditionally, congresses and exhibitions are renowned for producing lots of unnecessary waste. At the 13<sup>th</sup> Congress of ECCO, we actively demonstrate our commitment to greener meetings as best as we can with a number of measures. For details please refer to the ECCO Congress website ([www.ecco-ibd.eu/ecco18](http://www.ecco-ibd.eu/ecco18)).



## *Face-to-face with ECCO*

Following the great success of the “Face-to-face with ECCO” in the previous years, this year’s “Face-to-face with ECCO” will again be held at the ECCO Booth (entrance hall) during the coffee breaks. Please stop by the ECCO Booth to have a chat with ECCO Officers in an informal atmosphere and to engage in lively discussions about IBD and ECCO’s initiatives!

## *Floor plans*

Please refer to page 123.

## *General regulations*

Visitors of the 13<sup>th</sup> Congress of ECCO are kindly asked to adhere to the following rules and regulations:

- Entrance to the 13<sup>th</sup> Congress of ECCO and affiliated events is granted only with the congress badge. Entrance to the “ECCO Interaction: Hearts and Minds” is only granted with an entrance ticket.
- The congress organiser may not be held liable for any theft and/or loss of visitors’ individual property. It is the visitors’ sole responsibility to keep their belongings safe.

## *Industry exhibition*

Please refer to page 120.

## *Information on Vienna*

For information on Vienna, such as tours, restaurants, museums, churches/synagogues/mosques, please refer to the desk “Vienna information” next to the registration area in the entrance hall.

## *Insurance and liability*

Neither the congress organiser nor Messe Wien will assume any responsibility whatsoever for damage or injury to persons or property during the congress. Participants are recommended to arrange their personal travel and health insurance.

## *Internet access*

Internet access is provided in the Internet Lounge located in the exhibition hall (Hall C). Please limit the viewing time to max. 5 minutes per person. Free WiFi is provided throughout the congress venue. Please use the network ECCO18, no password is required.

## *Language*

The official language of the congress is English. No simultaneous translation will be provided.



European  
Crohn's and Colitis  
Organisation

# Become a member!

3-year membership:  
Regular & Y-ECCO  
Members save up to 20%



Be a bee in our hive to experience  
the ECCO Spirit

## To reach our objectives, our members can access the following ECCO Initiatives:

- Reduced Congress fee
- JCC – Journal of Crohn's and Colitis (12 online issues/year)\*
- e-CCO Learning Platform incl. e-Courses & e-Library
- Monthly eNewsletter
- Access to online members' area
- Voting rights in General Assembly (President-Elect, Treasurer, Secretary)
- Quarterly ECCO News – The society's magazine
- Educational and networking activities
- Guidelines, ECCO Fellowships, Grants and Travel Awards
- Priority access to ECCO UR-CARE - United Registries for Clinical Assessment and Research

Scan and contact the ECCO Office  
[www.ecco-ibd.eu](http://www.ecco-ibd.eu)



\*For Regular Members (incl. Y-ECCO) only; online access only

### *Lost and found*

For lost and found service at Messe Wien, please stop by the ECCO Booth (entrance hall) or the ECCO Congress Office (VIP Lounge C).

For help in locating property lost outside Messe Wien, please contact the registration desk.

### *Medical facilities*

Medical assistance can be provided by qualified onsite staff in a first aid room. In case you need to seek first aid, please contact the Hall Manager located at the entrance of the exhibition hall (Hall C).

### *Members' Lounge*

Exclusively for its members, ECCO provides a comfortable lounge area for private meetings and to recharge electronic devices.

This year the Members' Lounge is kindly supported by Tillotts Pharma.

Opening hours:

Thursday, February 15, 2018: 07:30-19:00

Friday, February 16, 2018: 07:30-19:00

Saturday, February 17, 2018: 07:30-13:00

### *Photos, Filming and Recording*

It is forbidden to film, take photos or record any presentation during the ECCO'18 scientific or educational programme and any poster presentation without the consent of the organiser (including smart phones, mobile devices, etc.).

Please note that the entire scientific programme as well as several educational activities will be recorded and published on ECCO's e-Learning platform after the congress and will be available for viewing for all ECCO Members free of charge. Furthermore, all abstracts and presentations (subject to speaker authorisation) are included in the e-Library.

### *Poster exhibition*


Please refer to page 71.

### *Programme changes*

ECCO cannot assume liability for any changes in the ECCO'18 Congress programme and programmes of the educational activities due to external or unforeseen circumstances.

## Public transportation

**Messe Wien** is well served by Vienna's metro system with the station "Krieau" on the purple Line U2 situated directly at the congress venue.



To get to the **ECCO Interaction** at Hofburg, 1010 Wien by public transport, we recommend to get off at station **U2** or **U3** "Volkstheater" or at station **U3** "Herrngasse".

## Registration and accommodation

All registration procedures for the 13<sup>th</sup> Congress of ECCO have been conducted online. In case you wish to register onsite, please refer to the registration desk in the entrance hall where you will be assisted with your queries.

### Registration desk and ECCO Congress Office

Opening hours of the ECCO Congress Office and the registration desk at Messe Wien:

Wednesday, February 14, 2018	<b>07:00 - 19:00</b>
Thursday, February 15, 2018	<b>06:30 - 19:00</b>
Friday, February 16, 2018	<b>07:00 - 19:00</b>
Saturday, February 17, 2018	<b>07:30 - 13:00</b>

The registration desk can be found in the entrance hall of Messe Wien.

The ECCO Congress Office is located in the VIP Lounge C, close to the exhibition hall.

## Registration fees

<b>Fee in EURO (including 20% Austrian VAT)</b>	<b>Early registration until November 8, 2017</b>	<b>Late registration until January 31, 2018</b>	<b>Onsite registration after January 31, 2018</b>
<b>ECCO Member Congress registration fees:</b>			
<i>Regular/Regular (Y-ECCO) Member Congress fee</i>	<b>250.-</b>	<b>320.-</b>	<b>400.-</b>
<i>Nurse Member Congress fee</i>	<b>55.-</b>	<b>95.-</b>	<b>145.-</b>
<i>Affiliate Member Congress fee<sup>1</sup></i>	<b>55.-</b>	<b>95.-</b>	<b>145.-</b>
<b>Non-Member Congress registration fees:</b>			
<i>Non-Member Congress fee</i>	<b>605.-</b>	<b>685.-</b>	<b>770.-</b>
<i>Nurse Non-Member Congress fee<sup>2</sup></i>	<b>355.-</b>	<b>395.-</b>	<b>545.-</b>
<i>Affiliate Non-Member Congress fee<sup>3</sup></i>	<b>355.-</b>	<b>395.-</b>	<b>545.-</b>
<i>Patient Advocate Congress fee<sup>4</sup></i>	<b>55.-</b>	<b>55.-</b>	<b>55.-</b>

<sup>1</sup>Students/PhD Students registering at the Affiliate Member Congress fee must upload a certificate of their Student/PhD Student status during the registration process. If no certificate is being uploaded, the registration process cannot be completed.

<sup>2</sup>Nurses registering at the Nurse Non-Member Congress fee must upload a certificate of their current nurse status and registration number during the registration process. If no certificate is being uploaded, the registration process cannot be completed.

<sup>3</sup>Students/PhD Students and delegates with the following professions may register for the Affiliate Non-Member Congress fee: Dietitian, Pharmacist, Psychologist. All delegates registering at this fee must upload a certificate of their professional status/Student or PhD Student status during the registration process. If no certificate is being uploaded, the registration process cannot be completed.

<sup>4</sup>Patient Advocates registering at this fee must upload a proof of their membership of a Patient Advocate Association during the registration process. If no certificate is being uploaded, the registration process cannot be completed. Please note that you might not have access to industry sponsored satellite symposia.

### Registration fee for delegates includes:

- Access to all scientific sessions
- Access to poster exhibition
- Access to industry exhibition
- Free copy of all congress documentation
- Certificate of attendance
- Access to congress abstracts
- Congress bag
- Coffee break

**Please note that in order to pick-up a pre-paid ticket, the passport/ID of the delegate must be shown.**

## Speakers' centre

The speakers' centre is located in the VIP Lounge D on Level 1 (accessible via the entrance hall). Speakers are asked to hand in their power point presentation preferably three hours prior to the presentation. The presentation will be transferred to the central congress server and will be available on a special congress notebook in the hall of the presentation. Due to time and technical reasons we kindly ask the speakers not to use their own notebook. Technical staff will be happy to assist.

In order to facilitate the process and reinforce the 2<sup>nd</sup> slide policy, faculty speakers are reminded to disclose their potential conflicts of interest in their ppt in line with UEMS regulations. Based on the submitted Col form of each speaker, a draft Col slide has been prepared and is made available in the Speakers' centre with a reminder that if the respective presentation does not yet include a disclosure form, the slide draft should be checked/amended and included in the ppt.

Opening hours of the speakers' centre at Messe Wien:

Wednesday, February 14, 2018	<b>07:30 - 18:00</b>
Thursday, February 15, 2018	<b>06:30 - 20:00</b>
Friday, February 16, 2018	<b>07:00 - 19:30</b>
Saturday, February 17, 2018	<b>07:30 - 13:00</b>

# ECCO Interaction: Hearts and Minds

**ECCO Interaction: Hearts and Minds** is THE event at ECCO to see and be seen, to network and engage. Anyone who has been to a previous ECCO Congress knows that it is a must and everyone is welcome, but places are limited.

This year's edition of the ECCO Interaction: Hearts and Minds will be held at the prestigious Hofburg.

**Date:** Friday, February 16, 2018

**Start time:** 20:00

**Venue:** Hofburg, Heldenplatz 1, 1010 Vienna

## Highlights of the evening:

- Y-ECCO Networking Reception from 20:00-21:00
- 3 course buffet dinner
- Live band
- DJ

## How to get to Hofburg from Messe Wien by using public transportation:

Take the metro **U2** from "Krieau" in direction to "Karlsplatz" and get off at the station "Volkstheater". You can either walk along the Ringstraße until you reach Hofburg on the left side or change into metro U3 in direction to "Simmering" and get off at the station "Herrengasse", which is located close to the back entrance of Hofburg.

**Tickets need to be picked up at the registration desk "ECCO Interaction: Hearts and Minds"** which is located in the entrance hall of Messe Wien.

**Access to the event is strictly granted with ECCO Interaction tickets only.** Please make sure to bring your ticket with you. **No ticket sale onsite at the Hofburg!**

## Y-ECCO Networking Corner

- Unique opportunity to meet key opinion leaders from the Governing Board and Operational Board of ECCO and to network with fellow Y-ECCO Members
- Where/When
  - At the ECCO Interaction: Hearts and Minds 2018
  - Hofburg
  - 20:00 - 21:00
- Welcome drinks served
- Join the main interaction following this great event
- Make sure you are registered and have your ticket with you!

# Industry exhibition

## Opening hours


Thursday, February 15, 2018	10:30 – 18:00
Friday, February 16, 2018	09:30 – 18:00
Saturday, February 17, 2018	09:30 – 13:00

## List of exhibitors & sponsors

Company	Booth number
<i>AbbVie</i>	4
<i>AbbVie</i>	11
<i>Amgen</i>	30
<i>Biogen</i>	3
<i>Boditech Med</i>	27
<i>Boehringer Ingelheim Pharma</i>	17
<i>BÜHLMANN Laboratories</i>	10
<i>Calpro</i>	43
<i>Celgene</i>	1
<i>Celltrion</i>	22
<i>Cisbio Bioassays</i>	41
<i>Diasorin</i>	39
<i>Dr. Falk Pharma</i>	9
<i>EFCCA</i>	44
<i>Eli Lilly</i>	19
<i>Eurospital</i>	28
<i>Ferring</i>	5
<i>Gilead</i>	23
<i>Grifols</i>	21
<i>Immundiagnostik AG</i>	36
<i>Janssen</i>	24
<i>Janssen</i>	25
<i>La Lettre de l' Hépatogastroentérologue (EDIMARK)</i>	33

Company	Booth number
<i>Medtronic</i>	45
<i>Mendes</i>	40
<i>Mimetas</i>	31b
<i>MSD</i>	15
<i>Nikkiso</i>	37
<i>Pfizer</i>	6
<i>Pfizer</i>	7
<i>Pfizer</i>	8
<i>Pharmacosmos</i>	42
<i>Philip Morris International R&amp;D</i>	35
<i>R-Biopharm</i>	29
<i>Robarts Clinical Trials B.V</i>	34
<i>Roche</i>	18
<i>Sandoz</i>	13
<i>Shield Therapeutics</i>	38
<i>Shire</i>	14 (14a/14b)
<i>Takeda</i>	12
<i>Takeda</i>	16
<i>Tani Medical</i>	31
<i>Theradiag</i>	32
<i>Tillotts</i>	2
<i>Wisepress</i>	20

# Exhibition plan



## Corporate Members

(as of January 15, 2018)

ECCO gratefully acknowledges the support of the following ECCO Corporate Members:

abbvie



GRIFOLS



SANDOZ A Novartis Division



# Floor plans

## Foyer D, Ground Floor

- Registration
- ECCO Booth
- UR-CARE Training Centre

## Foyer D, Level 1

- Speakers' Centre
- Panorama Restaurant

## Hall D

- Plenary Hall: Scientific sessions, satellite symposia

## Congress Centre


- Educational Activities
- Digital oral presentations
- Satellite Symposia

## Hall C

- Exhibition Hall: Industry and Poster Exhibition
- ECCO Members' Lounge
- Cloakroom
- Internet Lounge
- Parallel Hall: Scientific Session 9, Satellite Symposia
- Cash Catering

## The Mall

- ECCO Office
- Cash Catering
- Modern Times Restaurant




## Congress Centre Ground Floor

- 4<sup>th</sup> Basic ECCO: EduCational COurse for Industry (Stolz 1)
- 4<sup>th</sup> EpiCom Workshop (Lehar 2)
- 5<sup>th</sup> N-ECCO Research Forum (Lehar 1)
- 3<sup>rd</sup> ECCO Endoscopy Workshop (Lehar 4)
- 5<sup>th</sup> ECCO-ESGAR Ultrasound-MRI Workshop (Lehar 3)
- 6<sup>th</sup> ClinCom Workshop (Lehar 1)
- 6<sup>th</sup> SciCom Workshop: Fat in IBD – much more than an innocent bystander (Lehar 4)
- 12<sup>th</sup> N-ECCO Network Meeting (Strauss 1-2)
- 7<sup>th</sup> S-ECCO IBD Masterclass (Stolz 1-2)
- 3<sup>rd</sup> D-ECCO Workshop (Lehar 4)
- 16<sup>th</sup> IBD Intensive Advanced Course (Strauss 3)

Erdgeschoss


Ground floor



# Congress Centre Level 1

- 9<sup>th</sup> N-ECCO School (Schubert 1-2)
- 4<sup>th</sup> Y-ECCO Basic Science Workshop (Schubert 4-5)
- 5<sup>th</sup> P-ECCO Educational Course (Schubert 4-5)
- 3<sup>rd</sup> H-ECCO IBD Masterclass (Schubert 4-5)

**Obergeschoss**  
**1<sup>st</sup> floor**



# Index of speakers and abstract authors

2015 European Society of  
Coloproctology Collaborating  
Group DOP038

**A**bad, Lacruz A. OP034  
 Abedian, S. DOP011  
 Abitbol, V. DOP081  
 Adamina, M. 7<sup>th</sup> S-ECCO IBD  
 Masterclass in collaboration  
 with ESCP  
 Adegbola, S.O. OP017, DOP066,  
 N001, N002  
 Admyre, C. OP004  
 Ahmad, T. OP013, OP031, OP035  
 Aiello, A. DOP043  
 Akbari, M. DOP002  
 Al Bakir, I. OP010  
 Al Khouri, M. DOP029  
 Alcaín, G. OP034, P156  
 Aletaha, D. Scientific Session 1  
 Alexander, T. DOP057  
 Alhomrani, M. DOP060,  
 DOP061  
 Alizadeh, B. Z. DOP011  
 Allez, M. 3<sup>rd</sup> ECCO Endoscopy  
 Workshop, 7<sup>th</sup> S-ECCO IBD  
 Masterclass in collaboration  
 with ESCP, DOP057, DOP064  
 Allocca, M. DOP001  
 Alm, E. J. OP014  
 Almela, P. OP034  
 Almutairdi, A. DOP039  
 Alperovich, G. OP022  
 Andersen, V. DOP019  
 Anderson, C. OP013  
 Andonova, A. N0002  
 Anikster, Y. DOP015  
 Aniwani, S. OP025, OP026, DOP006,  
 DOP009, DOP051, DOP053  
 Ankersen, D. V. DOP031  
 Ann Flynn, H. DOP040  
 Arai, M. DOP056  
 Ardizzone, S. DOP001, DOP057  
 Arebi, N. 4<sup>th</sup> EpiCom Workshop,  
 DOP001, DOP019  
 Arena, V. OP018  
 Argmann, C. DOP012  
 Argüelles-Arias, F. OP034

Arias García, L. OP034  
 Arikan, D. DOP004, DOP008  
 Armuzzi, A. OP015, OP022, OP033,  
 DOP001, DOP026, DOP065,  
 DOP071, DOP074  
 Arnott, I. DOP072  
 Aronow B. DOP015  
 Artom, M. 12<sup>th</sup> N-ECCO Network  
 Meeting, N0001, N0002  
 Ashton, K. DOP028  
 Assa, A. DOP033  
 Asthana, A. 5<sup>th</sup> ECCO-ESGAR  
 Ultrasound-MRI Workshop  
 Atreja, A. DOP012, DOP069  
 Atreya, I. OP007, OP038, DOP076  
 Atreya, R. Scientific Session 4,  
 3<sup>rd</sup> ECCO Endoscopy Workshop,  
 OP004, OP007, OP012, OP038,  
 DOP004, DOP055, DOP076  
 Atrott, K. DOP079  
 Avivi, C. DOP015  
 Avni-Biron, I. DOP001

**B**abayan, A. DOP058  
 Badoglio, M. OP021  
 Baert, F. 16<sup>th</sup> IBD Intensive  
 Advanced Course, 4<sup>th</sup> Basic ECCO:  
 EduCational Course for Industry,  
 OP015, DOP003, DOP035, DOP046,  
 DOP047, DOP065, DOP071  
 Bager, P. 9<sup>th</sup> N-ECCO School,  
 5<sup>th</sup> N-ECCO Research Forum,  
 12<sup>th</sup> N-ECCO Network Meeting,  
 DOP028  
 Baiwir, D. DOP080, DOP082  
 Bajic, D. DOP088  
 Baker, A.-M. OP010  
 Baldassano, R. DOP008  
 Ballet, V. OP003  
 Bamias, G. DOP073  
 Banerjee, A. OP024  
 Bar-Gil Shitrit, A. DOP001  
 Barastegui, R. N0002  
 Barbieri, R. OP011  
 Barel, O. DOP010  
 Barkan, R. N0002  
 Barrachina, M. D. OP027

Barreiro-de Acosta, M. OP034  
 Barrett, J. OP013  
 Barshack, I. DOP015  
 Barthel, C. OP037  
 Baumgart, D. C. Scientific  
 Session 5, DOP001  
 Beaugerie, L. 4<sup>th</sup> EpiCom Workshop,  
 DOP032  
 Becher, B. OP030  
 Becker, E. OP038, DOP076  
 Becker, M. DOP073  
 Begka, C. DOP084  
 Behrens, F.  
 Belousova, E. DOP019  
 Belyakov, N. DOP059  
 Bemelman, W. A. 7<sup>th</sup> S-ECCO  
 IBD Masterclass in  
 collaboration with ESCP,  
 OP006, DOP083  
 Ben-Horin, S. Scientific Session 2,  
 16<sup>th</sup> IBD Intensive Advanced  
 Course, 5<sup>th</sup> N-ECCO Research  
 Forum, DOP001, DOP089  
 Bendtsen, F. DOP041  
 Beniwal-Patel, P. DOP048  
 Benoist, S. DOP037  
 BenShoshan, M. DOP015, DOP089  
 Ber, Y. OP034  
 Berends, S. DOP046  
 Berens, B. DOP048  
 Berg, S. OP015  
 Berger, A. DOP067  
 Bergey, F. OP002  
 Bermejo, F. OP034  
 Bettenworth, D. DOP044  
 Bewshea, C. OP013, OP031, OP035  
 Beyer-Berjot, L. DOP037  
 Bhagat, S. DOP014  
 Bhayat, F. DOP005  
 Bianchi, G. Scientific Session 5  
 Biedermann, L. OP037,  
 DOP001, DOP021  
 Biemans, V. DOP036, DOP052  
 Billmeier, U. OP004, OP012  
 Binder, M.-T. OP007  
 Bisschops, R. Scientific Session 11,  
 3<sup>rd</sup> ECCO Endoscopy Workshop  
 Blackwell, S. DOP066  
 Blake, A. DOP005

- Blanc, P. DOP029
- Bletard, N. DOP080, DOP082
- Bluemel, S. DOP088
- Boets, L. DOP020
- Bohm, M. OP025, OP026, DOP006, DOP009, DOP051, DOP053
- Boland, B. OP022, OP025, OP026, DOP006, DOP009, DOP051, DOP053
- Bonaz, B. DOP050, DOP014
- Bonder, M. J. OP014
- Bor, R. DOP007
- Bornstein, J. OP023
- Borody, T. OP019
- Borralho, P. 3<sup>rd</sup> H-ECCO IBD Masterclass
- Boschetti, G. DOP050
- Bossuyt, P. OP015, OP032, DOP001, DOP003, DOP004, DOP046, DOP065, DOP071
- Bouhnik, Y. DOP047
- Bouri, S. OP031
- Braun, T. DOP015, DOP089
- Brcerevic, I. DOP049
- Brennan, K. OP023
- Breton, A. DOP029
- Breynaert, C. DOP018
- Bridoux, V. DOP037
- Brierley, C. OP021
- Britton, G. J. DOP087
- Brocic, T. P. DOP049
- Brodmerkel, C. DOP012, DOP014
- Brom, A. DOP090
- Brooks, A. J. DOP070
- Brouquet, A. DOP037
- Brown, S. R. DOP066
- Bruckner, R. 4<sup>th</sup> Y-ECCO Basic Science Workshop
- Bruss, A. DOP048
- Bubis, M. DOP089
- Buckton, S. DOP028
- Buessing, M. DOP065
- Buisson, A. DOP032, DOP045
- Bujanda, L. OP034
- Burisch, J. DOP019, DOP031, DOP041, DOP064, DOP073
- Buskens, C. J. 7<sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP, OP006, DOP083
- Busquets, D. OP034
- Butter, M. DOP013
- Bálint, A. DOP007
- Bäbler, K. DOP013
- Börjesson, S. NO003
- Calabrese, E. 5<sup>th</sup> ECCO-ESGAR Ultrasound-MRI Workshop
- Calafat, M. OP034
- Calatayud, S. OP027
- Calvet, X. OP034
- Calvo, M. OP034
- Cancrini, C. DOP010
- Cannon, L. DOP045
- Cassinotti, A. OP021
- Castilla-Llorente, C. OP021
- Castillo, A. DOP012
- Cataldi, F. OP022, OP024, DOP062
- Cavicchi, M. DOP081
- Cañete Pizarro, F. OP034
- Cernoch, P. DOP021
- Chablaney, S. OP025, OP026, DOP006, DOP009, DOP051, DOP053
- Chalabreysee, M. NO002
- Chalkidi, N. DOP085
- Chan, G. OP033, DOP023, DOP025, DOP026, DOP027
- Chandrasinghe, P. OP017
- Chang, H. L. DOP069
- Chang, S. OP025, OP026, DOP006, DOP009, DOP051, DOP053
- Charlois, A. L. DOP050
- Charro, M. OP034
- Chauhan, U. 9<sup>th</sup> N-ECCO School, DOP028
- Cheifetz, A. DOP024
- Chen, N. DOP071
- Cheon, J. H. OP011
- Chitkara, D. OP005
- Chowers, Y. Scientific Session 12, 16<sup>th</sup> IBD Intensive Advanced Course
- Christodoulou, D. DOP001
- Chuah, C. S. DOP072
- Cimavilla, M. OP034
- Ciorba, M. A. DOP025
- Clarke, T. S. O. OP010
- Clasquin, E. DOP046
- Clemente, J. OP019, DOP087
- Clynen, I. 4<sup>th</sup> Basic ECCO: EduCational Course for Industry, 4<sup>th</sup> Y-ECCO Basic Science Workshop
- Cluzeau, V. NO002
- Cocchieri, A. NO002
- Coffey, C. 7<sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP
- Cohen, B. DOP069
- Cohen, R. D. DOP005, DOP045
- Coimbra Marques, C. DOP082
- Colard, A. DOP082
- Coletta, M. DOP001
- Collij, V. OP014
- Colombel, J.-F. Scientific Session 3, 6<sup>th</sup> ClinCom Workshop, OP009, OP015, OP019, OP023, OP025, OP026, DOP006, DOP009, DOP012, DOP032, DOP040, DOP051, DOP053, DOP065, DOP069, DOP071, DOP087
- Colombo, F. 7<sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP
- Connor, S. OP019
- Cornillie, F. DOP040
- Correale, C. OP018
- Correia, J. DOP060, DOP061
- Cosin-Roger, J. OP027
- Cotte, E. DOP037
- Cox, S. DOP086
- Cremer, J. DOP018
- Creyns, B. DOP018
- Crook, K. DOP066
- Csontos, Á. DOP007
- Čuković-Čavka, S. DOP019
- Cullen, G. DOP077
- Curran, M. DOP012
- Curtius, K. OP010
- Czuber-Dochan, W. 5<sup>th</sup> N-ECCO Research Forum, 12<sup>th</sup> N-ECCO Network Meeting, NO001, NO002
- D'Alessio, S. OP018, DOP016
- D'Haens, G. OP006, OP015, OP024, DOP023, DOP046, DOP047, DOP062, DOP063, DOP065, DOP071, DOP083
- D'Heygere, F. DOP035
- D'Hondt, A. DOP035
- D'Hoore, A. 7<sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP
- D'Incà, R. DOP019
- Daher, S. DOP033
- Dahlerup, J.F. DOP019
- Dalal, S. DOP045
- Dall'Oglio, L. DOP010
- Daly, M. OP011, OP035
- Danaliloglu, A. DOP065, DOP071
- Danese, S. Scientific Session 2, 6<sup>th</sup> SciCom Workshop, OP005, OP015, OP018, OP023, DOP016, DOP024, DOP026
- Danso-Abeam, D. DOP077
- Dart, R.J. DOP075
- De Angelis, P. DOP010
- de Boer, N. K. H. DOP036, DOP052
- de Bruyn, M. OP003, OP008
- De Corte, T. DOP035
- de Francisco, R. OP034
- de Jong, M. OP036
- De Jonge, W. J. DOP063

- De Klein, N. OP011  
 de Koning, M. A. DOP083  
 De Lange, K. OP013  
 De Pauw, E. DOP080, DOP082  
 De Pauw-Gillet, M.-C. DOP082  
 De Salvo, C. DOP074  
 De Vos, M. DOP003  
 de Vries, A. C. DOP022, DOP046, DOP052  
 De Vries, L. C. DOP063  
 Dederichs, F. DOP081  
 Dejaegher, K. DOP035  
 Dekens, J. OP014  
 Delaney, C. DOP043  
 Delvenne, P. DOP080, DOP082  
 Demuth, D. DOP002  
 Denet, C. DOP037  
 Denost, Q. DOP037  
 Denson, L.A. DOP015  
 der Heer-Damen, A. NO002  
 Derix, L. OP036  
 Desfourneaux, V. DOP037  
 Deshpande, N. OP019  
 Dewit, S. OP032  
 Dexheimer, P. J. DOP015  
 Di Martino, L. DOP074  
 Di Narzo, A. DOP012  
 Di Segni, A. DOP015, DOP089  
 Dibley, L. DOP028  
 Dierickx, D. OP021, DOP057  
 Dieterich, W. OP012  
 Digby-Bell, J. DOP075  
 Dignass, A. 16<sup>th</sup> IBD Intensive Advanced Course,  
 Dijkstra, G. OP011, OP014, DOP022, DOP036, DOP052  
 Ding, N.S. 9<sup>th</sup> N-ECCO School, 4<sup>th</sup> Basic ECCO: EduCational Course for Industry, DOP044  
 DL Magana, C. OP001  
 Dobrin, R. DOP012  
 Dobroluybova, E. DOP058  
 Docamp, M. DOP088  
 Doherty, G. 16<sup>th</sup> IBD Intensive Advanced Course, DOP064, DOP077  
 Domènech, E. Scientific Session 3, OP034, DOP081  
 Donchenko, I. DOP058  
 Dotan, I. 16<sup>th</sup> IBD Intensive Advanced Course, 7<sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP, DOP001  
 Dreesen, E. DOP047  
 Drvarov, O. DOP055  
 Dubinsky, M. DOP008, DOP012, DOP027, DOP068  
 Duffas, J.-P. DOP037  
 Dukler, A. OP008  
 Dulai, P.S. OP025, OP026, DOP006, DOP009, DOP051, DOP053  
 Duncan, J. DOP028  
 Duricova, D. DOP019  
 Dutch Initiative on Crohn and Colitis (ICC) DOP036, DOP052  
 Dutré, J. DOP003  
**E**  
 Efroni, G. DOP089  
 Egan, L. Scientific Session 11, 16<sup>th</sup> IBD Intensive Advanced Course  
 Ehrlich, D. DOP086  
 Eisele, C. DOP087  
 Ekbohm, A. OP016, DOP042  
 El Jurdi, K. DOP049  
 Elangovan, S. OP018  
 Eleonora A.M., F. OP014  
 Eliakim, R. DOP001, DOP089  
 Elliott, L.A. DOP077  
 Ellul, P. DOP019, DOP073  
 Epi-IBD study group DOP019  
 Esaki, M. DOP056  
 Escher, H. DOP030  
 Escher, J. DOP008  
 Espin, E. DOP078  
**F**  
 Fadeeva, N. DOP058, DOP059  
 Faith, J. OP019, DOP087  
 Faiz, O.D. DOP066  
 Faleck, D. OP025, OP026, DOP006, DOP009, DOP051, DOP053  
 Fantini, M. 3<sup>rd</sup> ECCO Endoscopy Workshop, DOP010  
 Farachi, S. DOP089  
 Farage Barhom, S. OP021  
 Farge, D. 5<sup>th</sup> N-ECCO Research Forum  
 Farrell, D. DOP008  
 Faubion, W. DOP037  
 Faucheron, J.-L. DOP033, DOP027  
 Feagan, B.G. Scientific Session 11, 6<sup>th</sup> ClinCom Workshop, 3<sup>rd</sup> H-ECCO IBD Masterclass  
 Fearnhead, N.S. DOP066  
 Fernández-Fernández, C. NO002  
 Fernández-Veledo, S. DOP078  
 Ferrante, M. 16<sup>th</sup> IBD Intensive Advanced Course, 9<sup>th</sup> N-ECCO School, 4<sup>th</sup> Basic ECCO: EduCational Course for Industry, 6<sup>th</sup> ClinCom Workshop, OP003, OP008, OP032, DOP001, DOP018, DOP020  
 Festen, E. OP011, OP028  
 Finke, J. OP021, DOP057  
 Fiocchi, C. Scientific Session 4, 4<sup>th</sup> Y-ECCO Basic Science Workshop  
 Fiorino, G. Scientific Session 6, OP018, DOP001  
 Fischer, M. OP025, OP026, DOP006, DOP009, DOP051, DOP053  
 Fischer, S. DOP055  
 Fitzpatrick, M. 16<sup>th</sup> IBD Intensive Advanced Course, 3<sup>rd</sup> H-ECCO IBD Masterclass  
 Flejou, J.F. DOP050  
 Flourie, B. OP005  
 Fogel, R. DOP021  
 Fournier, N. DOP048  
 Fox, C. OP032, DOP003, DOP046  
 Franchimont, D. OP011  
 Franke, L. OP033, DOP023, DOP024, DOP026  
 Friedman, G.S. DOP012, DOP014  
 Friedman, J. DOP086  
 Fromentin, S. OP014  
 Fu, J. DOP056  
 Fujiya, M. OP009, DOP019, DOP029  
 Fumery, M. DOP007  
 Fábán, A. NO002  
**G**  
 Gallego, M. DOP086  
 Galleron, N. OP034  
 García-Planella, E. OP034  
 García Sepulcre, M.F. OP034  
 García Sánchez, V. OP034  
 García-Bosch, O. OP034  
 García-López, S. Scientific Session 2  
 García-Olmo, D. OP018  
 Garlatti, V. DOP055  
 Garn, H. DOP074  
 Gasbarrini, A. 4<sup>th</sup> Basic ECCO: EduCational Course for Industry  
 Gece, K. 6<sup>th</sup> ClinCom Workshop, OP006  
 Geens, P. 4<sup>th</sup> Basic ECCO: EduCational Course for Industry  
 Gerasimidis, K. 9<sup>th</sup> N-ECCO School, 3<sup>rd</sup> D-ECCO Workshop  
 Gerhard, M. DOP088  
 Germain, A. DOP037  
 Ghersin, I. DOP033  
 Giannotta, M. DOP019  
 Gils, A. Scientific Session 5, DOP003, DOP047  
 Giner-Agudo, A. NO002

- Gingert, G. 7<sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP  
 Gisbert-Ferrandiz, L. OP027  
 Gisbert, J. 4<sup>th</sup> Basic ECCO: EduCational Course for Industry, OP034, DOP064  
 Glick Saar, E. DOP089  
 Goetz, M. DOP044  
 Goldis, A. DOP019  
 Gollins, J. DOP032  
 Golovics, P. DOP007  
 Gomollón, F. OP034  
 Gonzalez Lama, Y. DOP073  
 Goodhand, J. OP013, OP031, OP035  
 Goodman, W. DOP074  
 Gorelick, K. OP024, DOP062  
 Goren, I. NO002, DOP090  
 Goteti, S. OP022  
 Gottier, C. OP030, DOP013  
 Gower, C. DOP029  
 Gower-Rousseau, C. OP009  
 Graham, T. OP010  
 Graham, D. OP028  
 Greuter, T. OP037, DOP021, DOP073  
 Greveson, K. 9<sup>th</sup> N-ECCO School, DOP028  
 Griffiths, A. DOP008  
 Groen, H. DOP030  
 Grützmann, R. OP012  
 Guillon, F. DOP037  
 Guo, F. DOP044  
 Gupta, A. 5<sup>th</sup> ECCO-ESGAR Ultrasound-MRI Workshop  
 Gupta, N. OP025, OP026, DOP006, DOP009, DOP051, DOP053  
 Gurry, T. OP014  
 Gutiérrez, A. OP034
- H**aans, J. DOP034, DOP036  
 Haberman, Y. DOP015, DOP089  
 Haim, N. 7<sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP  
 Halfvarson, J. 16<sup>th</sup> IBD Intensive Advanced Course, 4<sup>th</sup> Basic ECCO: EduCational Course for Industry, 4<sup>th</sup> EpiCom Workshop, OP001, DOP019  
 Hall, R. DOP072  
 HallqvistEverhov, A. OP016, DOP042  
 Hamilton, B. OP031  
 Hampe, J. DOP044
- Hanauer, S. DOP024  
 Hansen, B.E. DOP022  
 Hansen, R. DOP081  
 Hantsbarger, G. DOP005  
 Hao, K. DOP012  
 Harlet, L. DOP035  
 Harrison, J. OP035  
 Harrow, P. DOP017  
 Hart, A. 4<sup>th</sup> Basic ECCO: EduCational Course for Industry, 3<sup>rd</sup> D-ECCO Workshop, OP010, DOP066  
 Hart, A. DOP014  
 Hartmann, A. OP012  
 Hartmann, P. DOP028  
 Hasselblatt, P. OP021, DOP057  
 Hausmann, M. OP027  
 Hawkey, C. OP021, DOP057  
 Hayday, A. DOP075  
 Hayden, K. DOP014  
 Heap, G. OP031, OP035, DOP004, DOP008  
 Hebuterne, X. DOP004  
 Hedin, C.R.H. DOP073  
 Heerasing, N. OP035  
 Heida, A. DOP030  
 Heil, A. NO002  
 Hendriks, D. DOP030  
 Hendy, P. OP035  
 Henriques, A. DOP085  
 Hering, L. OP030  
 Hernandez, V. DOP019  
 Heywood, N. DOP066  
 Hibi, T. DOP056  
 Higgins, P.D.R. OP022, DOP004, DOP024  
 Hildner, K. OP012  
 Hillmer, K. DOP088  
 Hind, D. DOP066  
 Hindryckx, P. Scientific Session 10, 9<sup>th</sup> N-ECCO School, 12<sup>th</sup> N-ECCO Network Meeting, 6<sup>th</sup> ClinCom Workshop, OP012, DOP055  
 Hirschmann, S. OP025, OP026, DOP006, DOP009, DOP051, DOP053  
 Hirten, R. DOP060, DOP061  
 Hodge, A. DOP036, DOP046, DOP052  
 Hoentjen, F. OP036  
 Hoentjen, F. OP014  
 Hofker, M.H. DOP056  
 Hojo, S. NO003  
 Hollman Frisman, G. DOP043  
 Holubar, S. DOP055  
 Homburg, U. OP017  
 Hompes, R. DOP056  
 Horiki, N. DOP087  
 Hu, J. DOP080  
 Hu, S.
- Huang, R. DOP012  
 Hudesman, D. OP025, OP026, DOP006, DOP009, DOP051, DOP053  
 Huguet, J.M. OP034  
 Hull, T. DOP043  
 Humblet, E. OP032, DOP003  
 Hummel, T. DOP030  
 Hurley, A. DOP012  
 Hurst, R.D. DOP045  
 Huyck, S. DOP040  
 Hyams, J. DOP008, DOP015  
 Hyman, N.H. DOP045  
 Hébuterne, X. OP024
- I**BD Pharmacogenetics Study Group OP035  
 Ido, A. DOP056  
 Iesalnieks, I. DOP081  
 Imai, T. DOP056  
 Imhann, F. OP014  
 Ipenburg, N. 12<sup>th</sup> N-ECCO Network Meeting, DOP028  
 Irizar, A. DOP012  
 Irving, P. Scientific Session 6, 16<sup>th</sup> IBD Intensive Advanced Course, 3<sup>rd</sup> ECCO Endoscopy Workshop, 12<sup>th</sup> N-ECCO Network Meeting, 3<sup>rd</sup> H-ECCO IBD Masterclass, DOP075, DOP086  
 Isaacs, K. DOP004  
 Israel, A. DOP090  
 Itzkowitz, S. DOP069
- J**acobstein, D. DOP014  
 Jaghult, S. DOP028  
 Jan, C. DOP018  
 Jankipersadsing, S.A. OP014  
 Jansen, M. OP010  
 Janssens, E. DOP035  
 Jelsness-Jørgensen, L.P. NO002  
 Jenkinson, P. DOP072  
 Jeuring, S. OP002  
 Johnson, S. DOP065  
 Jones, G. DOP072  
 Jones, S. OP023  
 Jones, T.V. DOP023  
 Jonkers, D. OP002, DOP034  
 Jonkers, D.M. OP014  
 Joosse, L. 4<sup>th</sup> Y-ECCO Basic Science Workshop  
 Jost, P. OP029  
 Juillerat, P. Scientific Session 5, 16<sup>th</sup> IBD Intensive Advanced Course, OP020

Jäghult, S.	5 <sup>th</sup> N-ECCO Research Forum, NO002	Kollias, G.	DOP085	Leedham, S.	OP010
		Konnikova, L.	DOP010	Lees, C.	3 <sup>rd</sup> D-ECCO Workshop, DOP072
		Konoplyannikov, A.	DOP058, DOP059, OP005	Lees, R.T.	DOP070
<b>K</b> aakoush, N.	OP019	Kopon, A.	OP005	Lefevre, J.	DOP037
Kabir, M.	7 <sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP	Kopylov, U.	DOP001, DOP089	Legido, J.	OP034
		Koskela, J.	OP035	Lemale, J.	DOP029
Kadire, S.	OP025, OP026, DOP009	Kosoy, R.	DOP012	Leong, R.	OP019
Kagramanova, A.	DOP058, DOP073	Kotze, P.G.	Scientific Session 6, 16 <sup>th</sup> IBD Intensive Advanced Course, 4 <sup>th</sup> Basic ECCO: EduCational Course for Industry, 7 <sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP, DOP039	Leppkes, M.	OP038
Kaimakliotis, I.	DOP019			Leroyer, A.	DOP029
Kalman, D.	OP016, DOP042			Levenez, F.	DOP086
Kamm, M.	OP019			Levhar, N.	DOP089
Kamperidis, N.	DOP001	Kreijne, J.E.	DOP022	Levine, A.	4 <sup>th</sup> Basic ECCO: EduCational Course for Industry, 3 <sup>rd</sup> D-ECCO Workshop
Kanai, T.	DOP056	Krichbaum, D.W.	DOP026		
Kane, S.	OP025, OP026, DOP006, DOP009, DOP051, DOP053	Kubo, M.	DOP011	Li, K.	DOP014
Kaplan, G.	DOP039	Kucharzik, T.	5 <sup>th</sup> ECCO-ESGAR Ultrasound-MRI Workshop, DOP001	Li, Y.	OP011
Karstensen, J.G.	DOP044			Lichtenstein, G.R.	DOP025
Kasarskis, A.	DOP012	Kuehn, V.	DOP004, DOP008	Lie, M.R.	DOP022
Katsanos, K.	12 <sup>th</sup> N-ECCO Network Meeting, DOP001, DOP064, DOP081	Kugathasan, S.	DOP008, DOP015	Liefferinckx, C.	DOP003
		Kuk, N.	DOP060, DOP061	Lightner, A.	7 <sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP
Katsanos, K.H.	DOP019, DOP073	Kupcinskaskas, L.	DOP019		
Katz, L.H.	DOP033	Kurilshikov, A.	OP014	Lim, R.	DOP060, DOP061
Kayhan, C.	DOP027	Kühbacher, T.	DOP055	Lin, E.	OP019
Kazmi, M.	OP021, DOP057	Kłopocka, M.	OP024	Lindgren, S.	DOP040
Keefe, L.	DOP069			Lindqvist, C.M.	OP001
Kemp, K.	5 <sup>th</sup> N-ECCO Research Forum, 7 <sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP, DOP028			Lindsay, J.	16 <sup>th</sup> IBD Intensive Advanced Course, 3 <sup>rd</sup> ECCO Endoscopy Workshop, 3 <sup>rd</sup> H-ECCO IBD Masterclass, DOP004, DOP017, DOP026, DOP040, DOP057, DOP086
Kennedy, N.	OP035	<b>L</b> abopin, M.	OP021	Lishchinskaya, A.	DOP058
Kennedy, N.A.	OP013, OP031	Lacerda, A.P.	OP022	Llaó, J.	OP034
Khalid, J.M.	DOP002, DOP067	Laghi, A.	6 <sup>th</sup> ClinCom Workshop, 5 <sup>th</sup> ECCO-ESGAR Ultrasound-MRI Workshop	Lo, B.	DOP041
Khomeriki, S.	DOP058	Lahad, A.	DOP089	Lobo, A.J.	DOP066, DOP070
Khorrani, S.	OP034	Laharie, D.	DOP047	Loftus, E.V.	OP025, OP026, DOP002, DOP004, DOP006, DOP009, DOP051, DOP053
Kierkus, J.	5 <sup>th</sup> P-ECCO Educational Course, DOP008, DOP064	Lahat, A.	DOP089		
Kievit, L.	DOP019	Laing, A.	DOP075	Lomer, M.	3 <sup>rd</sup> D-ECCO Workshop, DOP086
Kievit, W.	OP036	Lakatos, P.L.	16 <sup>th</sup> IBD Intensive Advanced Course, 3 <sup>rd</sup> ECCO Endoscopy Workshop, DOP019	Lopetuso, L.	DOP064
Kim, W.H.	DOP011			Lopetuso, L.R.	DOP074
Kindermann, A.	DOP030	Lakner, L.	DOP007	Lopez, R.	DOP044
Kinjo, F.	DOP056	Lalisang, R.	DOP034	Loriau, J.	DOP037
Kirchgesner, J.	4 <sup>th</sup> EpiCom Workshop	Lang, S.	OP030, DOP013, DOP079	Losic, B.	DOP012
Kitamura, K.	DOP056	Langholz, E.	4 <sup>th</sup> EpiCom Workshop, DOP019	Louis on behalf of the BIOCIRCLE group, E.	DOP032
Klaudia, F.	DOP007			Louis, E.	OP024, DOP003, DOP064, DOP080, DOP082
Klaus, J.	OP024	Lasch, K.	OP025, OP026, DOP051, DOP053		
Knittel, T.	OP004			Lu, C.	DOP039
Knyazev, O.	DOP058, DOP059	Latinovic, O.	DOP049	Lucendo, A.J.	OP034
Kochhar, G.	OP025, OP026, DOP006, DOP009, DOP051, DOP053	Lawendy, N.	OP033, DOP023, DOP024, DOP025, DOP026, DOP027	Ludvigsson, J.F.	OP016, DOP042
Kokke, F.	DOP030			Lukas, M.	DOP027
Koletzko, S.	DOP008	Lee, M.J.	DOP066	Lukin, D.	OP025, OP026, DOP006, DOP009, DOP051, DOP053, DOP066
Koliani-Pace, J.L.	OP025, OP026, DOP006, DOP009, DOP051, DOP053	Lee, S.D.	OP024	Lung, P.F.	DOP066
Koliaraki, V.	DOP085	Lee, W.-J.	DOP065, DOP071	Luo, M.	OP025, OP026,
Kollen, L.	DOP029				



Lyons, M.	DOP051, DOP053	Maser, E.	DOP069	Morsy, Y.	DOP079
Lázaro, J.	DOP072	Mason, I.	12 <sup>th</sup> N-ECCO	Moscariello, M.	OP033, DOP023
López Sanromán, A.	OP034	Massimino, L.	Network Meeting	Moss, A.C.	DOP026
	16 <sup>th</sup> IBD	Massot, C.	DOP016	Moutsianas, L.	OP013
	Intensive Advanced Course,	Mathieu, N.	DOP080, DOP082	Mudter, J.	OP012
	4 <sup>th</sup> Basic ECCO: EduCational	Mathôt, R.	DOP050	Mueller, M.	DOP063
	Course for Industry, OP021, OP034	Matsui, T.	DOP046	Mujagic, Z.	OP014
Löwenberg, M.	OP006, DOP022,	Matsumoto, T.	DOP044, DOP056	Mulcahy, H.	DOP077
	DOP046	Matsuoka, K.	DOP056	Muller Kobold, A.	DOP030
		Matthes, K.	DOP056	Munkholm, P.	DOP019, DOP031
		Maul, J.	DOP044	Munoz-Bongrand, N.	DOP037
		Maymó-Masip, E.	DOP073	Murciano, F.	NO002
<b>M</b> a, C.	DOP039	Mazzucchelli, G.	DOP078	Muñoz Vilafranca, C.	OP034
Maa, J.-F.	OP015	Mañosa, M.	DOP080, DOP082	Muñoz, C.	DOP081
Maaser, C.	Scientific Session 4,	McCarthy, N.	OP034	Myrelid, P.	OP016, DOP042
	5 <sup>th</sup> ECCO-ESGAR	McCoy, K.	DOP017, DOP086	Márquez, L.	OP034
	Ultrasound-MRI Workshop,	McGovern, D.	DOP084	Mínguez, M.	OP034
	DOP001	McNair, A.G.K.	OP035	Mücke, M.	DOP044
Maccarone, J.	OP005	Mearin, L.	DOP066	Mühl, T.	DOP055
Maccioni, F.	5 <sup>th</sup> ECCO-ESGAR	Mège, D.	DOP030	Müllner, K.	DOP007
	Ultrasound-MRI Workshop		7 <sup>th</sup> S-ECCO IBD	Münster, T.	OP012
Machiels, K.	OP003		Masterclass in collaboration		
Macias-Ceja, D.C.	OP027		with ESCP		
Macken, E.	OP032, DOP003	Mehandru, S.	DOP087	<b>N</b> aganuma, M.	DOP056
MacKenzie, T.	DOP068	Meij, De, T.	DOP030	Nagtegaal, I.	OP036
Maconi, G.	5 <sup>th</sup> ECCO-ESGAR	Mejias-Luque, R.	DOP088	Nagy, F.	DOP007
	Ultrasound-MRI Workshop	Menacho, M.	DOP078	Naik, S.	DOP048
Macpherson, A.J.	OP020	Merino, O.	OP034	Nair, N.	DOP087
Madrigal, R.E.	OP034	Merli, A.-M.	DOP082	Nancey, S.	DOP050
Maggiori, L.	7 <sup>th</sup> S-ECCO IBD	Meserve, J.	OP025, OP026	Napolitano, D.	NO002
	Masterclass in collaboration		DOP006, DOP009,	Narula, P.	DOP070
	with ESCP, DOP037		DOP051, DOP053	Navarini, A.	DOP073
Magro, F.	DOP019	Meurette, G.	DOP037	Navarro, E.	NO002
Mahajan, M.	DOP012	Meuwis, M.-A.	DOP080, DOP082	Nduka, C.I.	OP033, DOP024,
Maharshak, N.	DOP001	Michetti, P.	Scientific Session 6,		DOP025, DOP027
Maillard, M.H.	DOP084		16 <sup>th</sup> IBD Intensive		
Maljaars, P.	DOP036		Advanced Course	Neary, P.	DOP043
Maller, E.	DOP027	Miheller, P.	DOP007	Nebiki, H.	DOP056
Mansfield, J.	4 <sup>th</sup> Basic ECCO:	Milassin, Á.	DOP007	Neimark, E.	OP015, DOP065,
	EduCational Course	Milenkovic, Z.	DOP049		DOP071
	for Industry	Millan, M.	DOP078	Neufert, C.	OP007, OP012,
	4 <sup>th</sup> Basic ECCO:	Misselwitz, B.	OP037, DOP021		OP038, DOP076
	EduCational Course for Industry,	Mitchell, H.	OP019	Neuman, S.	DOP089
	3 <sup>rd</sup> D-ECCO Workshop, DOP001	Mitsuyama, K.	DOP056	Neurath, M.F.	OP004, OP005,
Mao, Q.	DOP087	Miyazaki, T.	DOP056		OP007, OP012, OP038,
Mao, R.	6 <sup>th</sup> SciCom Workshop,	Moens, A.	OP032		DOP055, DOP076
	DOP064	Mogno, I.	DOP087	Ng, S.C.	DOP011
Marion, J.F.	DOP069	Molander, P.	DOP001	Ng, W.	OP019
Marker, D.	DOP031	Molnár, T.	DOP007	Nielsen, K.R.	DOP019
Marot, G.	OP009	Monfort, D.	OP034	Nielsen, S.	OP019
Marshall, J.K.	DOP026	Moore, G.	DOP060, DOP061	Nijs, J.	OP032
Martens, E.	OP008	Moorghen, M.	OP010	Nissen, L.	OP036
Martins dos Santos, V.	OP002	Moortgat, L.	9 <sup>th</sup> N-ECCO School,	Noman, M.	DOP003
Martín Arranz, M.D.	OP034		NO002, DOP028	Norbruis, O.	DOP030
Martínez Montiel, P.	OP034	Mooser, C.	DOP084	Nordenvall, C.	OP016, DOP042
Martínez-Cadilla, J.	OP034	Mora, M.	OP034	Norman, P.	DOP070
Mas, E.	DOP029	Moreau, J.	DOP047	Norton, C.	5 <sup>th</sup> N-ECCO Research
Mascaraque, C.	OP018	Morell, B.	DOP021		Forum, NO001, NO002
Masclee, A.	OP002, OP014, DOP034	Morin, D.	DOP029	Nos, P.	OP034

- Novacek, G. DOP065, DOP071  
 Novak, K. 5<sup>th</sup> ECCO-ESGAR  
 Ultrasound-MRI Workshop,  
 DOP039  
 Nuñez-Roa, C. DOP078
- O**  
 Obialo, N. DOP013  
 Odes, S. DOP019  
 Oketani, K. DOP056  
 Oksanen, P. DOP019  
 Oldenburg, B. DOP036, DOP052  
 Olympie, A. DOP032  
 Olén, O. OP016, DOP042  
 on behalf of the  
 International TaTME  
 Registry Collaborative OP017  
 on behalf of the  
 Swiss IBD Cohort  
 Study Group OP037  
 Onida, F. OP021, DOP057  
 Oostenbrug, L. OP002, DOP034  
 Opendakker, G. OP008, P005  
 Orlova, N. DOP059  
 Ortiz-Masia, D. OP027  
 Öst, Å. OP001  
 Otobo, E. DOP069  
 Oury, C. DOP082
- P**  
 Palatka, K. DOP007  
 Panaccione, R. OP015, DOP024,  
 DOP039, DOP065, DOP071  
 Panis, Y. 7<sup>th</sup> S-ECCO IBD  
 Masterclass in collaboration  
 with ESCP, DOP037  
 PANTS Investigator  
 Consortium OP013, OP031  
 Panés, J. Scientific Session 1,  
 Scientific Session 12,  
 16<sup>th</sup> IBD Advanced Course,  
 4<sup>th</sup> Basic ECCO: EduCational  
 Course for Industry,  
 7<sup>th</sup> S-ECCO IBD Masterclass  
 in collaboration with ESCP,  
 OP034, DOP023, DOP025,  
 DOP040, DOP057  
 Paolantonio, P. 5<sup>th</sup> ECCO-ESGAR  
 Ultrasound-MRI Workshop  
 Papamichael, K. DOP064  
 Papp, M. DOP007  
 Paramsothy, R. OP019  
 Paramsothy, S. OP019  
 Parfenov, A. DOP059  
 Parga-Vidal, L. OP038  
 Pariente, B. OP009, DOP029,  
 DOP047
- Park, D.I. OP024  
 Parkes, M. 16<sup>th</sup> IBD Intensive  
 Advanced Course  
 Pasparakis, M. DOP085  
 Patel, A. DOP048  
 Patel, H. DOP067  
 Paulissen, G. DOP080  
 Pautrat, K. DOP037  
 Pavli, P. DOP081  
 Pedersen, N. DOP019  
 Pedersen, R.D. OP033, DOP023,  
 DOP025  
 Peeters, H. DOP003, DOP035  
 Pekow, J. DOP045  
 Pellino, G. OP017  
 Pellise, M. Scientific Session 11  
 Pencova, M. NO002  
 Penna, M. OP017  
 Pereira, B. DOP045  
 Perrigoue, J. DOP012  
 Pestour, S. DOP050  
 Peter, I. DOP087  
 Peters, L. DOP012  
 Peters, V. OP014  
 Pettersson, J. OP015, DOP004,  
 DOP008, DOP065, DOP071  
 Petrova, T. DOP084  
 Petrovic, S. DOP049  
 Petti, L. OP018  
 Peyrin-Biroulet, L. ScientificSession2,  
 4<sup>th</sup> EpiCom Workshop,  
 6<sup>th</sup> ClinCom Workshop,  
 OP022, DOP001, DOP002  
 Philip, G. DOP040  
 Phillips, R.K. DOP066  
 Picard, O. DOP089  
 Pierik, M. 4<sup>th</sup> EpiCom Workshop,  
 OP002, DOP034,  
 DOP036, DOP052  
 Pierre, N. DOP080  
 Pihl Lesnovska, K. 12<sup>th</sup> N-ECCO  
 Network Meeting,  
 NO002, NO003  
 Pineton de Chambrun, G. DOP029  
 Piontini, A. OP018  
 Pizarro, T.T. DOP074  
 Plevris, N. DOP072  
 Plevy, S. DOP012  
 Pleyer, U. DOP073  
 Polykratis, A. DOP085  
 Ponsoien, C. DOP036, DOP052  
 Ponsoien, C. OP006  
 Popp, V. DOP076  
 Popper, B. OP029  
 Posen, A. OP032  
 Powell, N. DOP075  
 Proudfoot, H. NO001  
 Prytz Berset, I. DOP064  
 Pu, Y. DOP084
- Pugliese, D. DOP001  
 Puig, L. DOP073
- Q**  
 Qu, T.B. DOP044  
 Queipo-Ortuño, M. DOP078  
 Quesada Calvo, F. DOP080,  
 DOP082  
 Quirk, D. OP033, DOP024,  
 DOP025, DOP027
- R**  
 Radice, S. NO002  
 Ragusa, S. DOP084  
 Rahal, M. OP025, OP026, DOP009  
 Rahier, J.-F. DOP003, DOP081  
 Rahier, J.-F. OP032  
 Rahili, A. DOP037  
 Raine, T. 16<sup>th</sup> IBD Intensive Advanced  
 Course, DOP001, DOP073  
 Raluy-Callado, M. DOP067  
 Ramos, L. OP034  
 Rana, N. DOP074  
 Rath, T. OP012, OP038  
 Rea, F. DOP010  
 Rechavi, G. DOP010  
 Regueiro, M. Scientific Session 10  
 Reid, S. OP012  
 Reinisch, W. 6<sup>th</sup> ClinCom Workshop,  
 OP015, OP024, DOP024,  
 DOP040, DOP065, DOP071  
 Renz, H. DOP055  
 Renz, J. DOP055  
 Ricart, E. OP021, DOP057  
 Rieder, F. DOP044, DOP073  
 Riera, J. OP034  
 Rimola, J. 5<sup>th</sup> ECCO-ESGAR  
 Ultrasound-MRI Workshop  
 Ringold, R. OP008  
 Rispens, T. DOP046  
 Rivas, M. OP011  
 Rivera, A. NO002  
 Rivero, M. OP034  
 Robinson, A. DOP008  
 Robinson, A.M. OP015, DOP004,  
 DOP065, DOP071  
 Roblin, X. DOP001  
 Rodríguez-Justo, M. OP010  
 Rodríguez, A. OP034  
 Rodríguez, C. OP034  
 Rodríguez, M.M. DOP078  
 Rodríguez-Moranta, F. OP034  
 Rodríguez-Pescador, A. OP034  
 Rogers, J. DOP012, DOP069  
 Rogler, G. Scientific Session 1,  
 16<sup>th</sup> IBD Intensive Advanced  
 Course, OP020, OP027,



- Su, A. DOP088  
 Su, C. OP033, DOP023, DOP024, DOP025, DOP026, DOP027
- Suarez-Farinas, M. DOP012  
 Subotic, B. DOP049  
 Subramanian, S. 6<sup>th</sup> SciCom Workshop
- Sultan, K. OP025, OP026, DOP006, DOP009, DOP051, DOP053  
 Svrcek, M. 3<sup>rd</sup> H-ECCO IBD Masterclass
- Swaminath, A. OP025, OP026, DOP006, DOP009, DOP051, DOP053
- Swertz, M. OP011  
 Szamosi, T. DOP007  
 Szepes, Z. DOP007  
 Szigethy, E. DOP069  
 Szymanska, E. DOP064  
 Szántó, K. DOP007
- T**  
 Takahashi, A. DOP011  
 Takenaka, O. DOP056  
 Tan, T. DOP054  
 Tanida, S. DOP056  
 Tanyngoh, D. DOP039  
 Tarabar, D. OP024, DOP049  
 Tarassishin, L. DOP087  
 Taub, P.R. OP033  
 Taxonera, C. OP034, DOP004  
 Teich, N. DOP040  
 Terdiman, J. OP022  
 Terrón-Puig, M. DOP078  
 Thakkar, R.B. DOP065, DOP071  
 The Crohn's & Colitis Foundation (CCF)-sponsored RISK study DOP015  
 The Leona M. and Hatty B. Helmsley Charitable Trust supported Israeli IBD Research Nucleus (IIRN) DOP089  
 Theeuwens, R. DOP028  
 Thompson, K.D. DOP032, DOP068  
 Thorrez, K. DOP035  
 Tigchelaar, E. OP014  
 Tilg, H. Scientific Session 9  
 Tiniakos, D. 3<sup>rd</sup> H-ECCO IBD Masterclass  
 Torkzad, M. 5<sup>th</sup> ECCO-ESGAR Ultrasound-MRI Workshop  
 Torres, J. Scientific Session 1, 3<sup>rd</sup> H-ECCO IBD Masterclass, DOP087  
 Tozer, P.J. 7<sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP, DOP066
- Tran, G. OP025, OP026, DOP009  
 Trapero, A.M. OP034  
 Travis, S. 16<sup>th</sup> IBD Intensive Advanced Course, 3<sup>rd</sup> ECCO Endoscopy Workshop, 6<sup>th</sup> ClinCom Workshop, OP015, OP021  
 Truffi, M. 4<sup>th</sup> Y-ECCO Basic Science Workshop
- Tsoukal, E.i. DOP001  
 Tsubouchi, H. DOP056  
 Tudor, D. DOP002, DOP054  
 Turcan, S. DOP019  
 Turchini, L. NO002  
 Turck, D. OP009, DOP029  
 Turner, D. Scientific Session 10, DOP008
- Turowska, A. DOP055  
 Tzivinikos, C. DOP081
- U**  
 Ullman, T. DOP069  
 Ulmschneider, J. OP004  
 Umanskiy, K. DOP045  
 Ungar, B. DOP001  
 Ungaro, F. OP018, DOP016  
 Ungaro, R. DOP012, DOP051  
 Uniken Venema, W. OP011, OP028  
 Usiskin, K. OP005
- V**  
 Keita, Å. OP001  
 V Sagi, S. OP025, OP026, DOP006, DOP009, DOP051, DOP053  
 Valli, P.V. DOP044  
 Valpiani, D. DOP019  
 Van Assche, G. OP003, OP008, DOP018, DOP020, DOP022, DOP054  
 van Besien, B. DOP035  
 van Bodegraven, A. DOP034  
 van den Bogaerde, J. OP019  
 van den Brink, M. DOP088  
 Van der Lely, L. DOP013  
 van der Meulen-de Jong, A. DOP022, DOP036, DOP052, DOP073  
 Van Der Woude, C. 16<sup>th</sup> IBD Intensive Advanced Course, DOP022, DOP036, DOP046, DOP047, DOP052  
 van Dijk, F. OP011  
 Van Domselaar, M. OP034  
 van Gaalen, F.A. DOP073  
 van Gisbergen, K. OP038  
 van Hamersveld, H.P. DOP063  
 van Hoeve, K. OP032
- Van Hooetegem, A. OP032  
 Van Hooetegem, P. DOP003, DOP035  
 Van Kemseke, C. DOP003  
 Van Moerkercke, W. OP032, DOP003  
 van Noord, D. DOP022  
 Van Rheenen, P. 5<sup>th</sup> P-ECCO Educational Course, DOP030  
 Van Sommeren, S. DOP011  
 van Tilburg, S. OP036  
 Vanasek, T. DOP065, DOP071  
 Vanmoerkercke, W. DOP035  
 Vantourout, P. DOP075  
 Vara-Hernández, A. NO002  
 Vardi, I. DOP010  
 Vasseur, F. OP009  
 Vavricka, S. 16<sup>th</sup> IBD Intensive Advanced Course, 5<sup>th</sup> ECCO-ESGAR Ultrasound-MRI Workshop, OP037, DOP021, DOP073, DOP081
- Vegh, Z. DOP019  
 Veereman, G. Scientific Session 10  
 Vela, M. OP034  
 Velayos, B. OP034  
 Vendrell, J. DOP078  
 Verdejo, C. OP034  
 Verjee, A. DOP066  
 Verkade, H. DOP030  
 Vermeire, S. 16<sup>th</sup> IBD Intensive Advanced Course, 7<sup>th</sup> S-ECCO IBD Masterclass in collaboration with ESCP, OP003, OP008, OP021, OP023, OP032, DOP002, DOP003, DOP005, DOP018, DOP020, DOP046, DOP047, DOP057
- Verseijden, C. DOP063  
 Verstockt, B. OP003, DOP001, DOP003, DOP018, DOP020  
 Verstockt, S. 4<sup>th</sup> Y-ECCO Basic Science Workshop, OP003  
 Verway, M. DOP028  
 Vester-Andersen, M. DOP041  
 Vetrano, S. OP018  
 Vetter, M. DOP055  
 Vicaut, E. DOP037  
 Vich Vila, A. OP011, OP014  
 Vieth, M. DOP055  
 Vijverman, A. DOP082  
 Villanacci, V. 3<sup>rd</sup> H-ECCO IBD Masterclass
- Vincze, Á. DOP007  
 Vind, I. DOP041  
 Visschedijk, M.C. OP014  
 Vitális, Z. DOP007  
 Voskuil, M.D. OP011, OP014, OP028, OP035



- W**adman, E. DOP014  
Wahida, A. OP029  
Waldner, M.J. OP012, DOP055  
Walker, G. OP035  
Walker, G.J. OP013, OP031  
Walls, D. DOP032  
Walsh, A. OP019  
Walshe, M. DOP077  
Wang, W. DOP012  
Wang, W. DOP027  
Wang, Y. DOP062  
Warusavitarne, J. 7<sup>th</sup> S-ECCO IBD  
Masterclass in collaboration  
with ESCP, OP017  
Watson, A. OP007  
Watson, E. DOP072  
Watson, M. N027  
Weedon, M. OP035  
Weersma, R. OP011, OP014, OP028,  
OP035, DOP011, DOP030  
Wei, G. DOP012  
Weigmann, B. DOP055,  
DOP076  
Weimers, P. DOP031  
Weiss, A. OP025, OP026, DOP006,  
DOP009, DOP051, DOP053  
Weiss, B. DOP010, DOP015,  
DOP089  
Welting, O. DOP063  
Wering, van, H. DOP030  
Werner, L. DOP010  
Wessels, M. DOP030  
West, R.L. DOP022
- Whelan, K. DOP086  
Wiendl, M. OP007  
Wierdsma, N. 9<sup>th</sup> N-ECCO School,  
3<sup>rd</sup> D-ECCO Workshop  
Wiest, R. OP020  
Wijmenga, C. OP014  
Wildenberg, M.E. 7<sup>th</sup> S-ECCO IBD  
Masterclass in collaboration  
with ESCP, DOP063  
Wilkins, R. 5<sup>th</sup> ECCO-ESGAR  
Ultrasound-MRI Workshop  
Wilkins, M. OP019  
Willemze, R.A. DOP063  
Wilson, D. 5<sup>th</sup> P-ECCO  
Educational Course  
Winter, H. DOP008  
Winters, A. OP025, OP026, DOP006,  
DOP009, DOP051, DOP053  
Wintjens, D. OP002, DOP034,  
DOP052  
Wong, S.H. DOP011  
Woodworth, D.A. DOP024
- X**avier, R. OP011, OP014  
Xiaofang, J. OP014
- Y**abal, M. OP029  
Yamazaki, K. DOP011  
Yanai, H. DOP001  
Yang, S.-K. DOP011  
Yao, R. DOP040
- Yarur, A. DOP048  
Yassin, N. DOP066  
Yilmaz, B. OP020  
Young, L. DOP028  
Yvellez, O. DOP049
- Z**abana, Y. OP034  
Zagorowicz, E. 4<sup>th</sup> Basic ECCO:  
EduCational Course for Industry  
Zakko, S. OP005  
Zargari, A. OP004  
Zega, M. NO002  
Zeissig, S. 6<sup>th</sup> SciCom Workshop  
Zeit, J. DOP021  
Zerbib, P. DOP037  
Zhan, X. OP005  
Zhang, B. DOP012  
Zhang, H. DOP024, DOP026,  
OP014  
Zhernakova, A. OP014  
Zhou, W. OP022  
Zhu, J. DOP012  
Zhu, W. DOP044  
Zmora, O. 4<sup>th</sup> Basic ECCO:  
EduCational Course for Industry,  
7<sup>th</sup> S-ECCO IBD Masterclass  
in collaboration with ESCP  
Zorzano, A. DOP078  
Zundler, S. OP007, OP038, DOP076

## Imprint

### *Publisher*

ECCO – European Crohn’s and Colitis Organisation

OCEAiN – Organisation, Congress, Emotion, Association, iNnovation GmbH

Ungargasse 6/13

1030 Vienna, Austria

Phone: +43-(0)1-710 22 42

Fax: +43-(0)1-710 22 42-001

E-Mail: [ecco@ecco-ibd.eu](mailto:ecco@ecco-ibd.eu)

Web: [www.ecco-ibd.eu](http://www.ecco-ibd.eu)



European  
Crohn’s and Colitis  
Organisation

To visit the ECCO website, please scan this code  
or look at [www.ecco-ibd.eu](http://www.ecco-ibd.eu)




Dieses Produkt entspricht dem Österreichischen Umweltzeichen für schadstoffarme Druckprodukte (UZ 24).  
This product conforms to the standards of the Austrian Environmental Seal of Approval for environmentally  
friendly printing products (UZ 24). Grasl Druck & Neue Medien, Bad Vöslau, UW-Nr. 715, [www.fairprint.at](http://www.fairprint.at)



Pfizer Satellite Symposium Session: ECCO 2018, Vienna

07.15 - 08.15, Friday 16th February 2018

Room Lehar 1-3, Reed Messe Wien



# Tackling today's challenges in managing IBD *a practical guide*

## Chair

**Professor Remo Panaccione**

*Professor of Medicine and Director of the IBD Clinic, University of Calgary, Canada*

**Addressing comorbid  
psychosocial risk factors  
in IBD: why, what and how?**

**Professor Iris Dotan**

*Director of the Division of Gastroenterology,  
Rabin Medical Center, Petah Tikva, Israel*

**Rising to the loss-of-response  
challenge with anti-TNFs**

**Professor Marla Dubinsky**

*Chief, Pediatric Gastroenterology and  
Hepatology, Icahn School of Medicine,  
Mount Sinai Hospital, New York*

**Closing the access gap to  
biologics: realising the  
biosimilar opportunity**

**Dr Charlie Lees**

*Consultant Gastroenterologist  
Western General Hospital, Edinburgh, UK*

 **Gastroenterology**

This symposium is not affiliated with ECCO. This programme is funded and organised by Pfizer Inc. Abbreviated Prescribing Information is available on the stand (Stand 7)  
PP-IFA-GLB-0814 | November 2017



# Working together to advance science and patient care



Visit Pfizer at booths  
**6 and 7**

